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ABSTRACT 
 
Discovery and Delivery of Synergistic Chemotherapy Drug Combinations to Tumors 
 
by 
 
Kathryn Militar Camacho 
 
 Chemotherapy combinations for cancer treatments harbor immense 
therapeutic potentials which have largely been untapped.  Of all diseases, clinical 
studies of drug combinations are the most prevalent in oncology, yet their 
effectiveness is disputable, as complete tumor regressions are rare.  Our research has 
been devoted towards developing delivery vehicles for combinations of 
chemotherapy drugs which elicit significant tumor reduction yet limit toxicity in 
healthy tissue.  Current administration methods assume that chemotherapy 
combinations at maximum tolerable doses will provide the greatest therapeutic 
effect – a presumption which often leads to unprecedented side effects.  Contrary to 
traditional administration, we have found that drug ratios rather than total 
cumulative doses govern combination therapeutic efficacy.  In this thesis, we have 
developed nanoparticles to incorporate synergistic ratios of chemotherapy 
combinations which significantly inhibit cancer cell growth at lower doses than 
would be required for their single drug counterparts. 
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 The advantages of multi-drug incorporation in nano-vehicles are many: 
improved accumulation in tumor tissue via the enhanced permeation and retention 
effect, limited uptake in healthy tissue, and controlled exposure of tumor tissue to 
optimal synergistic drug ratios.  To exploit these advantages for polychemotherapy 
delivery, two prominent nanoparticles were investigated: liposomes and polymer-
drug conjugates.  Liposomes represent the oldest class of nanoparticles, with high 
drug loading capacities and excellent biocompatibility.  Polymer-drug conjugates 
offer controlled drug incorporations through reaction stoichiometry, and potentially 
allow for delivery of precise ratios.  Here, we show that both vehicles, when armed 
with synergistic ratios of chemotherapy drugs, significantly inhibit tumor growth in 
an aggressive mouse breast carcinoma model.  Furthermore, versatile drug 
incorporation methods investigated here can be broadly applied to various agents.  
Findings from our research can potentially widen the therapeutic window of 
chemotherapy combinations by emphasizing investigations of optimal drug ratios 
rather than maximum drug doses and by identifying appropriate nanoparticles for 
their delivery.   Application of these concepts can ultimately help capture the full 
therapeutic potential of combination regimens.  
x 
 
TABLE OF CONTENTS 
Acknowledgements........................................................................................................iv 
Vita.................................................................................................................................vi 
Abstract........................................................................................................................viii 
List of Figures..............................................................................................................xiii 
List of Abbreviations.....................................................................................................xv 
 
1. Introduction ............................................................................................................... 1 
1.1. Cancer Therapies .................................................................................................. 1 
1.2. Organization of the Dissertation ......................................................................... 2 
1.3.  Current clinical chemotherapy combinations .................................................... 3 
1.4. Multi-Drug Delivery Carriers .............................................................................. 8 
1.5. Engineering combination chemotherapies ....................................................... 10 
 
2. Experimental Methods ............................................................................................ 12 
2.1. Cell culture ......................................................................................................... 12 
2.2. In vitro cell growth inhibition studies .............................................................. 12 
2.3. Synergy assessment, the Combination Index method ...................................... 14 
2.4. Confocal microscopy ......................................................................................... 15 
2.5. Apoptosis studies ............................................................................................... 16 
2.6. Liposome Fabrication........................................................................................ 16 
2.7. Nanoparticle characterization ............................................................................ 17 
2.8. Liposome cancer cell growth inhibition ........................................................... 18 
2.9. Drug release ....................................................................................................... 18 
2.10. In vivo antitumor efficacy and toxicity ........................................................... 19 
2.11. Statistical analyses ........................................................................................... 20 
 
3. Synergistic Chemotherapy Pairs .............................................................................. 21 
3.1.  Defining synergy ............................................................................................... 21 
3.2. Single chemotherapy anticancer efficacy .......................................................... 22 
3.3. Synergy search ................................................................................................... 25 
xi 
 
3.4. Dependence of synergy on drug ratio ............................................................... 28 
3.5. Mechanistic study of 5FU and DOX enhanced cancer cell kill ......................... 36 
3.6. Topoisomerase inhibitor combination.............................................................. 41 
3.7. Mechanistic study of CPT and DOX enhanced cancer cell kill ......................... 48 
3.8. Summary of chemotherapy combination studies ............................................. 51 
 
4. Liposomes for combination chemotherapy co-delivery.......................................... 54 
4.1. Advantages of liposomes ................................................................................... 54 
4.2. Our approach for chemotherapy co-delivery .................................................... 56 
4.3. Effect of cationic charge on liposomal DOX activity ........................................ 58 
4.4. Synthesis of 5FU analogues for liposome entrapment ..................................... 62 
4.5. Liposome encapsulation of 5FU analogues ...................................................... 66 
4.6. Synergistic activity of 5FURW and DOX ........................................................... 71 
4.7. Co-encapsulation of 5FURW and DOX in liposomes ....................................... 73 
4.8. In vivo efficacy of 5FURW and DOX co-loaded liposomes .............................. 78 
4.9. Summary of liposomes for synergistic chemotherapy delivery ........................ 86 
 
5. Polymer-drug conjugates for chemotherapy co-delivery ........................................ 89 
5.1. Advantages of polymer-drug conjugates ........................................................... 89 
5.2. CPT- and DOX-PVA conjugates ........................................................................ 90 
5.3. CPT- and DOX- conjugated to HA .................................................................... 95 
5.4. Synergy of CPT- and DOX-conjugated HA ..................................................... 102 
5.5. In vivo antitumor efficacy of CPT-HA-DOX ................................................... 106 
5.6. CPT-HA-DOX tolerability in vivo .................................................................... 110 
5.7. Summary of HA-conjugates for synergistic combinations delivery ................ 113 
 
6. Impact of nano-carrier properties on therapeutic efficacy .................................... 115 
6.1. Physical and chemical properties of nano-carriers .......................................... 115 
6.2. Low molecular weight polymer-drug conjugates ............................................ 116 
6.3. Polymer-drug chemical linkers ....................................................................... 123 
6.4. Mass transport across lipid bilayer of liposomes ........................................... 130 
xii 
 
6.5. Nanoparticle stability ...................................................................................... 140 
6.6. Summary of nanoparticle property effects ..................................................... 142 
 
7. Reflections and Future Directions ......................................................................... 145 
7.1. Challenges with multi-drug delivery ............................................................... 145 
7.2. Comparison of liposomes and polymer-drug conjugates ............................... 148 
7.3. New methodology for developing combination chemotherapy nano-vehicles .... 
 ................................................................................................................................. 151 
7.4. Extension of our approach .............................................................................. 153 
 
References ...................................................................................................................155 
 
  
xiii 
 
LIST OF FIGURES 
Figure 1.1. Schematic of the enhanced permeability and retention (EPR) effect.. 4 
Figure 1.2. Proposed nanoparticle co-delivery of combination chemotherapy.... 7 
Figure 3.1.  Effect of incubation time on DOC dose-effect reproducibility........... 23 
Figure 3.2. In vitro cancer cell growth inhibition of single chemotherapy drugs. 25 
Figure 3.3. Synergy assessment for drugs combined in equal potencies.............. 27 
Figure 3.4. Synergy assessment for 5FU+DOX combined at various R................ 30 
Figure 3.5. In vitro cytotoxicity of 5FU+DOX in cancerous and healthy cells..... 32 
Figure 3.6. D50 ratios for BT-474 relative to MCF 10A.......................................... 34 
Figure 3.7. ROS detection in 5FU+DOX treatments............................................. 38 
Figure 3.8. Top I + Top II inhibitors synergy screen............................................. 44 
Figure 3.9. CPT+DOX interactions in 4T1 and bEnd.3 cells................................. 47 
Figure 3.10. Apoptotic assessment of CPT+DOX-treated cancer cells................. 50 
Figure 4.1. Phospholipid and liposome schematic................................................ 55 
Figure 4.2. Mechanism for loading DOX into liposomes...................................... 57 
Figure 4.3. Cell inhibitory effects of DOX-L or +DOX-L....................................... 60 
Figure 4.4. DOX internalization post-incubation with DOX, DOX-L or +DOX-
L.............................................................................................................................. 61 
Figure 4.5. Characterization of 5FU analogues...................................................... 66 
Figure 4.6. CIs for 5FUR+DOX, 5FURW+DOX, and 5FURW-L+DOX-L............ 72 
Figure 4.7. In vitro anticancer activity of 5FURW and DOX co-loaded 
liposomes................................................................................................................ 77 
Figure 4.8. Tumor growth inhibition of syn-L.................................................. 79 
xiv 
 
Figure 4.9. Tumor growth inhibition of 7 injections of DAFODIL........................ 81 
Figure 4.10.  Tumor growth inhibition of 4 injections of DAFODIL..................... 83 
Figure 4.11.  Tumor growth profiles of mice treated with DAFODIL.................... 84 
Figure 5.1. Cell inhibitory effects of CPT-PVA or DOX-PVA................................. 92 
Figure 5.2. Anticancer activity of CPT-PVA + DOX-PVA and CPT-PVA-DOX..... 94 
Figure 5.3. Cell inhibitory effects of CPT-HA or DOX-HA.................................... 97 
Figure 5.4.  Internalization of HA, CPT-HA, or DOX-HA..................................... 99 
Figure 5.5 CPT or DOX release from HA-conjugates............................................ 1o2 
Figure 5.6. Anticancer activity of CPT-HA + DOX-HA and CPT-HA-DOX.......... 103 
Figure 5.7. Activity of CPT-HA + DOX-HA and CPT-DOX-HA against murine 
4T1 breast carcinoma cells..................................................................................... 106 
Figure 5.8.  Tumor growth inhibition of CPT-HA-DOX or CPT+DOX................ 108 
Figure 5.9. Histology analysis of excised tissues post-treatments........................ 111 
Figure 6.1. In vitro cancer cell inhibition of 10kDa CPT-HA-DOX....................... 118 
Figure 6.2.  Tumor growth inhibition of 10kDa CPT-HA-DOX............................ 122 
Figure 6.3. The impact of various PVA-drug linkers on drug activity and 
internalization........................................................................................................ 127 
Figure 6.4. In vitro anticancer activity of CPT-PVA-DOX with non-
hydrolyzable and hydrolyzable linkers................................................................... 129 
Figure 6.5. 1-D model of drug diffusion through intra-liposomal space............... 131 
Figure 6.6.  Effect of membrane properties on liposomal drug release................ 137 
Figure 6.7.  Effect of nanoparticle age on cancer cell cytotoxicity......................... 141 
 
xv 
 
LIST OF ABBREVIATIONS 
5FU 5-Fluorouracil 
5FUG 1-[(aminomethyl)-ester]methylene-5-fluorouracil 
5FUR 5-Fluorouridine 
5FURW Tryptophan 5-fluorouridine ester 
5FUW Tryptophan 5-fluorouracil ester 
Boc-glycine N-(tert-Butoxycarbonyl)glycine 
Chol Cholesterol 
CI Combination index 
CPT Camptothecin 
CPT-11 Irinotecan 
D Diffusivity 
D50 Concentration which inhibits 50% cell growth 
Da Dalton 
Da1, Da2 Damköhler numbers 
DCM Dichloromethane 
DIC N,N′-Diisopropylcarbodiimide 
DOC Docetaxel 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane 
DOX Doxorubicin 
DMAP 4-(dimethylamino)pyridine 
DMEM Dulbecco's modified eagle's medium 
DMSO Dimethyl sulfoxide 
DSPC 1,2-Distearoyl-sn-glycero-3-phosphocholine 
EDC N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride 
EPR Enhanced permeability and retention 
FBS Fetal bovine serum 
FdUMP 5-fluorodeoxyuridine monophosphate 
FUMP 5-fluorouridine monophosphate 
GEM Gemcitabine 
H&E Hematoxylin and eosin 
xvi 
 
HA Hyaluronic acid 
HMFU Hydroxymethyl-5-fluorouracil 
HPMA N-(2-hydroxypropyl)methacrylamide 
i.v. Intravenous 
J Mass flux 
kb Reverse reaction rate 
kf Forward reaction rate 
km Lipid membrane permeability 
LAP Lapatinib 
MEBM Mammary epithelial basal medium 
mPEG-DSPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] 
MTD Maximum tolerable dose 
MW Molecular weight 
MWCO Molecular weight cut off 
NMWL Nominal molecular weight limit 
PEG Polyethylene glycol 
ppt Precipitate 
PVA Poly(vinyl alcohol) 
R Molar ratio of drugs combined, in alphabetical order 
RPMI Roswell Park memorial institute medium 
S-PVA Succinylated poly(vinyl alcohol) 
s.c. Subcutaneous 
t1/2,R Time for half of drug to release 
τL Residence time of one DOX molecule in liposome 
Tm Phase transition temperature of lipid membrane 
TFA Trifluoroacetic acid 
Top I/II Topoisomerase I/II 
TPT Topotecan 
 
  
1 
 
Chapter 1 
Introduction 
1.1. Cancer Therapies 
 Of the most common cancer treatments, chemotherapy unmistakably bears 
the greatest stigma. Surgery removal is often associated with high success rates, 
particularly when the cancer is confined to a primary tumor and can be easily located 
[1].  Radiation therapy can be honed in to only expose tumors to high energy beams, 
rendering  the procedure effective at killing cancer cells and relatively painless to 
other areas of the body [2].  Chemotherapy, however, is at best described by the 
American Cancer Society as "strong drugs to treat cancer" [3], which is a slight 
euphemism for the reality: drugs which indiscriminately inhibit the growth of cells, 
be them cancerous or healthy, and often cause adverse side effects.  Because of this 
inability to differentiate between which cells to kill, chemotherapy is often used 
when surgery or radiation alone is insufficient to treat the cancer.  However, if 
chemotherapy were engineered in such a fashion to only destroy cancer cells and 
leave healthy cells unscathed, side effects would be diminished and chemotherapy 
may be just as potent of a therapeutic, if not more, than radiation or surgery. This is 
the motivation which drives thousands of labs, academic or industrial, private or 
public, across many disciplines and countries – the Mitragotri lab at UCSB being no 
exception. Where our lab has made our mark, specifically where my Ph.D. research 
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has aimed to contribute to this enormous field, is in the simultaneous delivery of 
multiple chemotherapy drugs to tumors. 
 
1.2. Organization of the Dissertation 
 This dissertation explains the advantages of multi-chemotherapy treatment 
regimens, pitfalls in current chemotherapy combinations, and novel strategies we 
have developed to capture the therapeutic potential of potent chemotherapy 
combinations in animal models.  In particular, we explore nanoparticles which can 
incorporate two chemotherapy agents, and can passively accumulate in tumor tissue 
by escaping blood circulation through tumor endothelium's characteristic leaky 
pores, known as the enhanced permeability and retention (EPR) effect [4, 5]. In 
Chapter 3, we present pairs of chemotherapy drugs which demonstrate high activity 
against cancer cell growth in vitro, and serve as model pairs for concurrent tumor 
delivery in subsequent studies.  In Chapter 4, we explore the oldest chemotherapy 
nanoparticle vehicle, liposomes, and apply it to the delivery of potent drug pair 5-
fluorouracil and doxorubicin. We then exploit a relatively new chemotherapy vehicle, 
polymer-drug conjugates, in Chapter 5, for the concurrent delivery of camptothecin 
and doxorubicin to 4T1 mammary tumors in mice.  Chapter 6 addresses other 
nanoparticle properties apart from drug payload which vastly impact drug uptake 
into cells, and hence influence therapeutic efficacy. 
 Collectively, our studies expose the complexities of multi-drug delivery, 
elucidate the advantages and disadvantages of each nano-vehicle for clinical 
applicability, and provides a methodology for designing potent combination 
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chemotherapy therapeutics. While our work here focused on specific chemotherapy 
pairs and two major types of drug vehicles, the information gathered has allowed us 
to develop a multi-drug delivery approach which can be applied to different classes 
of chemotherapy agents and various vehicles. We hope that our findings can be 
absorbed and applied by other drug delivery and cancer researchers, in hopes to 
facilitate in the design of more effective and less formidable cancer therapeutics. 
 
1.3.  Current clinical chemotherapy combinations 
 Chemotherapy combinations have been clinically tried since the 1960s, and 
were initially inspired by the success of polychemotherapy in treating drug-resistant 
strains of tuberculosis [6, 7].  The "Holy Grail" of chemotherapy combinations 
promises a multi-mechanistic approach at killing malignant cells to treat the 
metastatic and chemotherapy-resistant cancers which single chemotherapy  agents 
often fail at. Yet current clinical trials show mixed results.  Some combinations are  
in  fact  more  potent  than  single  agents,  but  many  are  merely  comparable  or  
even  less effective at prolonging cancer patient survival [8-12].  Often the 
combinations are associated with greater side effects [13], likely due to amplified 
toxicity in healthy tissues where both drugs accumulate.  Despite the prevalence of 
multi-chemotherapy regimens in cancer therapies, there is a stark lacking of true 
success stories which consistently halt tumor progression and prolong patient 
survival.  Inherently, this begs the question if there is true merit to their use in the 
clinic.  Fundamentally, however, the poor efficacy and heightened toxicity of 
combinations pose two questions: 1. Are two drugs truly better than one at inhibiting 
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cancer growth? and 2. Is it possible to avoid augmented side effects with 
combinations?  During the course of my Ph.D., I've aimed to address both questions, 
utilizing in vitro drug screens against cancer cells for the former, and engineering 
safe drug delivery vehicles for the latter. 
 
Figure 1.1. Schematic of the enhanced permeability and retention (EPR) effect. 
 
Tumor vasculature, highlighted on the right, is characteristically leaky due to the wide 
fenestrae present between poorly aligned endothelial cells (red), a phenomena which occurs 
due to rapid angiogenesis.  Nanoparticles (green) below 200 nm in diameter can passively 
escape blood circulation through these pores to access tumor tissue.  On the contrary, healthy 
tissue consists of highly organized endothelium, whose tight junctions only small molecules 
(black) can diffuse through.  Therefore, freely circulating small molecule chemotherapy drugs 
can passively accumulate in both healthy and malignant tissue, whereas nanoparticles 
preferentially localize in tumors. 
 
 
 The criteria which typically govern whether two chemotherapy agents are 
combined for clinical testing are if the drugs demonstrate some tumor reduction 
capabilities when used alone, and if their anticipated side effects do not overlap.  If 
yes to both, the two drugs are considered a sound candidate for clinical trials.  
However, neither of these criteria guarantee that the combination will elicit better 
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tumor inhibition.  Although drugs from different classes attack cancer cell growth via 
different mechanisms, unprecedented drug interactions can lead to antagonistic, 
additive, or synergistic cancer inhibition, which lead to reduced, identical, or 
enhanced therapeutic efficacy, respectively, with respect to the individual drugs.  
Because drug interactions are difficult to predict, these interactions are currently 
best studied empirically, in a petri dish of isolated cancer cells. Thus, the first efforts 
of my Ph.D. focused on identifying drug pairs which synergistically inhibit cancer 
cell growth in vitro.  Even if drugs are more effective at inhibiting cancer cell growth 
in vitro, however, they may not necessarily perform the same in vivo. 
 Drugs of various classes possess unique chemical and physical properties, 
which govern their clearance and metabolization in the body. Hence, two drugs 
injected in free solutions will not necessarily co-localize in tumor tissue, and may not 
be able to simultaneously attack the cancer cells with multiple cell death 
mechanisms.  For example, doxorubicin (DOX) and camptothecin (CPT) are both 
topoisomerase enzyme inhibitors, but their chemical structures differ in that DOX is 
an anthracycline and CPT is a quinone alkaloid.  DOX has been reported to exhibit a 
clinical half life of 4 minutes [14], whereas that of CPT is much longer, 71-90 minutes 
[15].  Thus, their biodistribution to various tissues, not excluding the tumor, may 
vary drastically. Often clinical combinations are administered sequentially in order 
to avoid simultaneous occurrences of side effects, but this may also prevent 
concurrent drug delivery to tumors and potentially reduce combination therapeutic 
efficacy.  It is noteworthy that the order of drugs as well as dose schedule can 
influence therapeutic efficacy [16-18], but only concurrent drug exposures were 
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considered herein, and the main focus was to identify synergistic drug ratios. 
Concurrent polychemotherapy delivery is not typically tried clinically, and is limited 
due to the presence of adverse side effects. 
 To overcome treatment-related side effects, nanoparticles have been utilized 
as a superior delivery alternative to free drug solutions. Unlike drug molecules which 
are small enough to diffuse through capillary walls into tissues, nanoparticles 
ranging between 10 nm and 200 nm in size can only passively diffuse into tissue 
through large pores in the endothelial wall [19].  Thus, tumor tissues which exhibit 
disordered blood vessel structure and leaky endothelial walls tend to passively 
uptake nanoparticles; furthermore, their poor lymphatic drainage prevents leakage 
of nanoparticles once accumulated [4, 20]. This phenomena is known as the 
enhanced permeability and retention effect (EPR) and is schematically demonstrated 
in Figure 1.1.   Nanoparticles carrying chemotherapy payloads will hence allow the 
preferential accumulation of drugs in tumors.  Moreover, nanoparticles can 
encapsulate and protect drugs from quickly becoming cleared from circulation or 
from metabolization into inactive forms.  Drug clearance occurs within minutes from 
intravenous administration, owing to their small size and filtration through the 
kidneys.  Nanoparticles, however, can be engineered to larger sizes than the renal 
filtration cutoff (~5nm) [21], and can instead act as a drug depot which slowly 
releases the drug and prolongs its circulation.  DoxilTM, for example, is a liposomal 
formulation of DOX which extends the drug's elimination half life from 4 minutes in 
its free form to 3 hours [14].  Longer drug circulation allows for greater number of 
passes through tumor endothelium, and more chances to escape and treat tumor 
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tissue.  Hence, nanoparticles are multifunctional drug carriers which can not only 
prevent drug accumulation in healthy tissue, but can also direct therapies to tumors 
and, as a result, potentiate therapeutic efficacy while also reducing side effects. 
 
 
Figure 1.2. Proposed nanoparticle co-delivery of combination chemotherapy. 
 
Conventional combination chemotherapy administration (left) involves infusions or bolus 
injections of drugs in free solution, often sequentially.  Differences in drug pharmacokinetics 
result in distinct biodistributions and varied uptake in tumors.  In contrast, the proposed 
nanoparticle co-delivery of polychemotherapy (right) encapsulates multiple drugs in a single 
carrier, unifies drug pharmacokinetics and ensures concurrent arrival in tumors.  Hence, the 
administered drug ratio is also the ratio which is exposed to the tumor.  Adapted from [23]. 
 
 Nanoparticles for the concurrent delivery of multiple chemotherapy drugs is a 
particularly promising and burgeoning area of research [22].  Co-encapsulation of 
multiple drugs in a single nanoparticle will unify their pharmacokinetics and ensure 
simultaneous arrival in tumors (Figure 1.2).  Nanoparticles can also alleviate the 
amplified toxic side effects associated with polychemotherapy by preventing 
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immediate drug distribution to healthy tissues. Thus, multi-drug loaded 
nanoparticles have the potential to both improve the survival rates and quality of life 
of patients treated with polychemotherapy. 
 
 
1.4. Multi-Drug Delivery Carriers 
 Traditional nanoparticles which have been investigated for chemotherapy 
delivery are composed of three main materials: lipids, polymers, or organometallic 
compounds [20].  Of the three, lipid- and polymer-based particles have had the most 
prevalence clinically due to their biodegradability and safety, and have also been the 
most investigated for multi-drug encapsulations.  Liposomes in particular have had 
the most clinical success in delivering multiple chemotherapy drugs.  They consist of 
phospholipids which self-assemble to form an aqueous core surrounded by a lipid 
bilayer membrane, so multiple hydrophilic drugs can be trapped inside. Drugs can 
either be incorporated during liposome self-assembly, or post-fabrication by crossing 
the lipid bilayer and retaining in the inner aqueous environment.  Celator 
Pharmaceuticals currently has three multi-drug loaded liposomes in clinical trials 
against various cancers.  One formulation, CPX-351, achieves a 5:1 ratio of 
cytarabine and daunorubicin by incorporating cytarabine during liposome 
fabrication and daunorubicin post-fabrication. CPX-351 was able to elicit a whopping 
9 complete responses of 43 patients with acute myeloid leukemia in Phase I clinical 
trials with acceptable tolerability, and is currently in ongoing Phase III trials [24].  
Although this particular formulation has been met with great success, it is unclear 
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whether the same encapsulation methods can be universally applied to other 
chemotherapy combinations. 
 Polymeric nanoparticles are widely utilized for multi-drug delivery, owing to 
the versatile drug incorporation methods.  Drugs can either be physically absorbed 
inside a polymeric nanoparticle, governed by hydrophobic-hydrophilic interactions, 
or chemically conjugated to functional groups on the polymeric backbone.  One key 
advantage of polymeric nanoparticles over liposome-based carriers is controlled 
incorporation through reaction stoichiometry.  In pre-clinical studies, gemcitabine 
(GEM) and DOX were co-conjugated to N-(2-hydroxypropyl)methacrylamide 
(HPMA) and were more potent at inhibiting tumor growth compared to their free 
drug counterparts [25].  HPMA conjugated to GEM and DOX were not able to 
completely eradicate the tumor, but the drug pair was not optimized to 
synergistically inhibit cancer cells in this study.  Although polymeric nanoparticles 
carrying multiple chemotherapy agents have not entered clinical trials, polymer-drug 
conjugates bearing single drugs are in ongoing trials, and implicate the potential of 
these vehicles for improving polychemotherapy delivery. 
 Regardless of the nanoparticle type, the ultimate test for their applicability for 
multi-chemotherapy delivery is their ability to incorporate synergistic drugs.  Multi-
drug delivery only bears merit if the drugs enhance each others' potencies; 
otherwise, it's not economical or time-efficient to incorporate another drug which, at 
best, elicits the same survival rate as either of the individual drugs.  It is also likely 
that the added drug will cause more adverse side effects, a sacrifice which may only 
be validated if therapeutic efficacy were significantly improved.  However, drug 
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encapsulation may not easily be controlled, especially if one drug prefers conjugation 
or physical entrapment more than the other due to differences in chemical 
properties.  Therefore, synergistic drug incorporation is a non-trivial feat, and it is 
not currently clear which particle type is more advantageous for these purposes. 
 
1.5. Engineering combination chemotherapies 
 The approach we adopted to develop safe and effective chemotherapy 
combination delivery methods was to first empirically identify drug pairs which 
synergistically inhibit cancer cell growth, and to further encapsulate the model 
combinations in nanoparticles which can passively accumulate in tumors. Only 
drugs from different chemotherapy classes were assessed for synergistic cancer cell 
kill, in order to simultaneously attack different pathways of cell proliferation.  Two 
nanoparticles were investigated for combination chemotherapy co-delivery, 
liposomes and polymer-drug conjugates.  While liposomes are more conventional 
nanoparticles, water soluble polymers can exhibit hydrodynamic radii between tens 
and hundreds of nanometers to surpass kidney filtration and exploit the EPR effect 
[26, 27], thereby also classifying as nanoparticles.  Liposomes typically encapsulate 
drugs through passive techniques, while polymer-drug conjugates incorporate drugs 
through chemical conjugation.  Both types of nanoparticles have been shown to 
encapsulate high single drug payloads, and have demonstrated clinical efficacy at 
reducing tumor progression [28-30].  Herein, we elucidate their potential for 
combination chemotherapy delivery, while also uncovering disadvantages to each. 
Particular emphasis is given towards the applicability of each vehicle for various 
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classes of chemotherapy agents.  A plethora of chemotherapy combinations have 
been investigated clinically, and even more pre-clinically; however, to advance these 
promising regimens forward to successful therapies, multi-drug delivery carriers 
which can be universally applied to drugs of various classes must be developed. 
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Chapter 2 
Experimental Methods 
2.1. Cell culture: All cell lines were purchased from ATCC (Manassas, VA, USA) 
and grown in a humidified incubator maintained at 5% CO2 at 37˚C.  BT-474 human 
breast cancer cells were cultured in Hybri-Care medium (ATCC) supplemented with 
10% fetal bovine serum (FBS) , and 4T1 murine breast carcinoma cells were cultured 
in RPMI-1640 medium supplemented with 2.05 mM L-glutamine, 10% FBS and 1% 
penicillin/streptomycin. Murine brain endothelial cell line bEnd.3 was cultivated in 
DMEM medium supplemented with 4 mM L-glutamine, 4500 mg/L glucose, 1 mM 
sodium pyruvate, 1500 mg/L sodium bicarbonate (ATCC), 10% FBS and 1% 
penicillin/streptomycin. MCF 10A human breast epithelial cells were cultured in 
MEBM basal medium supplemented with 2 mL bovine pituitary extract, 0.5 mL 
hydrocortisone, 0.5 mL human epidermal growth factor, and 0.5 mL insulin, all of 
which were obtained from Lonza Walkersville Inc. (Walkersville, MD, USA).  All 
other medium and medium supplements, unless otherwise noted, were obtained 
from Thermo Scientific (Waltham, MA, USA). 
 
2.2. In vitro cell growth inhibition studies: To assess drug effects on cell 
proliferation, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 
Life Technologies, Carlsbad, CA, USA) in vitro cell cytotoxicity assays were utilized.  
When living cells internalize MTT, they convert MTT to an insoluble formazan.2-4 
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dye.  Thus the amount of living cells scales linearly with the intensity of the dye.  The 
MTT protocol is as follows: In a 96-well plate, specified cell concentrations were 
mounted in a total volume of 100 µL full cell culture media/well and allowed to 
adhere overnight.  For BT-474, bEnd.3, and MCF 10A studies, the initial cell seeding 
density was 1.0 x 104 cells/well.  For 4T1 cytotoxicity studies, the cell seeding density 
was 1.0 x 103 cells/well. The media was then replaced with fresh media containing 
drug, nanoparticles, or drug-loaded nanoparticles.  The cells were incubated with 
drug and/or nanoparticle solutions for designated times at 37°C and 5% CO2.  BT-
474, bEnd.3, and MCF 10A cells were incubated with agents for 72 hours, whereas 
4T1 cells were incubated for 48 hours.  Initial cell concentrations and drug 
incubation times were chosen such that untreated cells reached 70% confluency after 
the designated time period.  Afterwards, the media was replaced with 0.5 mg/mL 
MTT in media and returned to 37°C and 5% CO2 for 4 hours.  Media was then 
replaced with 100% dimethyl sulfoxide (DMSO) to solubilize intracellularly reduced 
MTT (formazan crystals), and formazan dye intensity was determined by absorbance 
measured at 570 nm in a Tecan Infinite M200 Pro plate reader (Mӓnnedorf, 
Switzerland).  The fraction of inhibited cell growth, also known as fractional cell 
inhibition, was calculated by subtracting absorbance of live cells in experimental 
wells from that of control cells and normalizing against control cells. Experimental 
data was fit to the Median Effect (ME) model (Equation 2.1) developed by T.C. Chou 
and P. Talalay [31], 
(2.1) 
fi
fu
=   
D
D50
 
m
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where fi and fu refer to fraction of cells inhibited and uninhibited, respectively, m 
dictates the shape of the drug dose-cell inhibition (also known as "dose-effect") 
relationship, D is the drug concentration which elicits fi cell growth inhibition and 
D50 is the drug concentration required to inhibit 50% cell growth. D50 and m were 
derived for each drug by fitting experimental D, fi values to linearized Equation 2.1 
via linear regression analysis. 
 
2.3. Synergy assessment, the Combination Index method: T.C. Chou and P. 
Talalay's Combination Index (CI) method was adopted to identify synergistic 
chemotherapy pairs.  The CI is defined in Equation 2.2: 
(2.2) 
Dx,1 and Dx,2 represent doses of drug 1 and 2, respectively, which inhibit x% cell 
growth when used alone.  On the other hand, D1 and D2 are the combination doses of 
drug 1 and drug 2, respectively, which also inhibit x% cell growth.  Hence, the CI can 
be considered as the dose reduction achieved by combining the drugs compared to 
their single drug administration.  A CI of less than 1 indicates synergy, a CI equal to 1 
denotes the additive effect, and a CI greater than 1 occurs if the drugs are 
antagonistic.  Graphs representing CI often include a solid black line which 
represents additivity (CI=1) in order to help visualize these regimes of interactions.  
To find Dx,1 and Dx,2 for CI evaluation, the dose D of each drug must be defined as a 
function of inhibition, x.   For this, the ME model (Equation 2.1) determined for each 
individual drug was utilized, where x is simply fraction cell growth inhibition, fi.  
CI =  
D1
Dx,1
+
D2
Dx,2
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2.4. Confocal microscopy: Confocal laser scanning microscopy was utilized to 
visualize cells and any fluorescent markers, such as, but not limited to, internalized 
fluorescent drugs.  Cells were seeded at a density of 80,000 cells per 300 μL media 
in a Nunc Lab-Tek 8-well chambered borosilicate coverglass (Thermo Scientific; 
Waltham, MA, USA), and were allowed to adhere overnight.  Post-treatment with 
indicated fluorescent drugs, nanoparticles, or other specified markers, cells were 
washed twice with warmed PBS (pH 7.4), followed by staining with nuclear dyes at 
37˚C, 5% CO2.  In the case of DOX-exposed cells, Hoechst nuclear dye was utilized at 
a concentration of 25 μg/mL for 30 minutes.  For CPT-exposed cells, to avoid overlap 
fluorescence between CPT and nuclear marker, DRAQ5 was used to stain nuclei at a 
concentration of 5 μM in media for 60 minutes.  Cells were washed twice more in 
warmed PBS and finally suspended in media immediately prior to imaging.  All cells 
were imaged live with an Olympus Fluoview 1000 spectral confocal equipped with a 
60X silicon oil objective and a 37˚C temperature-controlled imaging chamber.  DOX, 
fluorescein, CPT, Hoechst and DAPI were excited with the following lasers: 488 nm 
10 mW Argon gas (DOX or fluorescein), 405 nm 50 mW diode (CPT or Hoechst), 
and 635 nm 20 mW diode (DRAQ5).  For general oxidative stress detection studies, 
carboxydichlorofluorescein and DOX were both excited utilizing a 488 nm 10 mW 
Argon gas laser and visualized with 492-560 nm and 574-674 nm optical filters, 
respectively.  Z-stacks of 10 μm were captured and subsequently analyzed with 
ImageJ 1.47h software (NIH).  Each z-stack was collapsed into an averaged image, 
and fluorescence intensity was reported as the raw integrated density divided by 
number of cells.  An average of 25 cells was imaged in each field view.  Where 
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provided, images are representative of all samples in the experimental group, and 
are shown as averaged z-stacks. 
 
2.5. Apoptosis studies: Apoptosis assessment was made based on Annexin V and 
Sytox Green counterstaining.  Studies followed the Life Technologies Apoptosis 
Assay protocol, with few modifications tailored to BT-474 cells.  Briefly, cells were 
seeded at a concentration of 100 x 104 cells per 25 cm2 cell culture flask in a total 
volume of 10 mL media, and allowed to adhere overnight.   Cells were exposed to 
drug solutions for 72 hours, as previously described.  After drug exposure, adherent 
and floating cells were harvested at a concentration of 1 x 106 cells/mL in Annexin V 
binding buffer, and 200 μL of each sample were incubated with 5 μL of Annexin V-
647 and 1 μL of 1 μM Sytox Green.  After 15 minutes of dye incubation, cells were 
diluted 5X in ice cold Annexin V Binding Buffer, and immediately analyzed via flow 
cytometry in a Becton Dickinson FACSAria cell sorter (Franklin Lakes, NJ, USA).  To 
quantify Annexin V-647 and Sytox Green fluorescence, a 633 nm laser with 660 PMT 
and a 488 nm laser with 530 PMT, respectively, were utilized.  Cells gated as –AV/-
SG were live, cells with +AV/-SG were pre-apoptotic, and cells gated as +AV/+SG 
were either late apoptotic or necrotic. 
 
2.6. Liposome Fabrication:  Liposomes were fabricated utilizing the 
conventional thin film evaporation method [32], and all lipids were purchased from 
Avanti Polar Lipids (Alabaster, Alabama, USA).  Specified lipids were co-dissolved in 
chloroform and methanol in a round-bottom flask, and organic solvent was removed 
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using a Buchi R-210 rotary evaporator at reduced pressure and 60˚C (5˚C above the 
lipid transition temperature) in order to form a thin lipid film.  The film was 
subsequently hydrated in 250 mM ammonium sulfate at 60˚C to form large 
multilamellar vesicles.  Small, monodisperse vesicles were produced by passing 
vesicles 21 times through an extruder (Avestin LiposoFast Extruder) with 100 nm 
polycarbonate filters.  A transmembrane ammonium sulfate gradient was generated 
by passing the liposomes through a Sephadex G-25 PD-10 size exclusion column of 
molecular weight cut off (MWCO) 5000 Da (GE Healthcare Life Sciences; 
Piscataway, NJ, USA) equilibrated with PBS (pH 7.4) [45].  DOX was encapsulated 
by incubation with liposomes after generation of the transmembrane ammonium 
sulfate gradient for 30 minutes at 65ºC.  5FU encapsulation methods are reported in 
the respective sections of Chapter 4. To remove free drug, liposomes were finally 
passed through a Sephadex G-25 PD-10 column. 
 To measure drug encapsulation, 50 µL of drug-loaded liposomes were 
dissolved in 950 µL methanol through vortexing and sonication.  The dissolved 
liposomes were centrifuged at 12000 g for 20 minutes to allow the lipids to pellet.  
The supernatant was collected, diluted serially, and their absorbances were 
measured at 480 nm, 266nm,  264 nm, 268 nm, 268 nm, and 394 nm to quantify 
DOX, 5FU, 5FUG, 5FUW, 5FUR, and 5FURW concentrations, respectively.   
 
2.7. Nanoparticle characterization: Nanoparticle sizes and ζ potentials were 
determined utilizing dynamic light scattering and electrophoretic light scattering, 
respectively, on a Malvern ZetaSizer Nano ZS.  Samples were diluted at minimum 
18 
 
100X in distilled de-ionized water immediately prior to analysis, and each 
measurement is reported as an average of 3 independent sets of at least 13 runs each 
± SD. 
 
2.8. Liposome cancer cell growth inhibition: In vitro anticancer efficacy of 
drug-loaded liposomes was determined via calcein-AM cell viability assay.  Cells 
were seeded overnight as described in Section 2.2, followed by liposome incubation 
with fresh media.   Post-incubation with liposomes, media was aspirated and 
replaced with 1 µM calcein-AM in PBS for 30 minutes at room temperature.  
Fluorescence intensity of intracellularly hydrolyzed calcein-AM was measured using 
excitation and emission wavelengths of 490 nm/520 nm.  Fractional cell inhibition, 
fi, was calculated by subtracting fluorescence of live cells in experimental wells from 
those of untreated cells and normalizing against untreated cells.  D50 and m were 
derived for each drug by fitting experimental D, fi values to linearized Equation 2.1 
(ME model) via linear regression analysis. 
 
2.9. Drug release:  Drug release of drugs from drug-loaded nanoparticles was 
achieved utilizing Slide-A-Lyzer MINI Dialysis Devices of 10,000 MWCO (Life 
Technologies, Grand Island, NY).  Drug-loaded nanoparticles were placed in dialysis 
cups with fresh PBS buffer (pH 7.4), and were inserted into microcentrifuge tubes 
containing 1 mL PBS.  Dialysis devices were placed at 37˚C and allowed to shake at 
100 RPM.  At indicated time points, concentrations of drug in the medium 
surrounding the dialysis cup were determined via absorbance.  External PBS buffer 
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was replenished at each time point.  Drug release was fit to exponential release 
profiles in order to estimate time required for half of the drug to release, indicated by 
t1/2,R. 
 
2.10. In vivo antitumor efficacy and toxicity: A mouse 4T1 breast tumor 
model was utilized to evaluate in vivo tumor reduction by combination 
chemotherapy formulations.  All experiments were performed according to approved 
protocols by the Institutional Animal Care and Use Committee of the University of 
California, Santa Barbara.  Six to eight week old female BALB/c mice were purchased 
from Charles River Laboratories (Wilmington, MA, USA).  Tumor inoculation was 
achieved by subcutaneously (s.c.) injecting 1x105 4T1 cells in the abdominal 
mammary gland in order to prevent interference with normal bodily functions.  Prior 
to injection, 4T1 cells were washed twice in PBS and re-suspended in sterile saline 
(0.9 wt/vol% NaCl).  Tumor inoculation was designated as day "1". Mice were 
randomly assigned to experimental and control groups, and were treated every other 
day with specified formulations beginning on day 3 post-inoculation unless 
otherwise indicated.  Treatments were administered via intravenous (i.v.) tail 
injections, and complete dosing schedules are specified for each study.  Tumor 
growth inhibition was assessed with tumor volume, quantified by V = ½ (l) x (w)2, 
where l is the longest tumor diameter and w is the shortest tumor diameter 
measured by a digital caliper.  Mice were euthanized when tumor volumes exceeded 
1000 mm3, weight loss exceeded 15% of initial body weight, or if appeared 
moribound, and these dates were recorded for survival rate calculations. Kaplan–
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Meier plots represent the percentage of animals remaining in each treatment group 
as a function of time following tumor inoculation. 
 Caspase-3 immunohistochemistry and hematoxylin and eosin (H&E) 
histology analyses were performed on excised tumors post-treatment in order to 
further assess tumor growth inhibition.  Tumors were fixed and further sent to Mass 
Histology Services, Inc. (Worcester, MA, USA), where the tissues were paraffin-
blocked, stained, and analyzed.  To evaluate formulation toxicity, body weights were 
measured daily.  Additionally, liver, spleen, heart, and lung organs were harvested at 
the end of the experiments, fixed and further analyzed by Mass Histology Services, 
Inc. via H&E staining. 
 
2.11. Statistical analyses: Statistical significance was assessed via the two-tailed, 
unpaired Student’s t-test in Microsoft Excel.   One star indicates significance with p 
< 0.05, and two starts indicate p < 0.01. 
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Chapter 3 
Synergistic Chemotherapy Pairs 
3.1.  Defining synergy 
 When two drugs are combined, one of three results occurs: synergy, the 
additive effect, or antagonism.  Synergy implies mutual enhancement of both drugs, 
not simply an increase in therapeutic efficacy for only one drug.  Antagonism is the 
opposite of synergism, where the combination results in lower efficacy.  The additive 
effect occurs when neither efficacy of the drugs is altered, and the drugs can be 
thought of as non-interacting [31].  However, it is evidently difficult to assess synergy 
[33].  For example, if two drugs each provide 60% cell death when used alone, an 
additive effect would not be simple addition of their efficacies, as 120% cell growth 
inhibition is not possible.  In the 1980s, T.C. Chou and P. Talalay derived a method 
for the ease of synergy assessment: the “Combination Index” (CI) method [31].  The 
CI is a measurement of synergy, and it can be calculated with a series of drug dose-
effect experiments, such as cell inhibition assays.  According to this method, CI = 1 
indicates additivity, CI > 1 denotes antagonism, and CI < 1 describes synergy.  
Furthermore, the lower the CI, the more synergistic the pair. 
 Drugs which are synergistic can accomplish greater efficacy with smaller 
doses of either drug.  Smaller doses can potentially lead to reduced side effects, 
provided that the drugs do not also synergistically inhibit healthy endothelial or 
epithelial cell growth,  as well as slowed drug resistance due to less drug exposure.  
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Because harsh side effects and tumor resistance are notorious pitfalls of 
chemotherapy, cancer treatments can considerably benefit from chemotherapy 
synergy.  Breast cancer in particular is the second most common cancer among 
women, counting for nearly 1 in 3 cancer cases in women in America [34].  Thus any 
advancements in breast cancer chemotherapy can potentially benefit millions.  
Moreover, combination chemotherapies are typical treatment regimes for 
carcinomas of the breast; some are already FDA-approved (capecitabine + docetaxel 
[35, 36], lapatinib + letrozole [37], cyclophosphamide + methotrexate + 5-
fluorouracil [38]), and numerous others are in clinical trials.  Therefore, the 
preliminary screen for synergistic pairs included four FDA-approved breast cancer 
drugs with different mechanisms: docetaxel (DOC; antimicrotubule agent), lapatinib 
(LAP; tyrosine kinase inhibitor), 5-fluorouracil (5FU; antimetabolite), and 
doxorubicin (DOX; topoisomerase II inhibitor).  A thorough search for synergistic 
chemotherapy combinations helped to identify model drug pairs for nanoparticle 
encapsulation. 
 
3.2. Single chemotherapy anticancer efficacy 
 First, individual drug activities were assessed for cancer cell growth 
inhibition.  It was necessary to understand the capabilities of each drug alone so that 
they could later be compared to the therapeutic efficacies of drug combinations.  
DOC, LAP, 5FU, and DOX are all FDA-approved chemotherapy drugs for the 
treatment of breast cancer, proceed through different mechanisms, and are often 
included in combination chemotherapy regimens.  The efficacies of single agents 
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were determined by exposing the drugs to BT-474 human breast cancer cells, 
followed by cell viability assessment via MTT cytotoxicity assays (Section 2.2).  
However, prior to determining the anticancer efficacies for all drugs, it was necessary 
to optimize general drug incubation conditions.  Incubation time had to be long 
enough to allow drug internalization as well as sufficient interactions with its 
intracellular target, yet short enough that the cells could be healthily maintained.  
The incubation conditions also needed to ensure reproducible results between 
separate experiments. 
 
Figure 3.1. Effect of incubation time on DOC dose-effect reproducibility. 
 
DOC was exposed to BT-474 for various incubation times, and cancer cell viability was 
assessed via MTT cytotoxicity assays.  Dashed lines represent fits to the ME model.  Data 
represented as mean ± SD (n ≥ 8).  D50 (µM) and R2 corresponding to the ME models for 12, 
24, 48 and 72 hours were (1028114 ± 1.2E7, 0.08), (411 ± 428.3, 0.64), (38 ± 27.9, 0.75), and 
(23 ± 12.0, 0.89). 
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 To determine a sufficient incubation time, a model drug, DOC, was exposed to 
BT-474 cells for 12, 24, 48, and 72 hours.  Experimental data was then fitted to the 
median effect (ME) model (Equation 2.1), and all results are seen in Figure 3.1.  
Reproducibility seemed to improve with incubation time, as indicated by the reduced 
error bars, and the median effect model best fit data from 72 hour incubations, with 
R2 closest to 1.  The poor consistency observed at short incubation times is likely due 
to the lag time between drug internalization and drug action.  Because DOC is highly 
hydrophobic, it can diffuse easily into cells through the cell membrane, and thus can 
be internalized in vitro within 4 hours [39].  However, it is commonly found that 
apoptosis only occurs many hours after taxane treatment on cancer cells, often 24 or 
48 hours [40, 41].  Thus, literature suggests that DOC activation time is indeed 
multiple days, and the results obtained here correlate well with previous work.  In 
addition, the D50 concentration  (required to inhibit 50% cell growth) determined 
after 72 hour drug incubation, 23± 12.0 µM, was consistent with previously reported 
values (33.1 ± 9.3 µM) [42]. Therefore, a 72 hour incubation period was chosen for 
all future dose-effect studies. 
 The cancer cell growth inhibitory effects were further assessed for all single 
chemotherapy agents, and are shown in Figure 3.2.  The doses required to impact 
cell growth evidently differ between each drug, and are an indication of their varied 
strengths.  For example, the concentrations of LAP, 5FU, and DOX which inhibit 
50% cell growth fluctuate by different orders of magnitude.  LAP only requires 0.08 
µM, while 5FU needs to be present in a 6000-fold greater concentration of 487 µM. 
DOX exhibits a potency between the two extremes, with a D50 concentration in the 
25 
 
tenths of µM, 0.3 µM.  These D50 concentrations are also congruent with previous 
literature reports [43, 44], and validate our findings. It is clear that all the single 
drugs are capable of high efficacies (≥ 75% cancer cell growth inhibition), but only at 
doses much greater than their D50 concentrations.  Combining these drugs could 
potentially decrease the doses needed for high efficacy, particularly if the drugs 
synergistically interact.  This would yield a much more potent drug than either single 
agent because the pair could significantly reduce tumor growth at lower doses than 
are currently clinically effective. 
 
 
Figure 3.2. In vitro cancer cell growth inhibition of single chemotherapy drugs. 
 
LAP, 5FU, or DOX were incubated with BT-474 human breast cancer cells for 72 hours, and 
cells were assessed for viability via MTT cytotoxicity assays.  Dashed lines represent fits to the 
ME model.  Data represented as mean ± SD (n ≥ 8).  D50 (µM) and R2 corresponding to the 
ME models for LAP, 5FU and DOX were (0.08 ± 0.01, 0.99), (487 ± 170.7, 0.98), and (0.30 ± 
0.02, 0.98). 
 
3.3. Synergy search 
 The completion of single drug treatments lead to combination studies, and 
with it, the exciting quest for synergy.  An ideal drug pair would exhibit synergistic 
cancer cell kill at low doses of either drug because high doses of chemotherapy tend 
to cause toxicity in healthy tissue as well as tumor resistance.  Thus, the highest 
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impact of polychemotherapy delivery would be achieved with a low dose drug 
combination.  In ambition to find such a drug pair, any combination of the four 
drugs could be tested and tried.  Additionally, each pair could be tested at varying 
concentrations of either drug.  A six-drug pair screen could easily turn into an 
unmanageable number of experiments.  To keep the screens at a reasonable amount, 
the first synergy trial consisted of drug pairs tested at equal potencies (Table 3.1). 
 
 
Table 3.1. Equal potency combinations tested in first synergy trial. 
 
 For these equal potency experiments, doses were ranged between one-fourth- 
and four-fold the D50 concentrations for each drug.  Two-drug combinations of LAP, 
5FU, DOX and DOC were assessed for synergy using the Combination Index (CI) 
method (Section 2.3), and select pairs are shown in Figure3.3.  LAP+DOC exhibit CI 
< 1 for all concentrations tested, implying high synergy, whereas LAP+5FU 
consistently yield CI > 1, indicating antagonism.  LAP+DOX are antagonistic, apart 
from their highest concentration which appears additive (CI=1).  The combination of 
5FU+DOX is antagonistic for low concentrations, but becomes increasingly 
synergistic (decreasing CI values) with increasing dose.  The most synergistic pair 
discovered was LAP+DOC, with CI values ranging between 0.08-0.35.  While this 
pair represents an excellent candidate for inhibiting BT-474 cancer cells, LAP is 
considered a targeted therapy since it targets membrane receptors EGFR (epidermal 
growth factor receptor) and HER2/neu (human EGFR type 2).  Hence, LAP, as well 
Screen 1 2 3 4 5
Drug 1:Drug 2 dose ¼D50 : ¼D50 ½D50 : ½D50 1D50 : 1D50 2D50 : 2D50 4D50 : 4D50
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as its combination with DOC, will only be effective against cancers which overexpress 
these receptors, which comprise only about 10% of all breast cancer cases [45].  In an 
effort to develop widely applicable multi-chemotherapy vehicles which can treat even 
the most challenging cancer cases, we chose not to conduct further studies on this 
drug pair.  Therefore, 5FU+DOX, the second-most synergistic drug pair, with CIs 
ranging between 0.41-0.66 at the higher doses, was further investigated. 
 
 
Figure 3.3. Synergy assessment for drugs combined in equal potencies. 
 
Combination indices (CIs) calculated for drug combinations of LAP+DOC, LAP+DOX, 
LAP+5FU, and 5FU+DOX exposed for 72 hours to BT-474 cells. Drugs were combined in 
equal potencies, as outlined in Table 3.1.  Black line (CI=1) indicates synergy cut-off, above 
which drugs exhibit antagonistic interactions.  Data represented as mean ± SD (n ≥ 8). 
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3.4. Dependence of synergy on drug ratio 
 The initial synergy screen presented in the previous section combined drugs 
in varying total concentrations, while the ratio between the two drug concentrations 
(R) remained constant.  However, it has been established in various literature 
reports that drug ratio can greatly impact CI, and hence synergy [46-49].  The same 
two drugs can elicit synergistic or antagonistic cancer cell kill depending on the ratio 
at which they are exposed to the cells.  To improve synergistic interactions between 
the 5FU+DOX combination identified in Section 3.3, a second synergy screen was 
conducted whereby the molar ratio between 5FU and DOX (R, 5FU:DOX) was varied 
by changing DOX concentration.  The drug doses used for this second screen are 
provided in Table 3.2.  For low ratios (R ≤ 75), DOX concentration was held constant 
at two-fold its D50, 0.3 µM, while 5FU concentration was varied.  For high ratios (R ≥ 
409), 5FU concentration was maintained at its D50, 487 µM, while DOX dose was 
varied.  These specific concentrations were utilized because the single drug efficacies 
at these concentrations should not elicit more than 60% cancer cell growth 
inhibition.  This leaves a sufficient range for improvement in cancer cell kill, and 
allows for easier identification of synergistic interactions. 
 A strong dependence of 5FU and DOX interactions on R is evident in Figure 
3.4.  For R ≥ 3276, where 5FU concentration dominates, CI is much greater than 1 
and implies severe antagonism.  CI values close to 1 occur for 75 ≤ R ≤ 409, 
suggesting that the drugs are non-interacting for this regime.  For R ≤ 19, where 
DOX dose dominates, CI values less than 1 are calculated and indicate synergy.  The 
greatest synergy between 5FU and DOX, however, occurs at R= 819 ± 64, with CI = 
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0.34 ±0.12.  Moreover, various total drug concentrations were tested at a constant 
R=819, and results in Figure 3.5a-b show that the pair consistently outperformed 
either 5FU or DOX alone.  Various drug concentrations at the highly antagonistic 
ratio of R=6551 ± 170 were also tested, and the resulting cancer cell kill was 
consistently less than that of 5FU alone.  Hence, for these representative synergistic 
and antagonistic drug ratios, R seemed to govern drug interactions more than total 
drug concentration.  This finding is promising for the co-delivery of synergistic 
chemotherapy drugs, because it is difficult to control precise drug concentrations in 
tumor tissue, whereas ratios can be controlled via incorporation in nanoparticles.  
The nanoparticles can then unify the transport of a predetermined ratio of drugs 
specifically to the tumor, as alluded to in Figure 1.2. 
 
 
 
Table 3.2. Various R of 5FU+DOX investigated for synergy. 
 
 
Low R Screen 1 2 3 4
5FU:DOX dose
0.0001D50 : 
2D50
0.0006D50 : 
2D50
0.023D50 : 
2D50
0.092D50 : 
2D50
R (M:M 5FU:DOX) 0.1 0.5 19 75
High R Screen 5 6 7 8 9
5FU:DOX dose 1D50 : 4D50 1D50 : 2D50 1D50 : 1D50 1D50 : ½D50 1D50 : ¼D50
R (M:M 5FU:DOX) 409 819 1638 3276 6551
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Figure 3.4. Synergy assessment for 5FU+DOX combined at various R. 
 
Combination indices (CIs) calculated for various ratios of 5FU+DOX exposed for 72 hours to 
BT-474 cells.  Drug doses used for this second synergy screen are provided in Table 3.2.  For 
R ≤ 75, DOX concentration was held constant at two-fold its D50, 0.6 µM, while 5FU 
concentration was varied.  For R ≥ 409, 5FU concentration was maintained at its D50, 487 
µM, while DOX dose was varied.  Black line (CI=1) indicates synergy cut-off, above which 
drugs exhibit antagonistic interactions.  Data represented as mean ± SD (n ≥ 6). 
  
 Another important factor which governs the clinical applicability of 
chemotherapy combinations is the adverse side effects that occur when multiple 
drugs accumulate in healthy tissue rather than tumors.  Because chemotherapy 
drugs cannot distinguish between healthy and malignant cells, they can easily 
distribute throughout the body, and toxicity is an inherent challenge.  Although 
nanoparticles can promote drug accumulation in tumors via the EPR effect, it does 
not eliminate uptake in healthy tissue.  In fact, a common issue with nanoparticles is 
their retention in organs highly involved in the mononuclear phagocyte system 
(MPS), such as the liver and spleen [50, 51].  To assess potential toxic effects that 
may occur in vivo, 5FU+DOX was challenged in vitro against two representative 
healthy cell lines, bEnd.3 mouse brain endothelial cells and MCF 10A human breast 
epithelial cells.  These cell types were chosen because any systemically-administered 
drug is susceptible to interactions and uptake by endothelial cells, as well as 
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epithelial cells in surrounding healthy tissue.  5FU+DOX were exposed to each cell 
line in the synergistic and antagonistic ratios of R=819 and R=6551, respectively, and 
toxicity was assessed via MTT assays.  The combination toxicities were also 
compared to 5FU treatment alone and DOX treatment alone, and the results are 
shown in Figure 3.5. 
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Figure 3.5. In vitro cytotoxicity of 5FU+DOX in cancerous and healthy cells. 
 
5FU+DOX in the synergistic ratio R=819 ± 64 (squares) or antagonistic ratio R=6551 ± 170 
(diamonds) were exposed to (a)-(b) BT-474 human breast cancer cells, (c)-(d) bEnd.3 mouse 
brain endothelial cells, or (e)-(f) MCF 10A human breast epithelial cells, and cell growth 
inhibition was evaluated via MTT cytotoxicity assays.  Single drug treatments of DOX (left, 
circles) and 5FU (right, circles) are shown for comparison.  Dashed lines represent fits to the 
ME model. Data expressed as mean ± SD (n ≥ 6). 
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 Although 5FU+DOX combined at R=819 consistently inhibited more cancer 
cell growth than either 5FU or DOX alone, the same was not true for the endothelial 
or epithelial control cells investigated.  For bEnd.3 cells (Figure 3.5c-d), R=819 
inhibited less endothelial cell growth than DOX alone, and for MCF 10A cells (Figure 
3.5e-f), the same ratio inhibited less epithelial cell growth than both DOX and 5FU 
alone.  Similarly, 5FU+DOX combined in the antagonistic ratio of R=6551 was less 
toxic than 5FU when exposed to MCF 10A, and only as toxic as DOX when exposed 
to bEnd.3.  The combination of 5FU+DOX actually reduced the toxicity in control 
cells, regardless of ratio, compared to 5FU or DOX administered alone.  Figure 3.6 
represents the same data in a different light.  Here, the D50 concentrations for BT-
474 cancer cells and MCF 10A epithelial cells are directly compared in a relative 
ratio.  Higher D50 ratios indicate higher drug concentrations are required to kill 
cancer cells compared to epithelial cells, and hence greater toxicity to epithelial cells.  
Lower D50 ratios imply that low drug concentrations can significantly kill cancer 
cells, but can't effectively kill epithelial cells.  In this manner, direct comparisons of 
D50 concentrations for cancer cells relative to healthy cells can act as a specificity 
metric.  Relative D50 concentrations < 1 indicate that the treatment more selectively 
kills cancerous cells over epithelial cells, whereas ratios > 1 suggests the opposite and 
that the drugs are more toxic to healthy cells.  As seen in Figure 3.6, the D50 ratio for 
both 5FU and DOX was reduced by simply combining them in the synergistic ratio 
R=819, relative to individual drug administrations.  We were able to reduce the D50 
ratio by 36-fold and 5-fold for 5FU and DOX, respectively.  This suggests that the 
drugs are more toxic to healthy cells when used alone, but can be tuned to more 
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preferentially inhibit cancer cells if combined in an optimal ratio.  Our findings 
introduce a new concept of creating chemotherapy specificity by unconventional 
methods; instead of incorporating antibodies or peptides which direct the toxic 
drugs to tumors, one can utilize combination chemotherapy at optimal drug ratios. 
 
 
Figure 3.6. D50 ratios for BT-474 relative to MCF 10A. 
 
Ratio of D50 (concentration required to inhibit 50% cell growth) for BT-474 breast cancer cells 
relative to MCF 10A breast epithelial cells.  Relative D50 concentrations are reported for 5FU 
(purple, left bars) and DOX (blue, right bars).  Relative D50 < 1 indicates greater specificity for 
cell inhibition of cancerous over epithelial cells.  For synergistic R=819, relative D50 
concentrations were 0.54 ± 0.21 and 0.47 ± 0.47  for DOX and 5FU, respectively.  D50s were 
determined from experimental fits of cell inhibition data to the ME model, and error is 
propagated from the standard error of the model fit. 
 
 This reduction in cell kill when incubated with healthy cells may be attributed 
to inherently different cytotoxicity mechanisms the drugs elicit depending on cell 
type.  For instance, susceptibility to cell death by 5FU treatment greatly depends the 
activity of various enzymes responsible for RNA and DNA incorporation, such as 
uridine phosphorylase, orotate phosphoribosyl transferase and thymidylate 
synthase.  The activities of these enzymes have been shown to differ between various 
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cancer cells and seemed to correlate with drug sensitivity [52].  Altered levels of 
these enzymes is one plausible reason for reduced combination activity in bEnd.3 
and MCF 10A cells.  More specifically, DOX has been previously reported to elicit 
apoptosis in endothelial cells and cancer cells via different pathways.  DOX-mediated 
generation of hydrogen peroxide has been shown to play a pivotal role in endothelial 
cell apoptosis but not in tumor cell apoptosis [53].  Such differences in drug 
sensitivity may prevent the interactions between 5FU and DOX that are seen in 
cancer cells, and provides a probable cause for reduction in combination activity.  
Results from these studies suggest that the enhanced cell inhibition of 5FU+DOX at 
R=819 is specific for cancer cells, and is not as toxic to endothelial or epithelial cells. 
In fact, the combination may not be any more toxic than either 5FU or DOX when 
administered as a single agent because the combination, at best, only inhibits as 
much cell growth as DOX alone.  This is a remarkable finding, since one challenge 
with combination chemotherapies is amplified adverse side effects due to co-
localization of multiple drugs in essential organs.  Our results suggest that this 
challenge can potentially be overcome by optimizing drug pair and ratio such that 
synergistic cell kill occurs in malignant cells, but not in healthy cells.  Further in vivo 
or ex vivo studies, whereby 5FU+DOX are exposed to tissues in their natural 
environments, would need to be executed to assess this hypothesis. 
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3.5. Mechanistic study of 5FU and DOX enhanced cancer cell kill 
 To understand the cause of synergistic interactions between 5FU and DOX, 
one of the mechanisms DOX utilizes to induce cell death was investigated: reactive 
oxygen species (ROS) generation.  DOX is known to induce apoptosis in endothelial 
and tumor cells by different mechanisms.  In endothelial cells, DOX induces cell 
death by ROS generation, whereas in tumor cells, DOX induces apoptosis by 
activating the p53 tumor suppressor gene [53].  By comparing ROS generation in 
cancer cells exposed to 5FU and DOX rather than DOX alone, one can investigate the 
impact of 5FU on DOX cancer cell cytotoxicity.  Post-incubation with either 
5FU+DOX at R=819, 5FU alone, or DOX alone, BT-474 cells were treated with 
general oxidative stress indicator carboxy-H2DCFDA (10 µM for 30 min), which 
forms carboxydichlorofluorescein upon acetate cleavage and oxidation.   Cells were 
then imaged utilizing confocal microscopy, and representative images are included 
in Figure 3.7.  Results demonstrate that negligible ROS generation was present in 
untreated cells and cells incubated with 5FU alone.  Little ROS generation was 
visualized in cells incubated with just DOX; on the contrary, significantly more ROS 
was present in cells treated with the synergistic combination of 5FU+DOX.  
Quantification of the ROS fluorescence indicator (Figure 3.7) suggests that ROS 
generation is slightly more than doubled when 5FU is included in the treatment 
compared to DOX incubated alone.  Therefore, the addition of 5FU amplifies the 
non-traditional mechanism by which DOX induces apoptosis in cancer cells, and 
enhanced ROS generation is a probable contribution to their synergistic anticancer 
activity.  Moreover, ROS generation has been found to effectively inhibit cancer cells 
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that have previously grown resistant to DOX treatments [54, 55], demonstrating that 
ROS generation is indeed a powerful cell inhibitory mechanism.  It seems plausible 
that heightened levels of ROS produced by 5FU+DOX lead to significantly greater 
cancer cell death than either drug alone, which produce lower levels of ROS. 
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Figure 3.7. ROS detection in 5FU+DOX treatments. 
 
Production of reactive oxygen species (ROS) in BT-474 cells exposed to no drug (top), 0.6 µM 
DOX (second from top), 487 µM 5FU (second from bottom), or 5FU+DOX at R=819 
(bottom).  Cells were exposed to free drug solutions for 24 hrs, incubated with 10 µM 
carboxy-H2DCFDA (green) for 30 minutes, washed and imaged live immediately via confocal 
microscopy.  DOX internalization is visualized in red. Scale bar=20 µm. Carboxy-H2DCFDA 
fluorescence intensity is reported as mean ± SD (n=3). 
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 The mechanism behind 5FU and DOX synergy may be multi-faceted, 
however, and cell cycle phase arrests may be another plausible cause for their 
combined anticancer potency.  5FU is considered to be a cell cycle-specific drug, as 
exposure to 5FU results in accumulation of cells in the G1/S phases [56-59]; 
meanwhile, the classification of DOX as a cell cycle-nonspecific drug is controversial.  
One convincing report by Y. Ling and co-workers demonstrated that DOX-induced 
cytotoxicity can be significantly enhanced by synchronizing cells in the S phase prior 
to DOX treatment [60].  By incubating cancer cells with a double thymidine block, 
they were able to promote cell accumulation in the S phase, and subsequently inhibit 
50% cell growth with ~3.28 fold lower DOX concentration than was necessary for 
asynchronized cells.  This enhanced cytotoxicity seemed directly correlated to G2/M 
phase arrest. The mechanism between 5FU and DOX synergy may be similar in our 
studies, since 5FU is (1) a thymidylate synthase inhibitor [61], which is consequently 
responsible for thymidine levels and hence similar to the thymidine block utilized by 
Y. Ling and co-workers, and (2) a proponent of S phase accumulation [56].  It is 
likely that 5FU first synchronizes cancer cells in the S phase, which further allows 
DOX to accumulate cells in the G2/M phase, and consequently cause enhanced cell 
death compared to single drug treatments, where concentrated phase arrests would 
otherwise be absent.  In a separate study, it was found that DOX anticancer synergy 
with silibinin, an active constituent of milk thistle seeds, was strongly correlated with 
enhanced G2/M phase arrests [62].  DOX and silibinin treatments alone resulted in 
19% and 41%, respectively, of cells in the G2/M phases, whereas their combination 
suspended88% of cells in the G2/M phases. This supplementary finding supports the 
40 
 
hypothesis that enhanced G2/M phase arrest can cause synergistic drug interactions,  
and could be another probable cause of 5FU and DOX synergy. 
 Collectively, the results presented in Section 3.4-3.5 form a strong basis for 
the use of 5FU and DOX in combination chemotherapy regimens.  This is far from 
the first time that the two have been identified as  a potent anticancer pair, as 5FU 
and DOX is included in nearly all chemotherapy regimens for the treatment of 
gastric cancers [8, 63-69], and has been employed in many breast carcinoma 
therapies as [16, 70, 71], well. However, our studies elucidate the grave impact that 
ratio between 5FU and DOX can impose on drug interactions; the drugs can either 
enhance cancer cell kill or significantly reduce it, depending on the ratio utilized.  As 
a result, R can have vast implications on therapeutic efficacy.  On the contrary, 
synergistic R was less toxic to both endothelial and epithelial cells compared to 
treatment with DOX alone, suggesting that the combination is specifically potent at 
killing cancer cells, and may be well-tolerated in vivo.  Controlled nanoparticle 
encapsulation of 5FU+DOX will allow the pair to simultaneously arrive in tumors at 
the prescribed synergistic ratio, and may be able to mimic the synergistic cancer cell 
kill so consistently demonstrated in vitro. Therefore, 5FU+DOX at R=819 was 
chosen as one of the model drug pairs investigated for multi-drug encapsulation and 
delivery in nanoparticles. 
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3.6. Topoisomerase inhibitor combination 
 All combinations previously explored for synergy consisted of FDA-approved 
drugs that are often used in polychemotherapy regimens.  However, there is a vast 
repertoire of drugs which have failed clinically due to toxicity or solubility issues, yet 
may have strong potential for comprising potent combinations.  Incorporation in 
nanoparticles can alleviate the challenges associated with these problematic 
anticancer drugs by prolonging systemic circulation and improving tumor uptake.  
To investigate whether these disreputable drugs can be made clinically relevant by 
multi-drug nanoparticle delivery, one FDA-approved drug was screened for synergy 
with one that is non-FDA-approved. 
 In particular, the drug pair chosen for synergistic screening was one that has a 
strong basis for enhanced therapeutic efficacy, that is, topoisomerase I and II 
inhibitors.  Topoisomerase (top) I and II are enzymes are essential for cell 
proliferation, as they alleviate DNA tension during replication.  Inhibitors of top I 
and II enzymes have been found to synergistically reduce cancer cell growth in vitro 
[72-76], and their combined anticancer potency is attributed to collateral drug 
sensitivity; top I-exposed cancer cells compensate the obstruction of DNA replication 
by enhancing top II activity, which further sensitizes the cancer cells to top II 
inhibitors  [77, 78]. However, their clinical applicability has been questionable due to 
little improvements in tumor reduction [9, 79, 80] and heightened side effects [80-
83].  DOX is the conventional FDA-approved topoisomerase II inhibitor which is 
consistently used in cancer treatments due to its well-established liposomal 
administration and marked efficacy.  In contrast, camptothecin (CPT) is the 
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archetypal non-FDA-approved topoisomerase I inhibitor which exhibits significant 
anticancer efficacy in vitro, but has failed clinically due to extreme gastrointestinal 
toxicity and myelosuppresion in phase II trials [84-86].  Various analogues of CPT 
have been developed to mitigate these unpredictable drug toxicities, with substantial 
focus on improving its water solubility.  Two successful CPT analogues, topotecan 
(TPT) and irinotecan (CPT-11), were able to improve the drug's water solubility, 
adverse side effects, and efficacy against human tumor xenografts in mice models 
[84].  Both are FDA-approved for various cancers, however they are notably less 
effective at cancer cell kill in vitro compared to the original CPT drug [87, 88].  
Despite this, their improved efficacy in vivo is likely attributed to their enhanced 
tolerability yielding higher maximum tolerable doses (MTDs) and hence a larger 
therapeutic window than the original CPT.  Therefore, in an effort to find a potent 
anticancer combination top I and II inhibitor, our synergistic screen included both 
the FDA-approved analogue CPT-11 and the original, more cytotoxic CPT. 
 Single drug treatments of CPT or CPT-11 on BT-474 cells (Figure 3.8a) verify 
that CPT-11 is less active than CPT at inhibiting cancer cell growth.  To assess if 
synergistic interactions exist between these top I inhibitors and DOX, various ratios 
of the combinations were exposed to cancer cells.  CPT+DOX consistently 
outperformed the cancer cell kill of either drugs when used alone (Figure 3.8b).  The 
enhancement of cancer cell kill seemed to increase with increasing R (CPT:DOX); 
similarly, CI decreased with increasing R (Figure 3.8c). These results indicate that 
CPT+DOX become more synergistic with increasing R, with the greatest synergy 
occurring when R > 2 (0.01 < CI < 0.08).  The highest CI was 1 ± 0.07, indicating 
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that CPT and DOX interactions were never worse than additive.  For molar ratios > 
2, the reported CI values are among the lowest, and therefore most synergistic, of 
reported drug interaction studies evaluated by the CI method [42, 46, 48, 62, 76, 89-
91].  This remarkable synergy renders CPT+DOX highly desirable for co-delivery to 
tumors.  Previous reports found CPT and DOX to be only additive in wild type rat C6 
glioma cells, but slightly synergistic in a CPT-resistant C6 cell line [89].  BT-474 
human breast cancer cells which were utilized in this study were found to be 
inherently resistant to CPT, with a D50 of 100 μM, nearly 50 times that of CPT-
resistant C6 cell lines reported in the literature.  However, when BT-474 cells were 
treated here with CPT and DOX at a molar ratio of R = 4.5, the pair was able to 
inhibit 95% cell growth at a CPT concentration 100-fold less than the D50.  Hence, 
the finding of CPT and DOX synergy in CPT-resistant cells is consistent with 
previous studies, and suggests that CPT and DOX are most potent when used against 
highly CPT-resistant tumor cells.  
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Figure 3.8. Top I + Top II inhibitors synergy screen. 
 
(a) Cell growth inhibition of BT-474 cells exposed to CPT (circles) or CPT-11 (squares).  
Dashed lines represent fits to the ME model.  D50 (μM) and R2 values corresponding to CPT 
and CPT-11 respectively are (104 ± 42, 0.93) and (570 ± 206, 0.95).  Cell inhibition elicited by 
combinations (blue, left) (b) CPT+DOX or (d) CPT-11+DOX combined at various R.  Single 
drug treatments of DOX (red, middle) and CPT (green, right) at concentrations which make-
up the combinations are juxtaposed for direct comparison.  CPT and DOX concentrations 
(μM) in (b) corresponding to each R were: 0.1 (0.05, 0.5), 0.3 (0.1, 0.36), 0.5 (0.2, 0.4), 1.0 
(0.4, 0.4), 2.3 (0.9, 0.4), 4.5 (1.35, 0.3), 9.0 (2.0, 0.22), and 15.0 (5.0, 0.33).  CPT-11 and DOX 
concentrations in (d) corresponding to each R were: 4.5 (1.75, 0.39), 9 (3.5, 0.39), 20 (7.0, 
0.35), 50 (14.0, 0.28), 100 (28.0, 0.28), 500 (28.0, 0.056), 1000 (28.0, 0.028).  Drug 
concentrations were chosen such that at least one of the individual drug doses inhibited 
between 40-60% cell growth.  CIs for each R of (c) CPT+DOX and (e) CPT-11+DOX. Data 
expressed as mean ± SD (n ≥ 6). 
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 Most ratios of CPT-11+DOX, on the other hand, were only as effective at 
cancer cell kill compared to single DOX treatments, as seen in Figure 3.8d.  
Consequently, CIs ranged between 0.8-1.15 for 4.5< R < 50 (Figure 3.8e), indicating 
that the drugs were additive and non-interacting.  The only synergy was observed at 
R = 100 (CI = 0.45), approximately two orders of magnitude higher than that needed 
for CPT+DOX synergy.  Thus, a much larger concentration of CPT-11 is required in 
combination with DOX compared to CPT in order to induce synergistic interactions.  
This is likely due to the lower efficacy of CPT-11, whose D50 is 5.5 fold higher than 
that of CPT.  CPT-11 is a pro-drug analogue of CPT which requires hydrolysis into its 
active ingredient SN-38, and this necessary metabolization, while helpful for in vivo 
applications, may be the root cause of reduction in therapeutic efficacy.  This 
reduction in CPT-11 in vitro efficacy is congruent with previous studies [87, 88], 
however our report of reduced synergy with DOX is an additional finding. 
 The more potent anticancer drug pair CPT+DOX was tested in two additional 
cell lines: the highly metastatic murine mammary cancer cells 4T1, and healthy 
murine brain endothelial cells bEnd.3.  These extensive cytotoxicity studies assess 
the applicability of CPT+DOX to aggressive forms of cancer, as well as its toxicity in 
healthy cells.  As seen in Figure 3.9a-b, CPT+DOX synergy was maintained in the 
aggressive 4T1 cell line, and with a slight shift in optimal synergistic ratios.  When 
CPT+DOX was exposed to 4T1 cells, CI < 1 occurred for R > 2.25, which is higher 
than the R > 0.3 threshold in BT-474 cells.  In stark contrast, however, the 
combination consistently inhibited less endothelial cell growth than CPT or DOX 
alone (Figure 3.9c-d), suggesting that the pair is considerably more toxic to cancer 
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cells than endothelial cells.  CI evaluation revealed extreme antagonism, regardless 
of ratio, in bEnd.3 cells, with CIs occurring at a minimum of 25, and as high as 3 x 
109.  This vastly reduced combination activity in endothelial cells may be attributed 
to the distinctly different cytotoxicity mechanisms the drugs elicit in endothelial 
cells, as alluded to in Section 3.4.  As described earlier, hydrogen peroxide is a major 
mechanism by which DOX induces apoptosis in endothelial cells, but not in cancer 
cells [53].  Furthermore, top I enzymes present in endothelial cells exhibit higher 
resistance to CPT-induced oligonucleotide cleavage compared to those expressed in 
cancer cells [92, 93].  Such differences in drug sensitivity may prevent synergistic 
interactions between CPT+DOX when exposed to endothelial cells, and provides a 
probable cause for reduction in combination activity.  Synergistic CPT+DOX 
interactions in 4T1 cells suggests that the combination can be broadly applied to 
metastatic and aggressive cancers, and their antagonistic interactions in bEnd.3 cells  
suggest that the potent pair will be less toxic than their free drug counterparts while 
in blood circulation.  Because the synergistic interaction between DOX and CPT 
seems specific to tumor cells, the pair may be less toxic in vivo compared to the 
higher doses of free drug that are required to inhibit tumor growth.  This concept of 
utilizing chemotherapy combinations to direct toxicity towards cancerous rather 
than healthy cells is consistent with our findings with 5FU+DOX in Section 3.4. 
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Figure 3.9. CPT+DOX interactions in 4T1 and bEnd.3 cells. 
 
Cell inhibition of 4T1 (top, left) or bEnd.3 (bottom, left) elicited by various R of CPT+DOX 
(blue, left), DOX (red, middle) or CPT (green, right) at concentrations which make-up the 
combinations.  CPT  and  DOX  concentrations  (μM), respectively, exposed to 4T1 cells (R, 
CPT:DOX) were: 0.1 (0.005, 0.05), 0.3 (0.01, 0.03), 0.5 (0.02, 0.04), 1.0 (0.04, 0.04), 2.3 
(0.04, 0.018), 4.5 (0.08, 0.018), 9.0 (0.04, 0.004), 15.0 (0.075, 0.005).  In the case of bEnd.3 
cells, CPT and DOX concentrations respectively utilized corresponding to each R ratio were: 
0.1 (0.04, 0.4), 0.3 (0.11, 0.4), 0.5 (0.2, 0.4), 1 (0.4, 0.4), 2.3 (0.45, 0.2), 4.5 (0.45, 0.1), 9 
(0.45, 0.05), 15 (0.3, 0.02).  Drug concentrations were chosen such that at least one of the 
individual drug doses inhibited between 20-60% cell growth.  CIs for each R of CPT+DOX are 
shown on the right.  Data expressed as mean ± SD (n ≥ 6). 
 
 Although CPT's poor water solubility limits its clinical use, results reported 
here demonstrate that it is a better match for DOX than its FDA-approved analogue, 
CPT-11.  Not only is the CPT+DOX synergy among the lowest of those reported in 
literature, but it occurs over a broad range of ratios.  Therefore, their encapsulation 
in nanoparticles for tumor co-delivery may not need to be stringently controlled.  
Further, incorporation of CPT+DOX in a nano-carrier, much like the pro-drug CPT-
11, can improve drug solubility in aqueous solution, and can act as a drug depot 
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which slowly releases drug rather than exposes the body to large, bolus amounts of 
it.  The toxicity of CPT can also be alleviated just by co-administration with DOX, as 
indicated by CPT+DOX extreme antagonism in bEnd.3 cells. In this manner, the 
unpredictable, adverse side effects often associated with CPT may be overcome; 
meanwhile, the antitumor efficacy of the drug can be significantly improved by 
combining it with DOX. 
 
3.7. Mechanistic study of CPT and DOX enhanced cancer cell kill 
 Since CPT and DOX inhibit DNA top I and II, respectively, which are required 
to relieve DNA supercoiling during transcription and replication, exposure of either 
drug to cancer cells results in DNA damage and can induce apoptosis.  To 
understand the enhanced cancer cell capabilities of CPT+DOX, cells were quantified 
for pre-apoptotic and late-apoptotic populations with Annexin V/Sytox Green 
counterstaining (Section 2.5) after incubation with the drug pair or individual 
agents. Scatter plots obtained from flow cytometry of Annexin V/Sytox Green 
counterstained cells are seen in Figures 3.9a-f. These plots were utilized to quantify 
early apoptotic and late apoptotic/necrotic populations in Figure 3.10g-h. Cells 
stained with low levels of Annexin V and Sytox Green (-AV/-SG) were live, with high 
levels of Annexin V and low levels of Sytox Green (+AV/-SG) were early apoptotic, 
and high levels of both were necrotic and/or late apoptotic.  Flow cytometry data 
indicated a significant increase in apoptosis when the drug pair was given in a 
synergistic ratio relative to treatment with DOX alone, and only little enhancement 
when provided in an additive ratio.  Cells exposed only to CPT exhibited low 
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percentages of apoptotic cells, incomparable to those treated with DOX alone, likely 
due to BT-474’s inherent resistance to CPT.  However, at a synergistic ratio (R = 4.5, 
CI=0.05 ± 0.01), CPT + DOX induced a 24% increase in early apoptotic population 
(Figure 3.10), whereas cells exposed to additive ratio (R = 0.1, CI = 1.00 ± .07) 
resulted in only a 2% increase.  This significant increase in early apoptotic 
populations improves the cancer cell inhibition of CPT+DOX at synergistic ratios, 
and facilitates potent efficacy at low drug concentrations. 
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Figure 3.10. Apoptotic assessment of CPT+DOX-treated cancer cells. 
 
Annexin V/Sytox Green assay was utilized to detect percentage of early apoptotic  cells in 
various drug-treated BT-474 cells. Cells were treated with the following drugs for 72 hours 
prior to staining and analysis via flow cytometry: (a) No Treatment (b) 4.73 μM CPT (c) 0.11 
μM CPT (d) 1.05  μM DOX (e) 4.73 μM CPT and 1.05 μM DOX (R = 4.5, representative 
synergistic dose) (f) 0.11 μM CPT and 1.05 μM DOX, in a molar ratio of (R = 0.1, 
representative additive dose). Representative flow cytometry plots are shown. Juxtaposed % 
cell populations represent averages ± SD (n=3). (g) Cell populations were quantified via flow 
cytometry as follows: early apoptotic (left, blue bars), and necrotic and/or late apoptotic 
(right, purple bars).  (h) Percent enhancement of early apoptotic cells relative to treatment 
with DOX alone.  Data represents mean ± SD (n=3). 
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 CPT+DOX studies reported here, in agreement with previous 5FU+DOX 
results, also underscore the importance of drug ratios in determining potency. At 
R=0.1, no improvement in cancer cell inhibition was seen (additive effect), but at 
R=2, significant synergistic potency was apparent. This study verifies that precise 
drug ratios can govern combination synergy, as others have established [47, 48], and 
emphasizes the need for controlled combination delivery to tumor tissue. Further, 
clinical trials of top I and II combinations utilize the less cytotoxic, FDA-approved 
analogues of CPT (CPT-11 or TPT); however, CPT-11 was demonstrated here to only 
exhibit synergy with DOX at a single ratio (R=100), while all other ratios 
investigated elicited additive drug interactions.  This use of a non-interacting drug 
pair may be the cause for the poor clinical efficacy of top I and II combinations.  The 
inclusion of the more cytotoxic, original CPT at R>2 with DOX in nanoparticles may 
help enhance overall responses and reduce adverse side effects currently elicited by 
top I and II combinations. Therefore, CPT+DOX was chosen as a second model drug 
pair for multi-drug encapsulation in nanoparticles and to promote their 
simultaneous arrival in tumors. 
 
3.8. Summary of chemotherapy combination studies 
 Through extensive in vitro combination studies, we have identified two 
chemotherapy pairs which synergistically inhibit cancer cell proliferation. 5FU+DOX 
were found by conducting synergy screens among FDA-approved drugs of distinct 
classes.  CPT+DOX were discovered though deliberate investigation of collaterally 
sensitive top I and II inhibitors, with the foresight that the most potent pair may not 
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consist of FDA-approved agents. In both cases, drug ratio governed anticancer 
potency.  For 5FU+DOX, R ≥ 3276 resulted in antagonistic interactions and hence 
reduction in cancer cell kill upon combination, whereas R ≤ 1638 synergistically 
inhibited cancer cell growth.  The effect on ratio was less dramatic for CPT+DOX; 
R=0.1 elicited additive interactions, while all other investigated ratios were 
synergistic.  These results illustrate the same conclusion: ratio plays a pivotal role in 
antitumor efficacy, and validates the need for multi-drug vehicles which can deliver 
precise ratios to tumors in order to capture the pair's full therapeutic potential. 
 Also noteworthy is the marked reduction in combination potency when 
exposed to control endothelial or epithelial cells.  This finding was consistent for 
both drug pairs, and suggests that the combination selectively kills cancer cells 
rather than healthy cells.  While more thorough studies are required to validate this 
concept, it proposes a new, unconventional methodology for tumor targeting 
therapies.  Rather than including antibodies or peptides which can recognize cancer 
cell surface markers, one can simply tune chemotherapy by delivering combinations 
at ratios that are more toxic to cancer cells than healthy cells.  This can be an 
incredibly powerful approach which modernizes nanoparticle therapies.  
Nanoparticle stigma is associated with its uptake in MPS organs such as the liver and 
spleen, and can cause adverse side effects if the drug payload is released or if it is 
non-biodegradable.  Thus, by improving drug payload specificity through 
combinations, one may still be able to reduce adverse side effects even if the 
nanoparticles accumulate in healthy tissue. 
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 The combinations discovered in this chapter are not entirely surprising, as 
variations of them have been used clinically.  5FU+DOX combined with 
methotrexate, collectively tokened as FAMTX, is considered one of the standard 
regimens for gastric cancer patients [8, 63].  Top I and II inhibitors CPT-11 and 
liposomal DOX have been combined in clinical trials for the treatment of ovarian and 
lung cancers [9, 94, 95].  Both of these combinations have shown slight 
improvements in partial responses (decrease in tumor size), but complete responses 
(disappearance of tumor) still remain rare [8, 9, 68, 94, 96].  Furthermore, the 
clinical applicability of top I and II inhibitors has become questionable due to 
heightened side effects [80, 81, 83].  Collectively, clinical data and our CI results 
demonstrate the high therapeutic potential of 5FU+DOX and top I+II inhibitor 
combinations.  However, there is a clear unmet need for improving their tumor 
reduction and side effects.  We have thus far demonstrated the ability to improve 
cancer cell kill by optimizing combination ratios, and hope to further reduce side 
effects by incorporation in nanoparticles. 
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Chapter 4 
Liposomes for combination 
chemotherapy co-delivery 
4.1. Advantages of liposomes 
 Liposomes represent the oldest class of nanoparticles for chemotherapy 
delivery.  It pioneered the field by becoming the first FDA-approved nanoparticle 
chemotherapy formulation in 1995 for DOX delivery [28], and has since been a 
staple in drug delivery for its numerous advantages over free drugs; to name a few, 
enhanced biocompatibility, extended systemic circulation, and ability to accumulate 
in tumor endothelium via the EPR effect [97, 98].  Scientists even proclaimed the 
properties of liposomes through poetry upon their discovery in 1962, such as the 
verse below: 
"Little fatty vesicles of bilayer fame 
protean and elusive, fragile all the same, 
aloof and enigmatic beneath your many skins, 
unyielding to the vigour of thousands of spins, 
descended from the pastures of Babraham we are told, 
you never ceased to wrinkle, expand and then to fold 
embracing sodium ions and such electrolytes. 
Twinkling guide stars to throngs of acolytes 
desirous of your membranous semi-barriers. 
Precursors of bion, potential drug carriers. ’ 
- Gregory Gregoriadis [99] 
 
Moreover, liposomes have been shown to significantly reduce cardiotoxicity 
associated with DOX treatments [100-102], the main adverse side effect which has 
55 
 
earned DOX's tokened name of "red death".  For all of these acclaimed advantages of 
liposomes, they were the first nanoparticle we sought to investigate for the co-
delivery of chemotherapy combinations. 
 
 
 
Figure 4.1. Phospholipid and liposome schematic. 
 
A representative phospholipid, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), is 
pictured, with its hydrophobic tails highlighted in red, and its hydrophilic headgroup shown 
in blue.  The tails consist of two 18-carbon saturated fatty acids, which is connected to the 
phosphocholine head via a glycerol group.  Phospholipids can vary depending on tail length, 
saturation, and charge of the headgroup.  Liposome formation occurs via self-assembly of 
phospholipids in water, where a phospholipid bilayer membrane entraps an aqueous pocket. 
 
 As alluded to in G. Gregoriadis' poem, liposomes consist of phospholipids 
which self-assemble in water to form a lipid bilayer membrane enclosing an aqueous 
core [98, 103].  The building block of these nanoparticles, phospholipids, contain 
hydrophobic fatty acid tails and hydrophilic head groups, as depicted in Figure 4.1, 
and this amphipathicity is the driving force behind self-assembly of lipid bilayers.  
Because liposomes consist of both a hydrophobic compartment (lipid bilayer) and a 
hydrophilic core, they can potentially incorporate both water-soluble and lipophilic 
Hydrophobic Tails
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Head Group
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drugs during the self-assembly process.  Phospholipids also come in various sizes 
and charges, just by modification of the carbon chain lengths or the headgroups.  
These seemingly small modifications have vast implications for their fate in vivo, 
and can be tuned for different purposes [50, 104].  Phospholipids which mimic those 
present in our very own cell membranes can be utilized for liposome fabrication, 
rendering the nanoparticles biocompatible and biodegradable.  Altogether, the ease 
of fabrication, versatility of drug payloads, and biocompatibility make for a coveted 
drug carrier which is exploited throughout the pharmaceutical industry. 
 
4.2. Our approach for chemotherapy co-delivery 
 Here, we hoped to implement the advantages of liposomal drug delivery for 
chemotherapy combinations, specifically the synergistic pair 5FU+DOX identified in 
Section 3.4.  Through multi-drug co-encapsulation in liposomes, we aimed to not 
only enhance the clinical therapeutic efficacies of 5FU+DOX, but we also proposed to 
improve upon the generation of liposomes in use today.  The current standard, of 
course, is DoxilTM, polyethylene glycol (PEG)-coated liposomal doxorubicin.  
Although DoxilTM revolutionized drug delivery for cardiotoxic chemotherapy drug 
DOX by alleviating adverse side effects, it remains unclear whether liposomal DOX 
elicits superior antitumor efficacy compared to free DOX.  Some clinical trials 
reported little or only comparable therapeutic efficacy [105-109], whereas other 
studies showed that liposomal DOX merely increased the tolerable dose, making it 
difficult to decipher whether liposomal entrapment actually enhanced antitumor 
efficacy [110, 111].  By including another drug (5FU) which synergistically enhances 
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DOX's activity against cancer cells, we aimed to obtain greater therapeutic efficacies 
than are currently possible with single drug-loaded liposomes. However, the well-
established method of liposomal DOX encapsulation involves a transmembrane 
ammonium sulfate gradient, which was specifically designed for anthracycline 
entrapment.  Therefore, to incorporate DOX and 5FU simultaneously in liposomes, 
we developed a method for 5FU encapsulation which is compatible with the 
transmembrane ammonium sulfate gradient.  This method is not unique to 5FU, but 
can be applied to its general class of chemotherapy drugs, nucleobase analogues, and 
hence can be a powerful tool for evaluating many chemotherapy drug pairs. 
 
 
Figure 4.2. Mechanism for loading DOX into liposomes. 
 
A transmembrane ammonium sulfate gradient is established in liposomes in order to 
encapsulate DOX into the aqueous core.  Free base DOX, designated as DOX-NH2, forms 
dimers with itself, and easily passes through the lipid easily as a neutral entity.  Inside the 
liposome, the high ammonium sulfate concentration allows constant exchange into protons 
and sulfate anions.  DOX-NH2 dimers become protonated, and form a precipitate with sulfate 
anion, which is highlighted in pink.  Adapted from [112]. 
 
(DOX-NH3)2SO4
2DOX-NH2 2DOX-NH2
(NH4)2SO4
2NH3+2H+SO42-
2H++SO42-
= DOX-NH2
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 Apart from increasing drug payload potency, promoting drug leakage is 
another effort which can enhance current liposomal efficacies. As seen in Figure 4.2, 
the transmembrane ammonium sulfate gradient loading mechanism promotes the 
formation of DOX precipitates in the liposomal core.  This mechanism relies on the 
amphipathic weakly basic nature of DOX.  Neutral-charged DOX can form dimers 
with itself via Π electron stacking of planar aromatic rings, can then easily pass 
through the lipid bilayer into the core, where it becomes protonated, and finally 
forms a precipitate with excess sulfate anions.  While this mechanism facilitates high 
DOX encapsulations, it is nearly irreversible, and in order to completely release the 
drug, the ammonium sulfate gradient must be collapsed [28, 112, 113].  To that end, 
we explored cationic liposomes for improved intracellular drug release.  Cationic 
liposomes can associate easily with cell membranes via ionic interactions [114], and 
can further fuse with cell membranes by flip-flopping with native anionic 
phospholipids [115, 116].  This fusion allows liposome drug payloads to escape and 
release into the cytoplasm or even nucleus [114, 117], where chemotherapy drugs can 
then attack their targets. We proposed that the improvement of both drug release 
(via positively-charged lipids) and drug payload potency (via chemotherapy 
combinations) will afford a second generation of liposomes which both ameliorates 
toxicity and augments therapeutic efficacy. 
 
4.3. Effect of cationic charge on liposomal DOX activity 
 Cationic lipids were previously shown to improve both cell uptake and drug 
payload release compared to zwitterionic and negatively-charged lipids [114, 115, 
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117].  Poor DOX release is an inherent issue when incorporated via the strong, nearly 
irreversible transmembrane ammonium sulfate gradient (Figure 4.2), so cationic 
lipids offer a means to enhance DOX intracellular concentrations and thereby 
facilitate drug-target interactions.  Because cationic liposomes exhibit the unique 
abilities to fuse with cell membranes and intracellularly release payloads, they have 
often been exploited for transfection purposes [118-120].  Transfecting liposomes 
typically contain a high content of positively-charged liposomes, 1:1 neutral:cationic 
lipids, and have been shown to be highly toxic [121].  Thus, to obtain the favorable 
properties of drug release while minimizing toxicity issues, only a small fraction of 
cationic lipids (10%) were embedded in the liposome membrane.  Positively-charged 
liposomes also exhibit high affinity for the negatively-charged fenestrae in tumor 
vasculature [122-124], and can thereby provide additional tumor-targeting, 
complementary to the EPR effect. 
 Zwitterionic liposomes (DOX-L) studied here were composed of 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) and cholesterol (Chol; Sigma-
Aldrich; St. Louis, MO, USA) in a molar ratio of 55:45, while cationic liposomes 
(+DOX-L) consisted of DSPC, 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP), and Chol in a ratio of 80:10:10.  Properties of neutral and cationic DOX-
liposomes are provided in Table 4.1.  Incorporation of 10 mol% DOTAP lipids shifted 
the zeta potential from -9.55 mV (zwitterionic liposomes) to +39.93 mV, without 
affecting liposome size or drug encapsulation.  Drug activity (Figure 4.3), however, 
was drastically enhanced upon cationic lipid incorporation.  The DOX-equivalent D50 
concentration was reduced 5-fold, from 33.5 µM to 6.7 µM, between the zwitterionic 
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and cationic liposomal formulations, respectively.  Both DOX-L and +DOX-L were 
less active compared to free DOX (D50 = 0.3 µM), which is expected since liposomes 
must first overcome the added barrier of active cell internalization before the drug 
can interact with its intracellular target. 
 
 
Table 4.1.Physical and chemical properties of DOX-loaded liposomes (n≥3). 
 
 
 
Figure 4.3. Cell inhibitory effects of DOX-L or +DOX-L. 
 
BT-474 cell viability after incubation with DOX in free solution (circles), DOX-L (diamonds), 
or +DOX-L (squares).  Cells were incubated with drug for 72 hrs then analyzed via calcein AM 
assay.  Data expressed as mean ± SD (n≥6). Dashed lines represent dose-effect curves fit to 
the median-effect model, with D50 and R2 of DOX, DOX-L and +DOX-L corresponding to 
(0.30 ± 0.02 µM, 0.98), (33.5 ± 19.2 µM, 0.92) and (6.7 ± 1.01 µM, 0.91), respectively. 
 
 To comprehend the improvement in DOX activity in +DOX-L compared to 
DOX-L, drug internalization studies were conducted.  BT-474 cells were incubated 
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with free DOX, DOX-L or +DOX-L at drug-equivalent concentrations of 1 µM and 
subsequently imaged via confocal microscopy in order to visualize and quantify 
internalized DOX.  Representative images in Figure 4.4a-d demonstrate similar 
intracellular DOX concentrations when cells were exposed to either free DOX or 
DOX-L.  However, cells incubated with +DOX-L exhibited greater DOX fluorescence 
than those exposed to DOX or DOX-L.  Quantification of fluorescence intensities is 
provided in Figure 4.4e, and indeed shows no statistical difference between DOX- 
and DOX-L-treated cells, but a 12-fold enhancement for cells treated with +DOX-L 
compared to DOX-L.  These results elucidate that cationic lipids improve DOX 
uptake and intracellular concentration, and verify the use of positively-charged lipids 
to promote DOX release.  All liposome formulations thereafter included 10% cationic 
lipids in order to facilitate drug release and to better preserve anticancer activity. 
 
 
Figure 4.4. DOX internalization post-incubation with DOX, DOX-L or +DOX-L. 
 
BT-474 cells imaged via confocal microscopy after 24 hr incubation with (a) no drug, or 1 µM 
drug-equivalent concentration of (b) DOX in free solution (c) DOX-L (d) +DOX-L.  After drug 
incubation, cells were washed, stained with Hoechst (blue), and immediately imaged live. (e) 
DOX fluorescence (red) intensity is reported as mean ± SD (n=3). Scale bars=20 µm. 
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4.4. Synthesis of 5FU analogues for liposome entrapment 
 To maintain synergistic drug ratios in vivo, both drugs should be entrapped in 
the same vehicle so as to circulate systemically as one unit in the prescribed ratio.  
The transmembrane ammonium sulfate gradient, however, was developed for the 
incorporation of amphipathic weak bases, geared specifically for anthracycline 
chemotherapy drugs, and presents difficulty for the entrapment of agents from 
different drug classes.  Thus, to incorporate 5FU and DOX in the same liposome, 
various modifications of 5FU were introduced and investigated for compatibility 
with the transmembrane ammonium sulfate gradient.  Each 5FU analogue modified 
the native drug's chemical properties to facilitate incorporation in liposomes.  This 
section describes the synthesis of each of these 5FU analogues, and Section 4.5 
provides the methodology behind each chemical modification. 
 The preparation of 5FUG, 1-[(aminomethyl)-ester]methylene-5-fluorouracil, 
was performed similarly to the procedure presented by T. Ouchi and co-workers 
[125], as shown in Reaction Scheme 4.1. Briefly, 80 μL (1.07 mmol) of aqueous 37 
w/w% formaldehyde was added to 100 mg (0.769 mmol) of 5FU and the reaction 
was kept at 60°C overnight under mild stirring.  The resulting solution was then 
concentrated using a Buchi R-210 rotary evaporator at 45°C and 30 mbar for 2 
hours, to obtain an viscous oil comprising a mixture of three products demonstrated 
in Reaction Scheme 4.1.  The hydroxymethyl‐5FU (HMFU) contained therein was 
recrystallized with ethanol and dissolved in dry DMSO, to which 180 μL of N,N′-
Diisopropylcarbodiimide (DIC; Sigma-Aldrich), 160 mg of N-(tert-
Butoxycarbonyl)glycine (Boc-glycine; Sigma-Aldrich), and 190mg of 4-
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(Dimethylamino)pyridine (DMAP; Sigma-Aldrich) were added.  The reaction was 
allowed for 6 hours at room temperature under vigorous stirring to yield the 
products shown in Reaction Scheme 4.1.  The solution was then copiously washed 
with 1N HCl and brine. The organic layer thus formed was dried with anhydrous 
sodium sulfate and evaporated to return an oily liquid. The 5FU-Glycine(Boc) was 
then precipitated and thoroughly washed with abundant ice-cold methyl isopropyl 
ether. To remove the Boc protection, 5FU-Glycine(Boc) was dissolved in 5 mL of 
50% trifluoroacetic acid (TFA) in dichloromethane (DCM) and the solution stirred 
for 1 h at room temperature.  5FUG was crystallized by solvent evaporation and 
purified using Sep-Pack 2mL C-18 columns (Waters; Milford, MA, USA), to separate 
the fraction containing the desired product.  Mass spectrometry analysis (Figure 
4.6a) verified that the desired product, 5FUG (m/z = 217),was present in high yield. 
 
Reaction Scheme 4.1. Chemical synthesis of 5FUG or 5FUW. 
 
(a) Reaction of 5FU and formaldehyde to form HMFU, followed by esterification with BOC-
glycine.  Three possible products are shown for each step.  (b) Final 5FUG obtained after BOC 
removal with 1:1 TFA:DCM, and  purification via Sep-Pak C-18 columns. (c) Replacement of 
BOC-glycine with tryptophan results in the formation of 5FUW. 
a
b c
5FUG 5FUW
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 5FUW, tryptophan 5-fluorouracil ester, was synthesized similarly.  
Tryptophan hydrochloride (Sigma-Aldrich) and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC; Sigma-Aldrich) were separately dissolved in 
dry DMSO in a proportion 1:1.1.  The activated tryptophan was then added to the 
HMFU synthesized above, and allowed to react overnight at room temperature 
under mild stirring, to form an ester of tryptophan and HMFU.  The product was 
precipitated in ice-cold water and the resulting crystals washed with acetone and 
dried. The 5FU-tryptophan ester was purified via reverse phase chromatography 
using Sep-Pack C18 cartridges and dried under vacuum. 
 
 
 
Reaction Scheme 4.2. Chemical synthesis of 5FURW. 
 
5FURW was synthesized by esterification of 5FUR and tryptophan. 
 
 The synthesis of 5FURW, tryptophan 5-fluorouridine ester, was achieved by 
Reaction Scheme 4.2.  5-Fluorouridine (5FUR; Sigma-Aldrich), tryptophan 
hydrochloride, DMAP and EDC were mixed in a proportion of 1:3:3.5:3.5 in 1:1 
DMSO:water, pH 6.5, and reacted overnight at 60 °C under mild stirring. The 
resulting 5FURW was purified via reverse phase chromatography using Sep-Pack 
EDC
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C18 cartridges and dried under vacuum. Nuclear magnetic resonance (NMR) spectra 
of the reactants and final product is provided in Figure 4.5b, acquired on a Varian 
600 MHz magnet. Characteristic chemical shifts of both 5FUR (a-c) and tryptophan 
(e-f) were present in 5FURW, with a noticeable spread in chemical shift compared to 
unreacted reagents.  These shifts are likely attributed to the significant change in 
electronic environment caused by the closer proximity of multiple aromatic moieties.  
The disappearance of (d) chemical shifts relative to unreacted 5FUR suggests the 
near-complete reaction of ribose hydroxyl groups.  Furthermore, integration of 
chemical shifts shows an average ratio of 1:2.95 for single protons corresponding to 
5FUR and tryptophan, respectively.  NMR characterization therefore confirms the 
reaction of 5FUR with tryptophan, in a molar ratio of 1:3. 
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Figure 4.5. Characterization of 5FU analogues. 
 
(a) Mass spectrometry analysis of the fraction containing 5FUG, obtained by Reaction 
Scheme 4.1.  (b) NMR spectroscopy of reactants and product of Reaction Scheme 4.2. Spectra 
of d6-DMSO, 5FUR, tryptophan, and 5FURW are designated as (1), (2), (3), and (4), 
respectively.  Characteristic peaks are labeled as a-f, and integrations are provided for the 
final product 5FURW. 
 
4.5. Liposome encapsulation of 5FU analogues 
 All 5FU analogues were methodically designed to improve drug encapsulation 
in liposomes.  Contrary to DOX, 5FU is small (130 Da vs. 543 Da) and neutral, which 
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allows it to permeate in and out of the lipid bilayer easily, further resulting in poor 
liposomal retention.  The overarching concept of all analogues was to synthesize 
prodrugs of 5FU, wherein the cleavable component vested similar chemical 
properties as DOX, such as amphipathicity, aromaticity and weak basicity.  To 
optimize 5FU encapsulation in cationic liposomes bearing a transmembrane 
ammonium sulfate gradient, each pro-drug was incorporated at various stages of 
liposome fabrication.   Only the method which yielded highest entrapment of each 
analogue is reported, and Table 4.2 summarizes the findings from these studies. 
Unmodified 5FU was best incorporated when introduced in the organic phase, and 
only resulted in 0.7 mol% relative to lipid. This poor retention substantiated the need 
for a novel 5FU liposomal encapsulation method.  It is noteworthy that 5FU 
incorporation in liposomes bearing a transmembrane ammonium sulfate gradient 
was previously tried, also to no avail [126].   
 The first attempt aimed to improve the basicity of 5FU through the 
incorporation of a free amine.  The free amine in DOX governs its ability to form a 
salt in the presence of ammonium sulfate.  To incorporate a free amine which is 
inherently non-toxic, the simplest amino acid, glycine, was conjugated to 5FU as 
described in the previous section.  The highest yield of 5FUG encapsulation in 
liposomes was 1.4 mol%, double that of unmodified 5FU, and was achieved by 
incorporation in the ammonium sulfate lipid film hydration solution.  However, to 
be able to fine-tune ratios in liposomes co-loaded with DOX, the yield of 5FU 
encapsulation should be similar to that of DOX, ~14-24 mol% drug with respect to 
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lipids [127].  Despite the free amine addition to improve drug basicity, 5FUG was still 
poorly incorporated at ten-fold lower encapsulations compared to DOX.   
 
Table 4.2. Physical and chemical properties of liposomes containing 
5FU analogues with lipid composition of 80:10:10 DSPC:DOTAP:Chol (n≥3). 
 
 The next derivative investigated was tryptophan conjugated to 5FU (5FUW), 
utilizing the same chemistry as 5FUG.  Tryptophan is weakly basic due to its free 
amine, but contrary to glycine, is also aromatic due to its indole moiety.  Aromaticity 
plays a crucial role in liposomal DOX encapsulation, as the intra-liposomal 
oligomerization of DOX is attributed to the Π electron stacking of planar aromatic 
5FU Analogue
Drug 
Incorporation 
(mol%)
Size (nm)
Zeta Potential 
(mV)
5FU 0.7  ± 0.2 173.5 ± 43 41.7 ± 9.8
5FUG 1.4  ± 0.5 161.8 ± 10.8 41.2 ± 1.8
5FUW 3.2  ± 0.4 167.4 ± 1.8 19.6 ± 0.6
5FUR 3.7  ± 0.2 177.4 ± 2.8 37.9 ± 1.0
5FURW 26.6  ± 2.4 163.8 ± 17.2 32.2 ± 6.5
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rings [128].  The integration of planar aromatic rings in a 5FU prodrug can facilitate 
Π electron stacking to other 5FU prodrugs as well as to DOX, and can potentially 
improve the retention of 5FU.  5FUW was best encapsulated when exposed to 
liposomes after generation of the transmembrane ammonium sulfate gradient, for 2 
hours at 65ºC.  The addition of the free amine and aromaticity in the 5FU analogue 
5FUW slightly improved drug incorporation to 3.2 mol%, and additional 5FU 
analogues were further investigated to enhance encapsulation. 
 5-fluorouridine (5FUR) is the ribosylated nucleoside analogue of 5FU, and is 
both a metabolite and precursor of the original drug.  5FU can be converted to 5FUR 
and vice versa in vivo through uridine phosphorylase, and thus both 5FUR and 5FU 
are metabolized to the same active products, 5-fluorouridine monophosphate 
(FUMP) and 5-fluorodeoxyuridine monophosphate (FdUMP) to elicit both RNA and 
DNA damage, respectively [54-56].  Because of this, 5FUR is projected to behave 
similarly to 5FU, including its synergistic interaction with DOX, and was 
investigated for encapsulation in liposomes.  5FUR is commonly utilized as a plant 
growth regulator and is therefore commercially available.  Unmodified 5FUR was 
also best incorporated post-generation of the ammonium sulfate gradient for 2 hours 
at 65ºC.  As seen in Table 4.2, 5FUR can be entrapped in liposomes to a greater 
extent than the original 5FU, about a five-fold enhancement to 3.7 mol% drug 
encapsulation. The more attractive advantage of utilizing 5FUR rather than 5FU, 
however, is that it inherently contains three hydroxyl groups for multiple 
conjugations of amino acids. 
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 The next derivate investigated for 5FU, consequently, was 5FUR triply 
conjugated to tryptophan (5FURW) via the hydroxyl groups (Section 4.4).  This 
modification should enhance both the basicity and aromaticity compared to the 
5FUG and 5FUW analogues, and was projected to improve drug incorporation in 
liposomes.  Like unmodified 5FUR, 5FURW yielded the greatest encapsulation when 
introduced after generation of the ammonium sulfate gradient for 2 hours at 65ºC.  
As seen in Table 4.2, 5FURW achieved the greatest entrapment out of all the 5FU 
analogues considered, a 38-fold enhancement to 26.6 mol%, which is very similar to 
the encapsulation yields of DOX.  The methodology to synthesize a 5FU analogue 
similar to DOX in both basicity and aromaticity resulted in encapsulation yields 
identical to that of DOX.  Therefore, 5FURW served as the 5FU analogue for further 
co-encapsulation with DOX in liposomes. 
 To the best of our knowledge, there is no reported method for encapsulating 
5FU in liposomes bearing a transmembrane ammonium sulfate.  In fact, it was 
previously reported that the exact opposite approach, utilizing basic media (~pH 
8.6), is required for liposomal encapsulation of 5FU [129].  A possible reason for this 
is that 5FU lacks a charge, and can therefore easily pass through the lipophilic 
bilayer to escape the liposome.5FU has only been reported to exist in anionic forms, 
which occur at neutral pH [130], and hence not in liposomes bearing an acidic pH 
gradient.  Thus, for the purpose of simultaneously co-delivering 5FU+DOX, it was 
imperative that we develop our own method. By employing the nucleoside analogue 
of 5FU, we were able to attach chemical moieties bearing the two key properties of 
DOX drive its liposomal incorporation: a free amine and aromaticity.  These 
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modifications were also designed to be hydrolyzable in order restore the active drug 
which is synergistic with DOX. While this approach was demonstrated only for 5FU, 
it can be theoretically applied to the entire class of nucleobase analogue 
chemotherapies, such as cytarabine, gemcitabine, and decitabine, all of which 
contain pendant hydroxyl groups that can be conjugated to tryptophan.  Tryptophan 
modification has implications not only for delivering agents that previously could not 
be liposomally entrapped, but also for combination co-delivery of the many drugs 
that can be compatible with this encapsulation method. 
 
4.6. Synergistic activity of 5FURW and DOX 
 Retaining drug synergy, however, is of the utmost importance next to feasible 
encapsulations of both drugs.  Prior to incorporating both 5FURW and DOX in 
liposomes, optimal synergistic ratios between the new 5FU analogue and DOX were 
identified.  BT-474 cells were exposed to various ratios of 5FURW and DOX, and 
synergistic interactions were assessed utilizing the CI method.  5FURW and DOX 
were tested in a broader range than the initial 5FU and DOX studies in order to 
identify multiple synergistic ratios, with the hindsight that some ratios may not 
feasibly be incorporated in liposomes.  The dependence of anticancer synergy on 
ratio is seen in Figure 4.6a.  Slight synergy occurred when low doses of 5FURW were 
combined with high doses of DOX (R=0.1), and extreme synergy was observed when 
high doses of 5FURW were combined with low doses of DOX (R ≥ 75).  These 
synergistic regimes are similar to the original synergistic interactions observed with 
unmodified 5FU and DOX, which occurred at R ≤ 0.5 and R = 819. 
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 Since 5FURW hydrolyzes directly to its precursor, 5FUR, synergistic 
interactions were also investigated between 5FUR and DOX.  As seen in Figure 4.6a, 
5FUR and DOX exhibit synergy at extreme ratios (R ≤ 1 and R = 600), as well.  While 
the exact synergistic ratios are slightly different, the regimes of synergy are similar 
across the various analogues of 5FU tested, and attests to the potent interactions 
between this particular combination.  It appears that low doses of 5FU combined 
with high doses of DOX and high DOX doses combined with low 5FU doses are 
synergistic regardless of whether the 5FU analogue is immediately active or requires 
metabolization first.  The discrepancies between exact ratios may be attributed to the 
need for hydrolytic cleavage or metabolization prior to the interactions of the active 
forms of both drugs. 
 
 
Figure 4.6. CIs for 5FUR+DOX, 5FURW+DOX, and 5FURW-L+DOX-L. 
 
(a) CI for 5FUR+DOX (blue, left bars) or 5FURW+DOX (green, right bars). Drug 
concentrations for 5FUR and DOX, respectively, corresponding to each R were: 0.1 (0.06, 
0.60), 0.5 (0.15, 0.3), 1.0 (0.3, 0.3), 5.0 (1.5, 0.3), 19 (2.9,0.15), 75 (11.25, 0.15), 150 (22.5, 
0.15), 300 (22.5, 0.075), 600 (45, 0.075).  Drug concentrations for 5FURW and DOX, 
respectively, corresponding to each R were: 0.1 (0.06, 0.60), 0.5 (0.15, 0.30), 1 (0.30, 0.30), 5 
(1.50, 0.30), 19 (5.60, 0.30), 75 (22.50, 0.30), 150 (45.00, 0.30), 300 (45.00, 0.15), 600 
(90.0, 0.15). (b) CIs calculated for various ratios of 5FURW-L and +DOX-L. Drug 
concentrations for 5FURW and DOX, respectively, corresponding to each ratio were: 0.1 
(0.30, 2.40), 0.5 (0.60, 1.20), 1 (1.20, 1.20), 5 (22.50, 4.70), 19 (45.00, 2.40), 75 (180.00, 
2.40), 150 (180.00, 1.20), 300 (180.00, 0.60), 600 (360.00, 0.60). BT-474 cells were exposed 
to combinations for 72 hours. Data shown as average ± SD (n≥6). 
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 After verifying that 5FURW was both easily incorporated in liposomes and 
synergistic with DOX, single-drug loaded liposomes were tested for synergy to assess 
whether particle encapsulation compromises drug synergy.  Combination indices 
were calculated for 5FURW-L and +DOX-L exposed to BT-474 cells, and the results 
are provided in Figure 4.6b.  Contrary to the free drug counterparts, the single drug-
loaded liposomes only synergistically inhibited cancer cell growth at one extreme 
regime, R ≤ 1.  Although the free drugs were synergistic for R > 75, the liposome-
encapsulated forms were highly antagonistic (CI » 1), with CIs two orders of 
magnitude greater than those of the synergistic ratios.  While this was a surprising 
finding, it is not unusual since particle encapsulation can impact drug internalization 
and intracellular concentrations, which can further alter drug-drug interactions.  
These results elucidate an added challenge of combination chemotherapy co-
delivery, that the ratios at which free drugs are synergistic are not necessarily the 
same as those of the liposome-encapsulated form. Since 5FU and DOX consistently 
elicited synergistic cancer cell kill at R ≤ 1, regardless of whether they were 
entrapped in liposomes, this was the regime that was sought for their dual 
encapsulation in liposomes. 
 
4.7. Co-encapsulation of 5FURW and DOX in liposomes 
 Finally, both 5FURW and DOX were simultaneously encapsulated in 
liposomes in order to create a nanoparticle that can conserve their synergistic ratio 
in vivo.  To achieve co-encapsulation, 5FURW was first introduced to liposomes 
bearing an ammonium sulfate gradient for 2 hours, followed by DOX loading for 30 
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minutes.    Two ratios, one synergistic and one antagonistic, were incorporated in 
liposomes, and a third formulation of PEGylated liposomes with the synergistic ratio 
was fabricated for in vivo studies. PEGylated liposomes were prepared using 
DSPC:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (mPEG-DSPE):DOTAP:Chol in a ratio of 75:5:10:10.  The physical and 
chemical properties of all three liposome formulations are listed in Table 4.3.  
Liposomes encapsulated with a ratio of 12.2 were designated as ant-L, as their free 
drug contents exhibited CI > 1 and should be antagonistic (Figure 4.6a).  Similarly, 
liposomes carrying a ratio of 0.18 were designated as syn-L, as their free drug 
contents elicited CI < 1 and should be synergistic.  The ability to incorporate various 
ratios of 5FURW+ DOX, spanning multiple orders of magnitude, verifies that the 
tryptophan modification developed in the previous section is a robust liposome 
incorporation method.  The sizes and diameters of ant-L and syn-L are very similar 
(156.9 nm vs. 149.8 nm and 36.2 mV vs. 35.7 mV, respectively); the primary 
difference between the two formulations is the ratio of their drug payloads. 
 
 
Table 4.3. Physical and chemical properties of liposomes containing 5FURW and DOX. 
 
Lipids composition for all liposomes was 80:10:10 DSPC:DOTAP:Chol, except for DAFODIL, 
which consisted of 75:5:10:10 DSPC:mPEG-DSPE:DOTAP:Chol.  Drug loadings and DLS 
measurements are reported as mean ± SD (n≥3). 
 
ant-L 12.2 0.45 ± 0.02 5.47 ± 0.94 156.9 ± 5.7 36.2 ± 0.5
syn-L 0.18 7.75 ± 0.09 1.41 ± 0.47 149.8 ± 15.1 35.7 ± 4.3
DAFODIL 0.15 14.82 ± 0.69 2.17 ± 0.23 168.8 ± 18.7 -23.0 ± 3.0
Liposome   
Formulation
R (5FURW:DOX)
DOX 
Incorporation 
(mol%)
5FURW 
Incorporation 
(mol%)
Size (nm)
Zeta Potential 
(mV)
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 However, this single difference in ratio dictates their anticancer activities, 
which is evident in the comparison of their 4T1 cancer cell growth inhibition.  In 
Figure 4.7a, ant-L exhibits similar cancer cell growth inhibition as liposomes 
containing only 5FURW.  On the contrary, syn-L exhibits superior cell inhibition 
compared to either 5FURW or DOX-loaded liposomes (Figure 4.7a-b).  To 
quantitatively compare the liposome formulations, CIs were calculated and averaged 
for all concentrations tested of ant-L and syn-L.  Indeed, ant-L elicited CI = 1.92 ± 
1.21, indicating antagonistic cancer cell kill, and syn-L resulted in CI = 0.31 ± 0.24, 
implying synergistic cell kill.  Thus, drug interactions in co-loaded liposomes were 
consistent with free drug interactions found in Figure 4.6a.   
 PEGylation of liposomes, especially positively charged, is necessary for 
prolonged systemic circulation because it prevents opsonization, allowing the 
nanoparticles to evade the immune system [104, 131].  Therefore, a PEGylated 
version of syn-L was fabricated and designated as DOX And 5FU Optimally 
Delivered In Liposomes (DAFODIL).  For DAFODIL, a small fraction (5 mol%) 
PEG2000-DSPE was incorporated in the lipid bilayer, and resulted in a slightly 
larger size of 168.8 nm compared to syn-L (149.8 nm), as well as a change in ζ 
potential.  Upon PEGylation, the cationic lipids became shielded, as was evident in 
the ζ potential of -23.0 mV.  Drug encapsulations and ratios were only slightly 
altered. The inclusion of PEG allowed twice as much DOX retention compared to 
non-shielded liposomes, and may be a result of the added barrier of long, hydrophilic 
polymeric chains which must be overcome for drug release. Despite this increase in 
drug incorporation, encapsulated drug ratio was only slightly shifted from R=0.18 to 
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R=0.15, in favor of greater free drug synergy.  The anticancer activity of DAFODIL 
surpassed that of syn-L, as seen in Figure 4.6a-b, which may be a consequence of the 
more favorable synergistic ratio DAFODIL carries.  Lastly, differential dug release 
from DAFODIL was measured via dialysis.  Results in Figure 4.6c show that 5FURW 
is released slightly faster than DOX, and that acidic conditions accelerate drug 
release.  Therefore, the effective free drug ratio which is exposed to cancer cells is 
slightly higher than the ratio encapsulated in liposomes, but is evidently still potent 
at inhibiting cell growth.  Fundamentally, these results show that the synergistic 
activity of 5FUR and DOX can be preserved when co-loaded in liposomes, with or 
without PEGylation, and provides promise for translating this combination in vivo. 
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Figure 4.7. In vitro anticancer activity of 5FURW and DOX co-loaded liposomes. 
 
4T1 cancer cell growth inhibition by various 5FURW- and DOX- co-encapsulated liposomes.  
(a) Comparison of 5FURW single-loaded liposomes (circles) to ant-L (R=12.2, diamonds), 
syn-L (R=0.18, squares), and DAFODIL (R=0.15, triangles).  (b) The same co-loaded 
liposomes in (a) are compared to +DOX-L (circles). Dashed lines represents fits to the median 
effect model. Average calculated CI for the cell inhibition data of ant-L and syn-L are 1.92 ± 
1.21 and 0.31 ± 0.24, respectively. Data reported as average ± SD (n≥6).  (c)  Drug release of 
5FURW at pH 5.5 (diamonds) and pH 7.4 (triangles) or DOX at pH 5.5 (circles) and pH 7.4 
(squares) from DAFODIL in PBS.  Data shown as average ± SD (n=3). Lines represent 
exponential fits to release profiles (t1/2,R = 14.1, 27.7, 26.9, and 35.3 for 5FURW pH 5.5, 
5FURW pH 7.4, DOX pH 5.5, and DOX pH 7.4 respectively). 
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4.8. In vivo efficacy of 5FURW and DOX co-loaded liposomes 
 To investigate if the drug delivery advantages of liposomes can be utilized to 
improve the efficacy of combination chemotherapies, liposomes co-loaded with a 
synergistic ratio of 5FURW and DOX were finally challenged against an animal 
tumor model in vivo. The highly metastatic and aggressive 4T1 mouse breast cancer 
model was adopted to challenge the formulations with more advanced, difficult to 
treat cancers.  This model was also chosen for its robust tumor formation in 
immuno-competent BALB/c mice, which allows for a more accurate depiction of 
nanoparticle clearance and efficacy compared to models in immuno-incompetent 
mice.  As seen in Figure 4.7a-b, liposomes co-loaded with a synergistic ratio of 
5FURW+DOX are effective at inhibiting 4T1 cancer cell growth in vitro.  However, 
this synergy may be difficult to capture in vivo due to uncoordinated drug 
pharmacokinetics and fast plasma clearance of the small molecule drugs when 
injected intravenously (i.v.) as free solutions.  Clinical studies have shown that 5FU 
and DOX exhibit elimination half lives of 8-22 minutes [132] and 4-5 minutes [14], 
respectively.  These rapid clearance rates demonstrate a clear need for nanoparticle 
delivery to ensure concurrent delivery to tumors. In vivo tumor growth inhibition 
studies comparing the efficacy of liposome and free drug formulations of 
5FURW+DOX will elucidate if liposomes are capable of overcoming the drug 
delivery challenges of combination chemotherapies. 
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Figure 4.8. Tumor growth inhibition of syn-L. 
 
(a) Tumor growth of mice bearing 4T1 breast cancer tumors, without treatment (circles), with 
i.v. injections of low dose syn-L (squares), or high dose syn-L (triangles).  Low dose syn-L 
treatments consisted of drug-equivalent doses of 1 mg/kg DOX + 0.3 mg/kg 5FURW, while 
high dose syn-L treatments consisted of 4 mg/kg DOX + 1.1 mg/kg 5FURW.  Arrows indicate 
days of treatment.  (b) Effect of treatment on body weight fluctuations. Data is reported as 
mean ± SE (n≥5). (c) Survival rates for all treatment groups. 
 
 Initial studies investigated the efficacy of non-PEGylated syn-L.  Mice we 
retreated with low dose (1 mg/kg DOX + 0.3 mg/kg 5FURW) or high dose (4 mg/kg 
DOX + 1.1 mg/kg 5FURW) syn-L via i.v. tail vein injections on Days 3, 5, 7, 9, 11, and 
13 post tumor-inoculation.  Control tumor-bearing mice were untreated. Tumor 
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volumes were recorded daily as a measure of therapeutic efficacy (Figure 4.8a), and 
body weight changes were reported (Figure 4.8b) as a measure of formulation 
tolerability.  Results showed no significant difference in tumor growth between syn-
L-treated mice and untreated mice, regardless of dose.  There was also no significant 
difference in body weight changes, suggesting no evident treatment-related toxicity.  
All three groups, however, displayed similar survival rates.  Comparisons of tumor 
growth and survival rates between liposome-treated and untreated mice 
demonstrate that the non-PEGylated liposome formulations are ineffective at 
reducing tumor burden.  Although syn-L is potent at inhibiting cancer cell growth in 
vitro, it is incapable of doing so in vivo. This was not surprising, since cationic 
liposomes are rapidly cleared by the MPS system [51, 104, 131, 133], thereby 
reducing the likelihood of accumulation in tumor tissue. 
 In order to manifest the potency of 5FURW+DOX in vivo, mPEG-DSPE was 
incorporated in the lipid bilayer.  PEG serves as a water soluble polymer that 
prevents protein opsonization and effectively disguises liposomes from MPS 
clearance [104, 131].  This further allows liposomes to circulate longer and increases 
the likelihood of tumor accumulation via the EPR effect.  The PEGylated version of 
syn-L, DAFODIL, was challenged against 4T1 murine breast carcinoma in vivo, at 
drug-equivalent doses of 3 mg/kg DOX + 0.62 mg/kg 5FURW for a total of 7 
alternating injections starting on Day 3.  The resultant tumor growth curves are seen 
in Figure 4.9a. 
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Figure 4.9.  Tumor growth inhibition of 7 injections of DAFODIL. 
 
(a) Tumor growth of mice bearing 4T1 breast cancer tumors, without treatment (circles), with 
i.v. injections of DAFODIL (squares), or free 5FURW+DOX (triangles), for a total of 7 
injections (n≥10). Mice were administered liposomes or free drugs in drug-equivalent doses 
of 3 mg/kg DOX + 0.62 mg/kg 5FURW.  Arrows indicate days of treatment. (b) Effect of 
treatment on body weight fluctuations. Data is reported as mean ± SE.  Mice were provided 
daily Diet Gel supplements starting on Day 17 in hopes to revert weight loss. (c) Survival rates 
for all treatment groups. 
 
 In stark contrast to its non-PEGylated counterpart, DAFODIL was able to 
significantly inhibit tumor growth by a remarkable 95% (31 vs. 623 mm3) compared 
to untreated tumors.  At 59% (256 vs. 623 mm3) tumor growth reduction, the free 
drug-equivalent administration was significantly less effective than the liposomal 
formulation.  These results are drastically different than those seen for the syn-L, 
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and emphasize the importance of stealth properties for chemotherapy drug delivery.  
Unfortunately, DAFODIL at the 7 injection high dosing schedule was toxic as evident 
by >10% body weight loss (Figure 4.9b).  Diet gel supplements were provided daily 
starting on Day 17, the onset of noticeable weight loss; however, the toxicity seemed 
irreversible.  Therefore, although DAFODIL reduced tumor burden, it did not 
improve overall survival rates (Figure 4.9c), and the study was terminated to prevent 
additional treatment-related toxicities. 
 Drug optimizations are common in the clinic, and often initial drug doses 
must be reduced in order to find a well-tolerated therapeutic window of drug 
formulations.  To see if a high therapeutic effect could be achieved with a lower, 
more tolerable dose of DAFODIL, the study was repeated with half the injections.  
Mice were injected at the same dose (3 mg/kg DOX + 0.62 mg/kg 5FURW) starting 
on Day 3 for a total of 4 injections.  As seen Figure 4.10a-b, significant tumor 
reduction was maintained at the 4 injection schedule without a reduction in body 
weight.  By day 23, the last day of >50% untreated mice survival, liposomes elicited 
91% (77 vs. 904 mm3) tumor growth inhibition, whereas free 5FURW+DOX at the 
same doses were only capable of inhibiting 39% tumor growth (547 vs. 904mm3).  
Moreover, all tumors treated with free 5FURW+DOX eventually grew to the same 
sizes as control mice, and hence were only able to extend average survival of 
untreated mice by 4 days (24 vs. 28 days). 
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Figure 4.10.  Tumor growth inhibition of 4 injections of DAFODIL. 
 
(a) Tumor growth of mice bearing 4T1 breast cancer tumors, without treatment (circles), with 
i.v. injections of DAFODIL (squares), or free 5FURW+DOX (triangles), for a total of 4 
injections (n=8 except for last two control data points where n≥5).  Mice were administered 
liposomes or free drugs in drug-equivalent doses of 3 mg/kg DOX + 0.62 mg/kg 5FURW 
(same as study in Figure 4.9).  Arrows indicate days of treatment. (b) Effect of treatment on 
body weight fluctuations. Data is reported as mean ± SE.  Significance is reported for Day 23.  
(c) Survival rates for all treatment groups.  
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Figure 4.11.  Tumor growth profiles of mice treated with DAFODIL. 
 
Individual tumor growth profiles of mice bearing 4T1 breast cancer tumors, treated with 4 i.v. 
injections of DAFODIL.  Mice were administered DAFODIL in drug-equivalent doses of 3 
mg/kg DOX + 0.62 mg/kg 5FURW (same as Figure 4.10).  Arrows indicate days of treatment.  
Bottom graph is a smaller scale version of the top graph, to provide greater detail. 
 
 Figure 4.11 shows the individual tumor growth profiles for each mouse treated 
with DAFODIL.  Contrary to free drug-treated mice, the majority of DAFODIL-
treated mice maintained low tumor sizes while 3/8 eventually developed recurring 
tumors.  Figure 4.11 shows that most liposome-treated mice reached a peak tumor 
volume between 50-80 mm3 on Day 28, followed by tumor regression and finally, 
complete eradication.  No detectable tumors in 5/8 mice was observed for the 
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remainder of the study.  The 3/8 liposome-treated mice with recurring tumors 
experienced significantly slowed tumor growth; all untreated mice had 1000 mm3 
tumors by Day 26, whereas the first liposome-treated mouse to reach 1000 mm3 
tumor volume occurred at Day 44.  Because of these immense therapeutic effects, 
treatment with highly synergistic DAFODIL significantly extended average survival 
by at least 44 days relative to untreated mice.  On the contrary, free 5FURW+DOX 
only extended median survival by 4 days relative to untreated mice.  To the best of 
our knowledge, this is the first time that 4T1 tumor growth was inhibited by >90% 
at a cumulative DOX dose < 15 mg/kg, either used as a single agent or combined 
with another chemotherapy drug [46, 134-141].  This enhanced therapeutic efficacy 
is likely attributed to the synergistic interactions between 5FURW+DOX, 
compounded with tumor accumulation due to cationic liposomal delivery. 
 In addition to successful tumor treatments, 4 injections of DAFODIL 
demonstrated good safety in tumor-bearing mice.  Unlike the higher dose schedule 
of 7 injections, the low dose schedule of 4 injections did not result in weight loss. 
Figure 4.10b shows that untreated tumor-bearing mice exhibited 5% increase in 
body weight, while liposome-treated mice gained 2% in body weight.  Overall growth 
is anticipated as the mice are only 6-8 weeks of age at time of tumor inoculation, and 
this difference in growth between treatment groups was found to be statistically 
significant.  However, it is likely that the increased weights of control mice was 
actually the tumor weights due to their large volumes.  In fact, it has been shown in 
literature that tumor volume can encompass up to 28% of total body weight [142-
144].  In addition, liposome-treated mice did not exhibit signs of pain or distress, 
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such as ruffled hair or reduced physical activity.  Therefore, mice treated with 4 
injection DAFODIL did not elicit any obvious signs of adverse side effects.  Mice 
treated with free 5FURW+DOX at the same doses, however, lost 5% body weight 
shortly before euthanasia.   
 To the best of our knowledge, this was the first instance of 5FU-incorporated 
liposomes in vivo which were well-tolerated and effective at inhibiting tumor 
growth.  Previously, liposomal 5FU encapsulation has been too low to allow 
injections of therapeutically active doses [123], or 5FU liposomes elicited ~20% body 
weight reduction and were toxic [145].  In the latter study, toxicity was attributed to 
fast leakage of 5FU from liposomes post-administration. Altogether, our studies 
demonstrate that PEGylated liposomal administration of 5FURW+DOX is more 
therapeutically effective and better tolerated than free 5FURW+DOX, and arguably 
compared to any liposomal of combination formulation of 5FU or DOX. PEGylation 
was required to extend circulation of and enhance tumor accumulation of cationic 
liposomes, while dose optimization was necessary to reduce side effects.  With these 
modifications, 5FURW+DOX co-loaded liposomes delivered a potent therapeutic 
which reverted aggressive 4T1 tumor growth in most mice, while also maintaining 
overall health. 
 
4.9. Summary of liposomes for synergistic chemotherapy delivery 
 Here, we sought to co-deliver the synergistic drug pair 5FU+DOX which is 
commonly employed in many gastric and breast cancer treatment regimens, in an 
effort to improve upon their therapeutic efficacy.  Although they encompass an 
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archetypal chemotherapy combination, they rarely achieve complete eradication of 
tumors [8, 96].  Cationic liposomes were investigated for multiple reasons: their 
ability to direct drugs to tumors via the EPR effect and negative fenestrae present on 
tumor endothelium [122-124], their ionic interaction with cell membranes which 
facilitate uptake and drug release [114-117], as well as for the general ability of 
liposomes to alleviate adverse side effects [100-102].  Single-drug loaded liposomes, 
such as DoxilTM, consistently reduce cardiotoxicity thereby increasing the maximum 
tolerable dose of DOX.  However, this extension of safe DOX doses does not 
necessarily improve antitumor efficacy.  By combining the power of combination 
chemotherapies with the targeting and stealth abilities of liposomes, we were able to 
administer low dose, yet potent payloads to tumors and achieve remarkable tumor 
reduction in a highly aggressive mouse breast cancer model. 
 This chapter elucidated the complexities in liposomal drug encapsulations.  
Because liposomes entrap and are surrounded by aqueous medium, water soluble 
drugs can diffuse easily in and out of the nanoparticles.  Transmembrane gradients 
which favor the encapsulation of a particular drug, such as the ammonium sulfate 
gradient, can be applied, but often are geared towards the retention of one drug and 
offer poor encapsulation of another.  5FU and DOX, for example, are easily 
incorporated in liposomes with drastically different acidities.  5FU is best entrapped 
in liposomes with pH 8.6 [129], while DOX is best encapsulated at liposomes bearing 
pH 4-5 [127].  To incorporate multiple drugs into a single liposome, novel driving 
mechanisms which are compatible with their differing chemical properties must be 
developed. Celator Pharmaceuticals, Inc. has developed multi-drug loaded liposomes 
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with huge success; cytarabine+daunorubicin loaded-liposomes (CPX-351) is in Phase 
III clinical trials for secondary acute myeloid leukemia, and two other formulations 
are in Phase II studies.  However, this is the first report, to our knowledge, which 
applied the well-established transmembrane ammonium sulfate gradient to 
nucleobase analogues, specifically 5FU.  Using a methodological approach, we were 
able to incorporate the chemical moieties which facilitate DOX incorporation into a 
hydrolyzable prodrug analogue of 5FU.  Furthermore, the modification required a 
non-toxic addition of tryptophan, and did not compromise synergy between 
5FU+DOX. 
 Although this study only focused on 5FU+DOX encapsulations, this same 
approach can be applied to many other ribosylated nucleobase analogues, provided 
that they possess hydroxyl groups for esterification with tryptophan.  What was once 
only useful for anthracycline incorporation into liposomes, the well-established pH 
gradient encapsulation method could now be utilized for multi-drug incorporation of 
numerous chemotherapy pairs.  Compounded with cationic stealth liposomes, 
combination chemotherapies could be delivered in vivo specifically to tumors at 
prescribed synergistic ratios.  This concurrent tumor drug delivery can result in 
amplified tumor reduction compared to free drug treatments. Our multi-faceted 
approach could be implemented to evaluate a plethora of anthracycline and 
nucleobase analogue combinations, in hopes to translate effective and safe 
anticancer therapeutics to the clinic. 
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Chapter 5 
Polymer-drug conjugates for 
chemotherapy co-delivery 
5.1. Advantages of polymer-drug conjugates 
 Conjugation to polymers can help achieve clinical efficacy of chemotherapy 
combinations by promoting drug accumulation in tumors rather than essential 
organs via the EPR effect [146-149], and by ensuring that the tumors are exposed to 
synergistic ratios of the drug pair. Polymer-drug conjugates are actively explored for 
the administration of single chemotherapy agents and have already shown clinical 
benefits over free drug injections [30, 150]: reduced liver accumulation, enhanced 
drug localization in tumors, and improved drug circulation times [151].  
Furthermore, since multi-drug incorporation is governed by chemical reactions as 
opposed to traditional hydrophobic encapsulations, precise ratios of the drugs can be 
conjugated to the polymer and delivered to tumor tissue.  This characteristic 
distinguishes polymer-drug conjugates from most nanoparticles, and is crucial since 
drug ratios can govern whether the combination is synergistic or antagonistic, as 
demonstrated in Chapter 3.  Hence, this class of nano-vehicles presents an elegant 
method to preserve drug ratios after administration in vivo.  To investigate polymer-
drug conjugates for polychemotherapy delivery, the model synergistic drug pair 
CPT+DOX identified in Chapter 3 was employed. To develop polymer-drug 
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conjugates for the concurrent delivery of multiple chemotherapy drugs, the 
conjugation chemistry was first established with a characteristic non-biodegradable 
polymer, poly(vinyl alcohol) (PVA).  The methodology was then applied to a CD44+ 
tumor-targeting biopolymer, hyaluronic acid (HA).   
 
5.2. CPT- and DOX-PVA conjugates 
 Nucleophilic acyl substitution was utilized to conjugate CPT and DOX onto 
PVA (10 kDa), the same chemistry which is commonly employed in clinical 
formulations [152, 153].As shown in Reaction Scheme 5.1, this synthesis comprised 
of two steps.  First, pendant hydroxyl groups of PVA (Sigma Aldrich) were partially 
succinylated (5%) by reaction with succinic anhydride (Sigma Aldrich) using4-
(dimethylamino)pyridine(DMAP) as a catalyst in dry DMSO. The reaction was 
allowed to proceed overnight, under moderate heating and stirring. The succinylated 
PVA (S-PVA) was precipitated and rinsed multiple times in acetone, and finally re-
dissolved in DMSO. The carboxyl groups on S-PVA were activated with EDC to 
further couple CPT and DOX, respectively through ester and amide bonds. The 
resulting polymer-drug conjugates were purified using size exclusion Sephadex G-25 
PD-10 columns (GE Healthcare Life Sciences; Piscataway, NJ, USA) of MWCO 5,000 
Da and concentrated with Amicon® Ultra centrifugal filters of MWCO 3kDa (EMD 
Millipore; Billerica, MA, USA).  CPT-PVA and DOX-PVA are the designations 
utilized for CPT- and DOX- conjugated PVA, respectively, synthesized via Reaction 
Scheme 5.1.  Conjugated CPT and DOX concentrations were determined via 
absorbance at 366 nm and 480 nm, respectively, of vehicle serial dilutions using a 
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Tecan Infinite M200 Pro plate reader.  The resultant single drug incorporations were  
0.39mol% CPT or 0.16mol% DOX relative to PVA.  These conjugation efficiencies are 
expected, since both reaction steps of Reaction Scheme 5.1, the succinic anhydride 
modification of PVA and the esterification of succinic acid, are known to be 
thermodynamically limited [154, 155]. 
 
 
 
Reaction Scheme 5.1. Reactions utilized for incorporation of DOX and/or CPT on PVA. 
 
Reaction 1a activates PVA hydroxyl groups with succinic anhydride to form EDC-reactive 
carboxylic acid side chains.  Reaction 1b shows further conjugation to nucleophilic drugs 
(designated as R1-OH or R2-NH2), with either hydroxyl or amine moieties.  Reaction Scheme 
5.1 was utilized for the synthesis of CPT-PVA, DOX-PVA, and CPT-PVA-DOX. 
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 In order to assess the impact of polymer conjugation on drug activity, initial 
studies evaluated the in vitro cancer cell growth inhibition of CPT-PVA and DOX-
PVA.  MTT cytotoxicity assays which were used to evaluate free drug activities in 
Chapter 3 were also applied to the polymer-drug conjugates.  As seen in Figure 5.1, 
both PVA-drug conjugates were active at inhibiting BT-474 cancer cell growth.  D50 
concentrations of DOX-PVA and CPT-PVA were 1.5 µM DOX and 14 µM CPT, 
respectively. In comparison, D50 concentrations of free DOX and CPT reported in 
Sections 3.2 and 3.6 were 0.3 µM and 100 µM, respectively; hence, conjugation to 
PVA reduced activity of DOX, whereas it enhanced activity of CPT.  The proposed 
cause of these shifts in drug activities are reduced intracellular availability of DOX, 
but improved intracellular concentrations of CPT, and these effects are investigated 
in Section 5.3. 
 
 
Figure 5.1. Cell inhibitory effects of CPT-PVA or DOX-PVA. 
 
Cell inhibition of human breast cancer cell line BT-474 in the presence of CPT-PVA (left) or 
DOX-PVA (right).  Cells were incubated with each polymer-drug conjugate for 72 hrs, then 
subsequently analyzed via MTT assay. Data expressed as mean ± SD (n≥12). Dashed lines 
represent dose-effect curves fit to experimental data using Chou and Talalay’s median-effect 
model.  D50 concentrations determined from the median-effect model are 1.5 ± 0.9 µM DOX 
(R2=0.99) and 14 ± 0.9 µM CPT (R2=0.97) for DOX-PVA and CPT-PVA, respectively. 
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 After establishing that CPT-PVA and DOX-PVA are still active at inhibiting 
cancer cell growth, the two single-drug vehicles were simultaneously exposed to 
cancer cells at various ratios to see if CPT+DOX synergy was also preserved in the 
polymer-bound form.  Combination interactions were evaluated and quantified 
utilizing the CI method (Section 2.3).  As a reminder, free CPT and DOX were 
demonstrated in Section 3.6 to synergistically inhibit BT-474 cancer cell growth at R 
>0.1 M:M CPT:DOX, with the greatest synergy occurring at R > 2.  Figure 5.2a-
bshows that the same synergistic ratios hold true for the PVA-bound drugs; for R > 
2.3, CI values were found to be « 1.  The anticancer activities of single drug-
conjugates which comprise the combinations are also seen in Figure 5.2a-b, and 
verifies that the combination of CPT-PVA + DOX-PVA is indeed more potent at 
inhibiting cancer cell proliferation than either of the individual constituents.   
 To determine whether drug synergy could be conserved in a single nano-
vehicle rather than two separate entities, both CPT and DOX were conjugated to the 
same PVA polymer.   The motivation behind these studies is that only multi-drug 
incorporated vehicles will ensure simultaneous drug exposure to tumors and be able 
to capture the combination's potency that is easily found in vitro.  CPT-PVA-DOX 
was also synthesized via Reaction Scheme 5.1, where CPT was first made to react 
with PVA for 2 hours, followed by the addition of fresh EDC and DOX for 30 
minutes.  This synthesis resulted in the conjugation of CPT and DOX in the molar 
ratio of R = 1.5 (0.015 mol% CPT and 0.010 mol% DOX), which falls within the 
synergistic range (R > 0.1) of the free drugs (Figure 3.8).  The anticancer activity of 
CPT-PVA-DOX conjugates against BT-474 cancer cell growth was evaluated via MTT 
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cytotoxicity assays, and compared to the anticancer activities of CPT-PVA and DOX-
PVA.  As seen in Figure 5.2c-d, CPT-PVA-DOX exhibited more than double the 
potency of either CPT-PVA or DOX-PVA alone.   These studies suggest that CPT and 
DOX synergy can be conserved upon polymer conjugation, provided that the 
polymer-bound drugs are still active and that the two drugs are combined in optimal 
ratios. 
Figure 5.2. Anticancer activity of CPT-PVA + DOX-PVA and CPT-PVA-DOX. 
 
(a) Cell inhibition of human breast cancer cell line BT-474 treated with combinations of CPT-
PVA and DOX-PVA at various molar ratios (blue, left bars).  Single PVA-conjugate treatments 
of DOX-PVA (red, middle bars) and CPT-PVA (green, right bars) at concentrations which 
make-up the combination are juxtaposed for direct comparison.  Drug concentrations (µM) of 
CPT and DOX respectively corresponding to each R ratio were: 0.1 (0.53, 5.34), 0.3 
(0.53,1.89), 0.5 (0.53,1.07), 2.2 (4.27, 1.90), 4.5 (4.27,0.95), and 9.0 (8.54,0.95). Data is 
represented as mean ± SD (n=6). (b) CI values calculated for CPT-PVA and DOX-PVA 
combinations seen in (a). BT-474 cell inhibition in the presence of CPT-PVA-DOX conjugates 
(squares) are compared to that of (c) CPT-PVA alone (circles) or (d) DOX-PVA alone (circles).  
Cells were incubated with formulations for 72 hours, and assessed for cell viability utilizing 
the MTT cytotoxicity assay.  Data is reported as mean ± SD (n≥6). 
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5.3. CPT- and DOX- conjugated to HA 
 While CPT and DOX co-conjugated to PVA showed promising efficacy, PVA is 
not biodegradable in vivo and may elicit more treatment-related toxicities.  
Furthermore, the molecular weight of PVA utilized in Section 5.2. may not be 
suitable for in vivo purposes since polymers ≤ 10 kDa are rapidly cleared from 
systemic circulation [156, 157].  Rather, polymers of 50 kDa MW or higher have been 
shown to effectively accumulate in tumor tissue due to their renal retention and the 
EPR effect [148, 158, 159].  Hence, to assess the therapeutic potential of CPT and 
DOX co-delivery with a more clinically relevant polymer, the drugs were conjugated 
to the biocompatible, biodegradable, and larger (250 kDa) biopolymer hyaluronic 
acid (HA).  HA was chosen not just for its biocompatibility, but also for its specificity 
for surface marker CD44, which is over-expressed on many cancer cells [160-162]. 
 
Reaction Scheme 5.2. Reactions utilized for incorporation of CPT and/or DOX on HA. 
 
CPT- and DOX-conjugation to HA occurs via single-step reaction which involves nucleophilic 
acyl substitution.  CPT-conjugation results from ester formation, and DOX-conjugation 
occurs from both aminolysis and ester formation with the glucoronic acid monomers present 
on HA.  Either aminolysis or ester formation occurs with DOX-conjugation since DOX 
contains both free amine and hydroxyl moieties.  In either case, the same reactants are 
utilized.  Carboxylic acid moieties are activated with EDC and DMAP to catalyze conjugation 
to nucleophilic drugs (designated as R1 and R2), containing either hydroxyl or amine moieties.  
R1 and R2 correspond to the same groups in Reaction Scheme 5.1. 
and/or
and/or
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 CPT and DOX were conjugated to HA (Creative PEGWorks; Winston Salem, 
NC, USA) via similar chemistry utilized for PVA conjugation, nucleophilic acyl 
substitution.  However, as seen in Reaction Scheme 5.2, only a one-step synthesis 
was needed due to the naturally-occurring carboxylic acid moieties present in the D-
glucoronic acid sugar.  Specifically, the carboxylic acid moieties of HA were 
conjugated to CPT via ester formation [163] and to DOX via both ester formation and 
aminolysis [164].  For all reactions, 100 mg of HA was dissolved in a 10 mL mixture 
of DMSO/water (1:1 by volume) under stirring and slight heating (40˚C).  DMAP and 
EDC were added at a molar ratio of 0.75:1 relative to HA monomers, and were 
allowed to activate the polymer for 1 hour under stirring.  To synthesize CPT-
conjugated HA (CPT-HA), CPT was slowly added to the reaction mixture at a molar 
ratio of 0.4:1 CPT:HA. In the case of DOX-conjugated HA (DOX-HA), DOX was 
dissolved in the reaction mixture in a molar ratio of 0.2:1 DOX:HA.  The reactions 
proceeded under slight heating (40˚C) for 3 days.  Afterwards, CPT-HA and DOX-
HA were separated from unreacted free drugs, EDC and DMAP via size exclusion 
chromatography through Sephadex G-25 PD-10 desalting columns (5000 MWCO) 
equilibrated in phosphate buffered saline (PBS, pH 7.4).  The reaction products were 
further concentrated in 0.5 mL centrifugal filter tubes (3000 NMWL) for a minimum 
of three runs, each at 16,000 g for 15 min.  For the final centrifuge run, an additional 
0.4 mL of PBS was added.  Concentrations of CPT and DOX were determined by the 
same methods reported for the PVA-conjugates.  In both CPT-HA and DOX-HA 
formulations, 1.6 mol% drug:HA was achieved.  The drug encapsulation in CPT-HA-
DOX was 5.9 mol% CPT and 1.8 mol% DOX. 
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 To evaluate the impact of HA conjugation on drug activity, cancer cell viability 
post-incubation with CPT-HA or DOX-HA was analyzed via MTT cytotoxicity assays.  
As seen in Figure 5.3, conjugation to HA reduced the activity of DOX compared to 
free drug, whereas the activity of CPT-HA was reduced only slightly compared to that 
of free CPT.  D50concentrations of DOX-HA and CPT-HA were 95.8 ± 47.5 µM DOX 
and 399.5± 34.5 µM CPT, respectively.  These correspond to a 322-fold and 4-fold 
augmentation, respectively, in D50 compared the free DOX and free CPT activities, 
and reflect the qualitative trends seen in Figure 5.3.  These differences in HA-bound 
and free drug activities are similar to the results seen for PVA-conjugates in Section 
5.2.  This is expected since the chemical conjugations and linkers are the same in 
both PVA- and HA-conjugates.  In the case of PVA-conjugates, however, CPT-PVA 
exhibited greater efficacy than free CPT, and this may be attributed to inherent 
differences in polymeric properties. 
 
Figure 5.3. Cell inhibitory effects of CPT-HA or DOX-HA. 
 
Cell inhibition of human breast cancer cell line BT-474 in the presence of CPT in free solution 
(circles) or CPT-HA (squares) (left) or DOX in free solution (circles) or DOX-HA (squares) 
(right).  Cells were incubated with each drug for 72 hrs, then analyzed via MTT assay. Data 
expressed as mean ± SD (n≥8). Dashed lines represent fits to the ME model.  D50 and R2 
corresponding to ME fits are (399.5 ± 34.5 µM CPT, R2=0.99) for CPT-HA and (95.8 ± 47.5 
µM  DOX, R2=0.82) for DOX-HA. 
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 Internalization and release studies were performed to investigate the origins 
of shifts in drug activity upon HA conjugation.  First, internalization of the carrier 
itself, HA, without drug was investigated via confocal laser scanning microscopy 
(Section 2.4).  These studies provided insight as to whether drugs must first 
completely hydrolyze from the polymer extracellularly prior to cell internalization or 
if the HA-drug entity is capable of entering cancer cells as a whole.  BT-474 cells 
were incubated with fluorescein-conjugated HA (Creative PEGworks; Winston 
Salem, NC, USA) for 6 hrs at 37˚C to mimic physiological conditions or 4˚C to 
prevent active endocytosis.  Fluorescence was quantified in averaged 10 µm z-stacks, 
and was normalized to cell count per image.  Results in Figure 5.4a show 
significantly more HA fluorescence, and hence cellular uptake, when exposed to cells 
at 37˚C as opposed to 4˚C.  Incubation at 4˚C prevents energy-intensive 
internalization mechanisms, and resulted in a four-fold reduction of intracellular 
HA.  Thus, cellular uptake of HA occurs via active internalization mechanisms, as 
confirmed by lack of internalization at 4˚C.   
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Figure 5.4. Internalization of HA, CPT-HA, or DOX-HA. 
 
(a) Quantitative fluorescence of fluorescein-conjugated HA present in BT-474  cells  after  6  
hours  of  incubation  at  37˚C  or  4˚C  and  5%  CO2. (b) Quantitative fluorescence of DOX or 
CPT in free solution (red, left bars) or as a HA-conjugate (green, right bars) present in BT-474 
cells after 24 hours of incubation at 37˚C and 5% CO2.  Data expressed as mean ± SD (n=3). 
(c) Representative images of CPT (cyan) internalization when incubated as a free solution 
(middle) or as a HA-conjugate (right).  Untreated cells are demonstrated on the left. Cells 
were labeled with DRAQ5 nuclear dye (red). (d) Representative images of DOX (red) 
internalization when incubated as a free solution (middle) or as a HA-conjugate (right).  
Untreated cells are on the left.  Cells were labeled with Hoechst nuclear dye (blue).  Scale bars 
= 20 µm. 
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 After verification that the polymeric carrier is readily internalized by BT-474 
cells, uptake of polymer-bound drugs were next investigated by visualizing the 
natively fluorescent drugs via confocal laser scanning microscopy.  These studies 
illustrate the effect of polymer-conjugation on intracellular drug concentrations. 
Cells were exposed to the same drug concentration, the free drug D50, of either the 
free drug solution or the HA-conjugate form for 24 hrs at 37˚C and 5% CO2.  CPT-
HA exhibited significantly enhanced uptake compared to free CPT (Figure 5.4b), 
possibly due to its enhanced water solubility upon conjugation to HA.  On the other 
hand, uptake of DOX-HA was only slightly less than that of free DOX (Figure 5.4b).  
Subsequent intracellular distribution of DOX-HA, however, was significantly 
different compared to that of free DOX (Figure 5.4c).  HA-bound DOX was localized 
mostly in punctate spots surrounding nuclei, whereas free DOX was more diffuse 
and co-localized with cell nuclei.  While free DOX is sufficiently small to permeate 
across the cell and nuclear membrane, DOX-HA is likely internalized via endocytosis 
and localized in endosomes. 
 Drug release from the polymer also plays a considerable role in intracellular 
drug distribution. Once internalized, DOX must release from the polymer via amide 
or ester hydrolysis and escape from the endosomes before reaching its nuclear 
target, top II.  Drug release profiles (Figure 5.5) indicate slow DOX release 
surmounting to only 25% after 72 hours, and a fast CPT release with near complete 
hydrolysis within 24 hours.  The difference in drug release rates may be attributed to 
greater stability of amide bonds compared to ester bonds in aqueous conditions.  
This alternate internalization pathway, slow drug release, and reduced 
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concentrations of free intracellular DOX may cause a time-lag between DOX 
internalization and activity, and may explain reduced cytotoxicity upon HA-
conjugation.  It is likely that the same shifts in DOX internalization and availability 
to top II occurs with PVA-conjugates, as DOX activity is also reduced upon PVA-
conjugation.  An exponential fit to the DOX release profile from DOX-HA reveals a 
half-life of 254 hours, and suggests that complete DOX release will be achieved on 
the order of 50-100 days.  Therefore, in order to realize the full therapeutic potential 
of DOX-HA, drug incubations for longer time-periods than are reasonably utilized 
may be warranted. 
 HA-bound CPT, on the other hand, improved intracellular CPT 
concentrations with no hydrolysis limitations; nearly 95% was released after 24 
hours.  Despite this, CPT-HA was less active compared to free CPT, and suggests that 
HA-conjugation restricts CPT's ability to interact with its intracellular target, top I. It 
is likely that released CPT remains confined within endosomes or lysosomes, and 
results in reduced anticancer efficacy.  On the contrary, PVA-bound CPT was more 
active at inhibiting cancer cell growth than free CPT, as seen in Section 5.2.  Since 
the conjugation chemistry and linkers are similar for both HA- and PVA-bound CPT, 
CPT should release from both polymers at the same rates. Hence, it is probable that 
PVA-conjugation either improves CPT-internalization or its ability to interact with 
top I, compared to HA-conjugation.  These enhancements further potentiate CPT's 
cancer cell inhibition when conjugated to PVA. 
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Figure 5.5. CPT or DOX release from HA-conjugates. 
 
Release of CPT (circles) or DOX (squares) from CPT-HA or DOX-HA, respectively, 
determined as wt% of initial drug conjugated to HA.  Lines represent exponential fits to 
release profiles (t1/2,R= 11 hrs, t1/2,R = 254 hrs for CPT and DOX, respectively).  Data represents 
mean ± SD (n=3). 
 
5.4. Synergy of CPT- and DOX-conjugated HA 
 After confirming that CPT-HA and DOX-HA are readily internalized by cancer 
cells and can inhibit their growth, CPT-HA and DOX-HA were mixed at various 
molar ratios and incubated with BT-474 cells, followed by CI analysis.  The 
combination inhibited more cancer cell growth than either CPT-HA or DOX-HA 
alone (Figure 5.6a).  The CI of the mixed conjugates (Figure 5.6b) was less than 1 for 
1 < R < 9 CPT:DOX, indicating that CPT-HA and DOX-HA were indeed synergistic at 
the same ratios that free CPT and DOX elicited synergy (Figure 3.8c). 
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Figure 5.6. Anticancer activity of CPT-HA + DOX-HA and CPT-HA-DOX. 
 
(a) Cell inhibition of human breast cancer cell line BT-474 treated with combinations of CPT-
HA and DOX-HA at various molar ratios (blue, left bars).  Single HA-conjugate treatments of 
DOX-HA (red, middle bars) and CPT-HA (green, right bars) at concentrations which make-up 
the combination are juxtaposed for direct comparison. Drug concentrations of CPT and DOX 
respectively in µM: 1 (11.7, 11.7), 4.5 (6.6, 1.5), 9 (26.4, 2.10), (b) CI values calculated for the 
CPT-HA and DOX-HA combinations shown in (a). (c) Cell inhibition of in the presence of 
CPT-HA (circles) or CPT-HA-DOX conjugates (squares). (d) Comparison of the cell inhibition 
of DOX-HA (circles) and CPT-HA-DOX conjugates of R = 3.2 CPT:DOX (squares). Cells were 
incubated with formulations for 72 hours, and assessed for cell viability utilizing the MTT 
cytotoxicity assay.  Data is reported as mean ± SD (n≥6). 
 
 It should be noted that although CPT and DOX undergo distinct release 
profiles from HA (Figure 5.5), this differential release does not compromise their 
synergy.  On the contrary, HA-conjugation may promote the pair’s synergistic 
interactions against cancer cell proliferation.  Whereas CPT and DOX in free solution 
only exhibit additive cancer cell kill at R = 1 (Figure 3.8c), their HA-bound 
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counterpart is synergistic (Figure 5.6b).  One hypothesis for this finding is that 
slower DOX release causes an effective free R greater than that bound to the 
polymer.  Thus, the intracellular free combination released from the polymer results 
in R > 2, meeting the synergistic requirement for CPT and DOX. Free CPT and DOX 
are more synergistic at greater R values (Figure 3.8c), with no apparent upper limit.  
In the case of polymer-bound CPT and DOX, however, there appears to be an 
optimal polymer-bound R, as indicated by a greater CI for R = 9 compared to R = 
4.5.  Although this finding is not completely understood, one possible explanation is 
that a minimum DOX-HA concentration is required in order for the concentration of 
released DOX to be therapeutically active and synergistic with CPT.  Because only 
25% of DOX is released from DOX-HA over a period of 72 hours, exposure of cancer 
cells to larger HA-bound R can significantly reduce the concentration of free DOX 
exposed to cancer cells.  It may be possible that a threshold DOX concentration is 
required for synergistic interactions with CPT.  Further studies will verify whether 
threshold drug concentrations exist for synergistic drug interactions. These initial 
results, however, demonstrate that CPT-HA and DOX-HA can deliver synergistic 
CPT and DOX ratios to cancer cells, despite the administration of a lower, bulk 
polymer-bound R. 
 CPT and DOX were then co-conjugated to HA to evaluate if potent cancer cell 
kill could be maintained when co-delivered in the same nano-vehicle. Without 
inclusion of both drugs in a single vehicle, the pair will undergo uncoordinated 
pharmacokinetics, and the tumor will not be exposed to the optimal drug ratio which 
maximizes potency. In the case of our particular chemotherapy combination, CPT 
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exhibits a distribution half life of 71-90 minutes in humans [15], whereas that of 
DOX is much shorter, approximately 4 minutes [14].  Therefore, it is proposed that 
co-conjugation to HA will ensure simultaneous arrival in tumors at the prescribed, 
synergistic ratio, and provide superior therapeutic effects compared to free drug 
administration. To synthesize CPT- and DOX-conjugated HA (CPT-HA-DOX), CPT 
was first conjugated to HA for 3 days via Reaction Scheme 5.2, followed by the 
subsequent reaction of DOX to CPT-HA for another 3 days.  For the purpose of 
demonstrating a synergistic drug-loaded carrier, HA carrying a molar ratio of R = 3.2 
CPT:DOX was investigated.  The content of CPT and DOX was determined via UV-
Vis spectroscopy to be 5.9 mol% and 1.8 mol%, respectively.  In vitro cytotoxicity 
studies show that CPT-HA-DOX inhibited more cancer cell growth than either CPT-
HA (Figure 5.6c) or DOX-HA (Figure 5.6d) alone.  Cell inhibition studies performed 
with mixed HA-conjugates and drugs co-conjugated to HA reveal that polymer-
conjugation preserved synergy between CPT and DOX.  While both formulations 
conserved the drug pair’s potency, only the latter can ensure simultaneous exposure 
to tumor cells, and can provide a means to capture the in vitro antitumor efficacy in 
vivo, as well. 
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Figure 5.7. Activity of CPT-HA + DOX-HA and CPT-DOX-HA against 
murine 4T1 breast carcinoma cells. 
 
(a) The cell inhibition of metastatic murine breast cancer cell line 4T1 treated with 
combinations of CPT-HA and DOX-HA at various molar ratios (blue, left bars).  Single drug 
treatments of DOX (red, middle) and CPT (green, right) at concentrations which make-up the 
combination are juxtaposed for direct comparison. CPT and DOX concentrations (μM), 
respectively, which composed each ratio (R, CPT:DOX) were: 1.0 (0.30, 0.30), 2.3 (0.34, 
0.15), 4.5 (0.68, 0.15).  (b) CI values calculated for CPT-HA and DOX-HA combinations in (a). 
(c) Cell inhibition in the presence of CPT-HA (circles) or CPT-HA-DOX conjugates (squares). 
(d) Comparison of the cell inhibition of DOX-HA (circles) and CPT-HA-DOX conjugates of R 
= 3.2 CPT:DOX (squares).  Dashed lines represent fits to the ME model. Cells were incubated 
with formulations for 48 hours, and assessed for cell viability utilizing the MTT cytotoxicity 
assay.  Data is reported as mean ± SD (n≥4). 
 
5.5. In vivo antitumor efficacy of CPT-HA-DOX 
 An orthotopic 4T1 breast cancer mouse model in BALB/c mice was utilized to 
assess the in vivo anticancer efficacy of CPT-HA-DOX.  A 4T1 model was chosen for 
its robust tumor formation in mice [165], and to challenge the synergistic conjugate 
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with a highly metastatic, aggressive cancer [166]. While all in vitro studies focused 
on the cell inhibition of BT-474 human breast cancer cells, CPT and DOX synergy 
was also verified in 4T1 cells and occurred at the same ratios as BT-474 (Figure 3.9 
and Figure 5.7). Mice were administered i.v. with designated formulations every 
other day for a total of 5 treatments (Days 3, 5, 7, 9, 11).  Treatments consisted of 
either CPT-HA-DOX or free CPT+DOX in equivalent drug doses of 2 mg/kg CPT and 
1.05 mg/kg DOX.  To prepare the free drug formulation, CPT was first dissolved in 
10 vol% Tween-80 in 0.9 wt/vol% NaCl to solubilize the highly hydrophobic drug.  
DOX was directly dissolved in 0.9 wt/vol% NaCl, and was subsequently mixed with 
the CPT solution.  CPT-HA-DOX was freshly prepared in 0.9% NaCl prior to 
injections. For comparison, untreated tumor-bearing mice were observed as 
controls. Results in Figure 5.8a show as high as 70% tumor volume reduction 
achieved by the free drug combination, and 50% tumor reduction achieved with the 
co-conjugated polymer relative to control.  This was surprising, as the free drug 
administration was projected to elicit lower therapeutic efficacy due to 
uncoordinated accumulation in tumors.  However, since CPT+DOX synergistically 
inhibit cancer cell growth for a wide range of ratios, the antitumor activity of this 
particular pair may not be severely impacted by the uncoordinated drug 
pharmacokinetics when administered as a free solution.  Thus, both HA-bound and 
free CPT+DOX elicited compelling therapeutic efficacies. 
  
108 
 
 
 
Figure 5.8. Tumor growth inhibition of CPT-HA-DOX or CPT+DOX. 
 
(a) Tumor growth of mice bearing 4T1 breast cancer tumors, without treatment (circles), with 
IV injections of CPT-HA-DOX (squares), or free CPT+DOX in 0.9% saline (triangles).  Mice 
were injected i.v. with CPT-HA-DOX or free CPT+DOX, at drug-equivalent concentrations of 
1.05 mg/kg DOX and 2 mg/kg CPT. Red arrows indicate treatment days. (b) Change in body 
weight of control mice (circles), CPT-HA-DOX-treated mice (squares), or CPT + DOX-treated 
mice (triangles). Data is reported as mean ± SE (n≥8). (c) Immunohistochemistry analysis of 
excised control tumors (left), tumors treated with CPT-HA-DOX (middle) or free CPT+DOX 
(right) stained for cleaved caspase-3 (apoptosis indicator).  Black arrows indicate 
representative stained apoptotic nuclei.  (d) Histology analysis of tumors treated with H&E.  
Circled areas represent necrotic tissue. All images were taken at 100X magnification and are 
representative of each group (n=3). 
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 Caspase 3 immunohistochemistry of tumor sections post-treatment was 
performed to further assess antitumor efficacy of CPT and DOX formulations.  
Despite greater gross tumor reduction in mice treated with free CPT+DOX, more 
apoptotic cells were found in CPT-HA-DOX-treated tumors (Figure 5.8c).  
Furthermore, H&E staining shows more necrosis in mice treated with CPT-HA-DOX 
compared to those treated with free CPT+DOX, as indicated by the greater 
occurrence of pyknotic (smaller) or missing nuclei (absence of purple staining) and 
overall pink rather than purple hue (Figure 5.8d).  Histology analyses also suggest 
that, while macroscopic measurements indicate that free CPT+DOX mixture is more 
effective in reducing tumor size, CPT-HA-DOX was more effective in inducing both 
necrosis- and apoptosis-induced cell death. Whereas free CPT+DOX attacks tumor 
cells predominantly via apoptotic mechanisms, CPT-HA-DOX exploits both potent 
mechanisms.  The implications of these two types of cell death for cancer therapies 
are unclear.  Chemotherapy drugs commonly initiate cancer cell death via apoptosis, 
but there are many potential benefits in necrotic-inducing agents [167, 168].  In 
contrast to apoptosis, necrosis is a rapid cell death mechanism which does not 
require a complex cascade of biochemical events [168].  Necrosis is also 
indiscriminatory in that the affected cells need not be in a certain cycle phase or 
express certain genes, and once initiated, immune cells are recruited in an 
inflammatory response to further attack the tumor [167].  Hence, necrotic-inducing 
agents can result in more rapid and vigorous cancer cell death compared to 
apoptotic-inducing drugs.  Our studies suggest that CPT-HA-DOX bears great 
potential for improving tumor growth inhibition compared to free CPT+DOX 
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administration, due to the added capability of necrosis-induced cancer cell death. 
Thus, although the gross tumor inhibition of CPT-HA-DOX was less than that of the 
free drugs, optimization of the current CPT-HA-DOX formulation may enhance 
therapeutic efficacy.  Other factors that were not investigated in this study, but could 
be implemented to improve anticancer potency, are described in Chapter 6. 
 Despite room for formulation optimization, particular significance of our 
findings is drawn to the low doses utilized for these immense therapeutic effects, 2 
mg/kg CPT and 1.05 mg/kg DOX.  Previous literature reports of murine tumor 
models treated with intravenous free drug solutions show that 2 mg/kg of free DOX 
by itself is incapable of significantly reducing tumor volume [169, 170], and that 1.5 
mg/kg free CPT administered alone results in 50% tumor reduction albeit with high 
variability [171].  In comparison, the studies reported here have identified a potent 
chemotherapy combination with high activity at low doses, and that HA-conjugation 
of synergistic ratios of CPT and DOX preserves the combination’s potency in vivo. 
 
5.6. CPT-HA-DOX tolerability in vivo 
 Apart from antitumor efficacy, tolerability of the treatment is equally 
important for clinical applicability.  To translate a powerful cytotoxic drug pair to a 
therapeutic, not only is accumulation in tumor tissue required, but also minimal 
exposure to healthy organs.  This feat can be mediated with HA-conjugation.  Here, 
the delivery vehicle itself targets tumor tissue, and additional targeting ligands are 
not needed.  CD44, a transmembrane glycoprotein overexpressed in many cancer 
types and in low expression in other tissues, is a principal receptor of HA; thus, drug 
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conjugation to HA can shift accumulation in tumors rather than healthy tissue [172-
174].  The natural abundance of HA in the human body also renders it biocompatible 
and biodegradable. 
 
 
Figure 5.9. Histology analysis of excised tissues post-treatments. 
 
Organs excised from control mice (left), mice treated with CPT-HA-DOX (middle), or 
CPT+DOX (right), and stained with H&E to assess formulation toxicity.  Images were 
acquired at 100x magnification and are representative of each group (n=3). 
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 In both CPT-HA-DOX and CPT+DOX treatments, negligible body weight 
change was observed (Figure 5.8b), and suggested no immediate toxicity concerns.  
To more extensively evaluate formulation toxicity, histology analyses of essential 
organs post-treatment were conducted.  Lung, spleen, and liver organs in both 
CPT+DOX-treated and CPT-HA-DOX-treated mice showed no toxicity (Figure 5.9).  
Heart sections resected from CPT-HA-DOX-treated mice indicated mild 
inflammation.  This may be explained by CD44 receptors and a large abundance of 
natural HA present in the heart [175].  Surprisingly, free solution CPT + DOX was 
also non-toxic to mice, with negligible body weight chances and no inflammation in 
the heart, lungs, liver, nor the spleen. The lack of chemotherapy toxicity may be 
attributed to the very low doses of CPT and DOX needed for synergistic tumor 
reduction.  Collectively, negligible body weight changes and H&E analysis of 
essential organs suggest that both formulations were well-tolerated with no severe 
side effects. 
 While both CPT-HA-DOX and free CPT+DOX exhibited high therapeutic 
potential and minimal toxicity in mice, free solution combinations of top I and II 
inhibitors are notorious for inducing adverse side effects in humans.  The most 
common repercussion of top I and II inhibitors, when administered as free drugs, is 
hematological toxicity [79, 81-83, 94, 176-180], and dose-limiting neutropenia has 
been reported to occur in as many as 50% of patients treated with top I and II 
poisons [83].  Polymer-conjugation to DOX, specifically DOX-HPMA, has already 
been shown to significantly reduce dose-limiting toxicities compared to free DOX 
[151], and is compelling evidence for the clinical use of polymer-bound drugs 
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compared to free drugs. Another advantage of the CPT+DOX combination 
administered here is the preferred cell kill of malignant cells over control endothelial 
cells, as demonstrated in Figure 3.9.  By identifying optimal drug ratios which 
synergistically inhibit cancer cells and antagonistically affect healthy cells, it may be 
possible to administer low, non-toxic free drug doses of the combination, as 
demonstrated here.  Conjugation of precise drug ratios to polymers ensures that this 
ratio is maintained in both tumor tissue and essential organs which cannot be 
avoided.  Collectively, these findings suggest that CPT-HA-DOX has the potential of 
reducing life-threatening toxicities and improving therapeutic efficacy compared to 
free CPT+DOX, although additional studies are required for further assessment. 
 
5.7. Summary of HA-conjugates for synergistic combinations delivery 
 Here, we developed plausible non-toxic methods for the delivery of the 
optimal ratios of top I and II inhibitors CPT and DOX identified in Chapter 3 which 
synergistically inhibit cancer cell growth.  Due to the potent synergy between CPT 
and DOX, only low doses of each drug are required to significantly reduce tumor 
volumes in murine 4T1 models – doses which elicit no visible toxicity in healthy 
organs. Hence, free drug administration of the pair offers one method to elicit 
significant antitumor reduction.  This is a remarkable finding, since free CPT elicits 
unpredictable side effects when administered at single drug therapeutic doses. By 
exploiting top I and top II poison collateral sensitivity, we have demonstrated a safe 
method to administer free CPT which is also therapeutically active.  This finding 
alone highlights the power of combination chemotherapy. 
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 HA-conjugation serves as another clinically translatable method for CPT and 
DOX administration, with the additional advantages of preserved synergistic drug 
ratios from the site of injection to tumor tissue, and enhanced tumor accumulation.  
This method can be broadly applied to various combination chemotherapies, since 
the conjugation chemistries are not specific to just top I and II inhibitors; the only 
prerequisite is the presence of nucleophilic moieties on the drug pair. HA co-
conjugation can particularly be advantageous for combinations which elicit adverse 
effects in the free drug form, since it can direct the therapies to CD44+ tumors.  
Furthermore, precise ratios can be controlled via reactant concentrations, which will 
ensure the delivery of the most potent, synergistic ratio to tumors.  This effect will be 
most impactful for chemotherapy combinations where synergistic interactions only 
occur for specific drug ratios. 
 
 
 
 
 
 
 
Data was reprinted from Journal of Controlled Release, vol. 21, K.M. Camacho, S. 
Kumar, S. Menegatti, D.R. Vogus, A.C. Anselmo, S. Mitragotri, Synergistic antitumor 
activity of camptothecin–doxorubicin combinations and their conjugates with 
hyaluronic acid, 198-207, Copyright 2015, with permission from Elsevier. 
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Chapter 6 
Impact of nano-carrier properties 
on therapeutic efficacy 
6.1. Physical and chemical properties of nano-carriers 
 The previous two chapters focused on the development of two specific nano-
vehicles for the co-encapsulation of synergistic chemotherapy pairs, with 
culminating evaluations of their in vivo efficacies.  Along the path to their 
development, however, many fundamental studies were conducted to determine 
optimal physical and chemical properties for effective drug delivery.  Tumor 
accumulation, nanoparticle internalization, drug release, and drug-target 
interactions must all occur in order for the carrier to be an effective drug vehicle.  
Because various nanoparticle properties can notably influence many or all of these 
factors, many literature efforts have focused on evaluating these interactions [50, 76, 
124, 181-186].  Here, we summarize similar findings that were discovered during the 
development of polymer-drug conjugates and liposomes for multi-drug delivery.  
Specifically, polymer molecular weight, polymer-drug linkers, lipid membrane 
properties, particle stability, and ζ potential effects were assessed.  Results reported 
here will unfold the impact of these particle parameters on combination 
chemotherapy efficacy. 
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6.2. Low molecular weight polymer-drug conjugates 
 Many literature reports demonstrate the superior tumor accumulation and 
plasma circulation of high molecular weight (~100 kDa) water-soluble polymers 
[148, 157-159], and for this reason, most biodegradable polymer-drug conjugates in 
clinical trials bear molecular weights >50 kDa [29, 187-189].  However, high overall 
tumor accumulation may not be enough to inhibit tumor growth. For example, 
micelles ranging between 30-100 nm have been found to equally penetrate highly 
permeable tumors in mice, but only sub-50 nm particles were found able to 
extravasate into tumor tissue with reduced vasculature and achieve greater tumor 
reduction [182, 190].  In another study, it was shown that low molecular weight 
polymers were more readily internalized by epithelial cells as compared to polymers 
greater than 80 kDa [191]; thus, high molecular weight polymers may impede 
conjugated drugs from reaching their intracellular targets. It is clear that carrier size 
governs drug distribution in tumor microenvironments, which further impacts drug 
activity.  Therefore, although low molecular weight polymer-drug conjugates are 
less-explored, they may elicit significant therapeutic efficacy. We have previously 
demonstrated the tumor reduction capability of high molecular weight 250 kDa HA 
bound to CPT and DOX [192].  Here, we extend our approach to low molecular 
weight 10 kDa HA to investigate whether uncommonly utilized small MW polymers 
bear merit for improving in vivo efficacy of chemotherapy combinations. 
 The same reaction scheme used in Chapter 5 (Reaction Scheme 5.2) was 
employed to conjugate both CPT and DOX to 10 kDa HA. By varying reactant ratios, 
two CPT+DOX ratios were achieved: 7.5 and 2.8 CPT:DOX.  The corresponding drug 
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incorporations were 14.4mol% CPT + 1.9mol% DOX for R=7.5, and 6.9mol% CPT+ 
2.4 mol% DOX for R=2.8.  It is noteworthy that the same chemistry and initial 
starting materials resulted in less than half as much CPT conjugation and hence a 
less synergistic ratio (R=3.2) in higher molecular weight 250 kDa HA; one possible 
reasoning is the reduced steric hindrance in smaller polymeric chains. Conjugation 
of chemotherapy drugs to polymers typically alters drug activity, as was evident in 
our previous study of 250kDa hyaluronic acid conjugated to CPT and DOX.  
However, drug activity should not be compromised so much as to entirely prevent its 
anticancer effects.  Therefore, initial studies evaluated the in vitro cancer cell growth 
inhibition of 10 kDa CPT-HA-DOX.As seen in Figure 6.1, both R=2.8 and R=7.5 10 
kDa CPT-HA-DOX  inhibited more 4T1 mouse breast cancer cell growth than R=3.2 
250 kDa HA, regardless of drug concentrations.   D50 concentrations of the 10 kDa 
conjugates (0.50 µM CPT + 0.07 µM DOX for R=7.5 and 0.24 µM CPT + 0.09 µM 
DOX for R=2.8) were determined by fitting experimental data to the median-effect 
model, and are lower than those corresponding to the 250 kDa conjugates (5.8 µM 
CPT + 1.8 µM DOX).  The D50 concentration of CPT is reduced as much as 24-times, 
and the DOX D50 dose is halved when the pair is exposed as a 10 kDa HA conjugate 
as opposed to a 250 kDa conjugate. This finding may be attributed to either the 
higher, more synergistic drug loading capabilities of the 10 kDa polymer, or due to a 
possible enhancement of cellular uptake with lower molecular weight polymers 
[193].  In either case, our studies indicate that low molecular weight polymers are 
capable of maintaining combination chemotherapy synergy, and are more effective 
than higher molecular weight polymers at inhibiting cancer cell growth in vitro.  Also 
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noteworthy is the slightly lower activity of R=7.5 CPT-HA-DOX compared to R=2.8 
CPT-HA-DOX. According to results in Chapter 3 (Figure 3.8), synergistic 
interactions between free CPT+DOX should increase with higher R, however the 
polymer-bound drugs here perform conversely.  This effect seems consistent across 
the two molecular weights investigated.  In Chapter 5 (Figure 5.6), it was shown that 
an optimal R (R=4.5) occurs when the CPT+DOX are bound to 250 kDa HA.  R=9 
yielded lower cell inhibition than R=4.5 and hence less synergy.  As alluded to in 
Chapter 5, it is possible that a threshold DOX concentration is necessary for 
CPT+DOX to  synergistically inhibit cancer cells.  Due to poor DOX release, HA 
bearing a large R may significantly reduce the amount of DOX available for cancer 
cell kill.  Therefore, while a clear R cut-off is not evident in free drug interactions, it 
is for both 10 kDa and 250 kDa HA conjugates.  Despite this, polymer-bound 
CPT+DOX at R~3 perform better when conjugated to 10 kDa HA as opposed to the 
larger 250 kDa HA. 
 
 
Figure 6.1. In vitro cancer cell inhibition of 10kDa CPT-HA-DOX. 
 
4T1 cancer cell viability after incubation with 10 kDa CPT-HA-DOX of R=2.8 (circles) or 
R=7.5 (triangles) as a function of CPT (left) or DOX (right) concentration.  For comparison, 
250 kDa CPT-HA-DOX R=3.2 (squares) from Figure 5.7 is provided. Data expressed as mean 
± SD (n≥6). 
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 The more potent of the two 10 kDa formulations, R=2.8 CPT-HA-DOX, was 
further evaluated in vivo to investigate if low molecular weight HA could also 
effectively deliver the synergistic pair to tumor tissues when presented with 
biological barriers.  Mice inoculated with 4T1 murine breast cancer cells were 
challenged with R=2.8 10 kDa CPT-HA-DOX at the same dosing schedule, i.v. tail 
vein injections on Days 3, 5, 7, 9, and 11 post-inoculation.  For this study, two doses 
were investigated: low dose 2 mg/kg CPT + 1.2 mg/kg DOX (same as 250 kDa 
studies), or high dose 3 mg/kg CPT + 1.8 mg/kg DOX.  Tumor growth inhibition, 
body weight changes, and survival rates elicited by these doses are reported in Figure 
6.2.  After 22 days, the low dose and high dose treatments respectively inhibited 47% 
and 37% tumor growth relative to untreated mice.  While CPT-HA-DOX-treated 
tumor volumes were statistically different from control mice, volumes between the 
different doses were not.  This suggests that, similar to 250 kDa CPT-HA-DOX, 10 
kDa conjugates are capable of providing significant therapeutic effects.  However, 10 
kDa conjugates seemed to perform no better or worse than the 250 counterparts, 
since both inhibited ~50% tumor growth (Figure 5.8).  However, the inhibition from 
250 kDa CPT-HA-DOX occurred as early as 12 days, whereas that of 10 kDa CPT-
HA-DOX appeared later, at 22 days post-inoculation.  Therefore, small molecular 
weight HA delays therapeutic effect compared to larger molecular weight HA.  
Despite providing significant tumor reduction, 10 kDa CPT-HA-DOX was not able to 
prolong survival rates relative to control mice.  Tumors inevitably grew to the same 
sizes as control mice, which was likely caused by the delay in antitumor activity.  
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Since tumor growth is exponential, it may be necessary to stagnate growth early in 
order to significantly improve overall survival. 
 One evident difference between 10 kDa and 250 kDa conjugates which may 
cause this disparity in antitumor activity is their size distributions.  Dynamic light 
scattering of the two formulations tested in vivo (Table 6.1) provided multi-modal 
distributions, likely attributed to anisotropic polymeric backbone scattering.  
However, the size regimes exhibited by the two conjugates vary drastically.  While 10 
kDa conjugates exhibit tenths and tens of nanometer particulates, 250 kDa 
conjugates exhibit sizes of tens and hundreds of nanometers. Both exhibit micron-
sized particulates, likely aggregates of pendant hydrophobic drug interactions. The 
differences in their nano-sized particles, however, may cause their discrepancies in 
therapeutic efficacies.  Since renal filtration can remove particles in the tens of 
nanometers [21], 10 kDa CPT-HA-DOX can be cleared more rapidly than 250 kDa 
CPT-HA-DOX.  Hence, 250 kDa conjugates may circulate longer and accumulate 
more in tumors.  However, nanoparticles in the tens of nanometers can penetrate 
deeper into tumor tissue [190], and can induce cancer cell death where larger 
conjugates cannot.  Although it is unclear how this difference in tumor distribution 
impacts antitumor efficacy, one hypothesis is that larger conjugates inhibit cancer 
cell growth in the peripheral tumor cells, while smaller conjugates inhibit cancer cell 
growth deeper within the tumor interstitium.   It is unclear why these discrepancies 
in tumor cell inhibition would elicit different times or delays of treatment efficacy, 
but there is evidently an impact of polymer size on antitumor potency. It may also be 
possible to prevent growth earlier than 22 days or prolong survival if the drug doses 
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were increased, especially since the maximum tolerable dose of DOX (20 mg/kg) 
[194] is ten-fold what was administered, in both the 10 kDa and 250 kDa studies.  
Here, doses were limited by low chemical conjugation efficiencies, and dose 
optimization will further elucidate the therapeutic abilities of low molecular weight 
HA.  Collectively, our findings encourage investigation of low molecular weight 
polymers for polychemotherapy delivery. 
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Figure 6.2. Tumor growth inhibition of 10kDa CPT-HA-DOX. 
 
(a) Tumor growth of mice bearing 4T1 breast cancer tumors, without treatment (circles), with 
i.v. injections of low dose 10 kDa CPT-HA-DOX R=2.8 (squares), or high dose 10 kDa CPT-
HA-DOX R=2.8 (triangles).  Low dose CPT-HA-DOX treatments consisted of drug-equivalent 
doses of 2 mg/kg CPT + 1.2 mg/kg DOX, while high dose CPT-HA-DOX treatments consisted 
of 3 mg/kg CPT + 1.8 mg/kg DOX.  Arrows indicate days of treatment.  (b) Effect of treatment 
on body weight fluctuations. Data is reported as mean ± SE, n≥10 at start of study, and varied 
accordingly to survival rates. (c) Survival rates for all treatment groups. 
 
 
 
 
Table 6.1. Multi-modal intensity-based size distribution of CPT-HA-DOX conjugates. 
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6.3. Polymer-drug chemical linkers 
 The chemical linkage between the drug and polymer is another variable that 
can greatly impact drug activity.  Depending on the chemical linker, the drug may be 
released from the polymer carrier at various rates or may not hydrolyze at all.  With 
regards to combination chemotherapy delivery, drugs that are conjugated to a 
polymeric backbone via different linkers may release at distinct rates.  This can have 
immense ramifications on the combination's potency, as therapeutic efficacy is 
heavily governed by the schedule and order of drugs administered [95, 195, 196]. In 
order to determine the effect of hydrolysis on drug activity, DOX was conjugated to 
10 kDa PVA via ester, amide, or hydrazone linkers using Reaction Schemes 5.1, 6.1, 
or 6.2, respectively, and the cancer cell growth inhibition was evaluated in vitro for 
all conjugates.  The conjugation achieved for the ester, amide and hydrazone-linked 
DOX were 0.25mol%, 0.81mol% and 0.03mol% DOX relative to PVA, respectively. 
Ester bonds are the most commonly used in literature due to ease of synthesis, and 
also represent hydrolytically labile bonds; amide-linked conjugates represent 
hydrolytically stable bonds, whereas hydrazone linkers are hydrolytically degraded at 
endosomal pH 5.0 but stable at physiological pH 7.4 [197, 198].  In vitro cancer cell 
cytotoxicity studies in Figure 6.3a show that the cleavable conjugates, ester-linked 
DOX (DOXePVA) and hydrazone-linked DOX (DOXhPVA), are active against cancer 
cells, whereas the non-cleavable amide-linked DOX (DOXaPVA) is not. 
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Reaction scheme 6.1. Chemical reactions utilized for incorporation of 
DOX and/or CPT onto PVA via amide linkers. 
 
Reaction 1a activates nucleophilic drugs (designated as R1-OH or R2-NH2) with succinic 
anhydride to form EDC-reactive drugs.  Reaction 1b shows amination of PVA side chains, 
which is further reacted with products of 1a in reaction 1c.  DOXaPVA was synthesized in this 
manner. 
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Reaction Scheme 6.2. Chemical reactions utilized for incorporation 
of DOX onto PVA via hydrazone bonds. 
 
Reaction 2a activates PVA hydroxyl groups with succinic anhydride to form EDC-reactive 
carboxylic acid side chains.  Reaction 2b shows hydrazine conjugation to activated PVA side 
chains.  Hydrazine-conjugated PVA is further reacted with a ketone-containing drug (DOX) to 
form a hydrazine-linked PVA-drug conjugate. DOX is designated as R2-COCH2OH. 
 
 Confocal studies were implemented in order to assess the impact of chemical 
linkage on drug internalization and potential correlations with anticancer activity.  
As seen in Figure 6.3b-c, cell internalization of DOX in the form of DOXePVA and 
DOXaPVA is much lower than that of free DOX, which suggests that polymer-drug 
conjugates require active internalization, whereas free DOX can diffuse through the 
cell membrane.  Furthermore, the internalization of polymer-bound DOX is dictated 
by the chemical linker, as indicated by the significant decline of drug internalization 
when introduced as DOXaPVA compared to DOXePVA. One possible reason for this 
sharp contrast is that drug hydrolysis may occur prior to cell entry in the case of the 
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ester-linked conjugate, which then allows DOX to become internalized via passive, 
non-energy intensive mechanisms. Also noteworthy is the difference in nuclear drug 
accumulation between the different conjugates. Since DOX inhibits topoisomerase II 
enzymes, drug co-localization within the nucleus may be directly correlated to its 
ability to inhibit proliferation.  As a free drug, nuclear accumulation of DOX is 
evident through the purple nuclear hue (red and blue co-localization) in Figure 6.3c.   
Less purple, and hence nuclear DOX accumulation, is seen in cancer cells incubated 
with DOXePVA, and barely any is observed in cancer cells incubated with DOXaPVA.  
Therefore, it seems that non-cleavable conjugates prevent DOX from escaping 
endosomes and reaching the nucleus, which in turn hinders its anticancer activity. 
Both internalization studies and cancer cell growth inhibition results suggest that 
DOX must be cleaved from the polymer at physiological conditions in order to 
remain active at inhibiting cancer cell growth, and the polymer-bound drug is not 
active prior to drug hydrolysis. 
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Figure 6.3. The impact of various PVA-drug linkers on drug activity and internalization. 
 
DOXePVA refers to ester-linked drug, which was synthesized via Reaction Scheme 5.1; 
DOXaPVA refers to amide-linked drug, which was synthesized via Reaction Scheme 6.1, and 
DOXhPVA refers to hydrazone-linked drug, which was synthesized via Reaction Scheme 6.3.  
(a) Comparison of the in vitro BT-474 cancer cell growth inhibition of the various linkers.  
DOXePVA is indicated by circles, DOXaPVA is represented by squares, and DOXhPVA is 
indicated by triangles.  (b) Fluorescence of DOX in free solution, DOXePVA, or DOXaPVA 
present in BT-474 cells after 24 hours of incubation at 37˚C and 5% CO2.  Initial drug 
loadings were 1 µM DOX-equivalents.  Data expressed as mean ± SD (n=3).  (c) 
Representative images of DOX (red) internalization from free solution (left), DOXePVA 
(middle), or DOXaPVA (right). Cells were labeled with Hoechst nuclear dye.  Images are 
averages of 10 µm z-stacks. Scale bar=20 µm. 
 
 To further investigate the effect of chemical linker on combination 
chemotherapy efficacy, DOX and CPT were co-conjugated to PVA utilizing 
physiologically labile and non-labile tethers.  CPT-PVA-DOX F1 utilized Reaction 
Scheme 6.1, which conjugated DOX and CPT via amide and ester bonds, respectively.  
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CPT-PVA-DOX F2 was synthesized with Reaction Scheme 5.1, which conjugated 
both drugs via ester bonds.  In the case of CPT-PVA-DOX F1, only one drug was 
hydrolytically labile and capable of releasing from the polymer under physiological 
conditions; on the contrary, CPT-PVA-DOX F2 can release both drugs since ester 
linkages were used to conjugate CPT and DOX.  Both schemes resulted in the 
conjugation of CPT and DOX in ratios at which the free drugs exhibited synergistic 
cancer cell kill, R > 0.1 (Figure 6.4a).  Also noteworthy is the poor conjugation 
efficiency of Reaction Scheme 5.1 compared to Reaction Scheme 6.1.  Whereas 
Reaction Scheme 6.1 achieved conjugations of 0.10 and 0.28 mol% CPT and DOX, 
respectively, Reaction Scheme 5.1 only yielded 0.01 mol% for both drugs.  This can 
be attributed to the overall less favorable nature of hydroxyl esterification compared 
to amide formations. 
 The activity of these two CPT-PVA-DOX conjugates against BT-474 cancer cell 
growth was evaluated via MTT cytotoxicity assays, and compared to the anticancer 
activities of the single ester-linked PVA-conjugates (Figure 6.4b).  CPT-PVA-DOX F1 
showed similar efficacy as CPT-PVA and DOX-PVA, with no clear advantage over 
either single drug conjugate.  On the other hand, CPT-PVA-DOX F2 exhibited more 
than double the potency of either CPT-PVA or DOX-PVA alone.  While the two 
formulations bear different drug ratios, both ratios of 0.36 and 1.50 are expected to 
exhibit synergy in the polymer form, as demonstrated in Figure5.2a-b.Thus, the 
differences in cancer cell growth inhibition can be clearly attributed to differences in 
linker chemistry.  Physiologically labile linkers such as esters and hydrazones 
enhance intracellular concentrations of drugs and thus maintain drug activity, 
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whereas hydrolytically stabile amide bonds significantly reduce drug activity as well 
as combination potency.  These results further emphasize the necessity of drug 
hydrolysis from the polymer in order to preserve both drug activity and combination 
synergy. 
 
 
Figure 6.4. In vitro anticancer activity of CPT-PVA-DOX with 
non-hydrolyzable and hydrolyzable linkers. 
 
(a) Properties of PVA-conjugates which utilized Reaction Schemes 5.1 or 6.1 to conjugate both 
CPT and DOX to the same polymer.  Cell inhibition of BT-474 cells in the presence of CPT-
PVA-DOX conjugates F1 (triangles) and F2 (squares) are compared to the cell inhibition of 
cells treated with (b) CPT-PVA alone (circles) or (c) DOX-PVA alone (circles).  CPT-PVA-DOX 
F2, CPT-PVA and DOX-PVA were synthesized utilizing esterification (Reaction Scheme 5.1) 
and are the same as reported in Figure 5.2.  Cells were incubated with formulations for 72 
hours, and assessed for cell viability utilizing the MTT cytotoxicity assay.  Data is reported as 
mean ± SD (n≥6). 
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6.4. Mass transport across lipid bilayer of liposomes 
 Poor drug release from liposomes is an inherent issue with the highly effective 
transmembrane ammonium sulfate gradient DOX encapsulation method [28, 112, 
113].  Y. Barenholz describes this effect as "no free lunch", suggesting that adequate 
drug release and high drug encapsulation often come at the cost of the other [112].  
As seen in the previous section, poor drug release from nano-vehicles can be 
detrimental to both single and combination therapeutic efficacies. To combat this 
challenge, a small amount of cationic lipids can be incorporated (Chapter 4) to 
facilitate intracellular DOX release. However, mass transport of drug from the inner 
aqueous core, across the lipid bilayer and to the extra-liposomal aqueous 
environment can be enhanced through a variety of liposomal property adjustments.  
Two alternatives were considered during the development of liposomes for 
chemotherapy co-delivery: reduction in ammonium sulfate concentration and 
cholesterol content. An analysis of mass transport barriers during DOX release will 
help reveal how these parameters can be tuned to accelerate drug release. 
 Inherently, slow DOX release is attributed to the highly efficient 
encapsulation method.  As depicted in Figure 4.2, an ammonium sulfate gradient is 
formed such that [(NH4)2SO4]intra-liposomal> [(NH4)2SO4]extra-liposomal.  DOX in its 
hydrochloride salt form is then co-incubated with the vesicles.  Since DOX is weakly 
basic, it will be present in its neutral form outside of the vesicle.  The high intra-
liposomal proton concentration drives DOX inside, where it becomes protonated and 
associated with a sulfate ion to form a final precipitate, (DOX-NH3)2SO4 [127].  Drug 
loading is performed above the phase transition temperature of the lipids (55˚C) to 
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facilitate transport across the lipid bilayer.  All reactions are reversible, but the final 
precipitate cannot cross the liposomal barrier at physiological temperature, 37˚C.  
Thus, when liposomal DOX is delivered intravenously, the precipitated DOX must 
revert back to the soluble DOX-NH2 before escaping the liposome.  Here, there are 
two main aspects of mass transfer which influence drug release: dissolution of the 
precipitate and diffusion of the soluble form across the bilayer.  We can address one 
aspect at a time, followed by a comparison of the consequences of each.  
 First, we consider mass transfer of soluble DOX, DOX-NH2.  DOX-NH2 must 
first diffuse within the aqueous core to reach the surface of the lipid bilayer; then it 
must cross the lipid bilayer.  The bilayer itself constitutes a resistance to mass 
transport; highly hydrophobic interactions and embedded cholesterol groups pose a 
barrier for a water soluble molecule to cross.  For simplicity, we model the intra-
liposomal space in 1-D, as seen in Figure 6.5.  Here, z=0 represents the center of the 
liposome and z=R indicates the lipid bilayer.  We model the bilayer as a membrane 
with permeability km.  The concentration of DOX-NH2 at the center is C0, whereas 
the concentration at the surface is CS. 
 
  
Figure 6.5. 1-D model of drug diffusion through intra-liposomal space. 
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The flux out of the lipid bilayer surface is: 
(6.1) 
Since the extra-liposomal space has no DOX before drug release, we can say: 
(6.2) 
We can also find the diffusive flux within the liposome: 
(6.3) 
where D is the diffusivity of DOX within the aqueous core 
(6.4) 
At steady state, the flux out of the bilayer and the diffusive flux must be the same.  By 
setting (6.1) and (6.3) equal, we find the relationship: 
(6.5) 
The Damköhler naturally presents itself in the dominator, as the ratio of the lipid 
permeability rate to the diffusion rate: 
(6.6) 
By looking at the limiting cases of Da1, we can find valuable information.  In the case 
where Da1≫1, we see that CS≪C0.  Permeation through the lipid bilayer occurs 
rapidly, and diffusion within the liposome is slow.  Thus, diffusion to the membrane 
surface limits the mass transfer of soluble DOX.  In the other case, where Da1≪1, we 
see that CS≈C0and CS is constant.  Thus, the supply of DOX to the lipid membrane is 
constant, but the permeability through the membrane is slow and limiting.  Given 
Jout = km∆C 
∆C = CS − 0 = CS  
JD = −D∇C 
∇C =
CS −  C0
R
 
CS =
C0
1 +
Rkm
D
 
Da1 =
Rkm
D
 
133 
 
that the diffusivity of DOX is approximately 4 x 10-6 cm2/s [199] and the average 
diameter of our DOX-liposomes is 150 nm (Table 4.1), the rate of diffusivity is 0.53 
cm/s.  Thus, the time it takes DOX to traverse the intra-liposomal space and reach 
the lipid membrane is on the order of 10-5 s and is considerably fast.  We expect that 
lipid permeability is the limiting mass transfer, where km≪D/R and therefore Da1≪1. 
We can now solve for the residence time of one DOX molecule in the liposome, τL.  If 
C is given in molecules per volume,  
(6.7) 
Where N is the number of DOX molecules and C=Cs=C0.  The molecular flux of a 
DOX molecule will be the liposomal area multiplied by the steady state flux 
described by (6.1): 
(6.8) 
The residence time of one DOX molecule in the liposome is N divided by Jm: 
(6.9) 
Thus, in the case where lipid membrane permeability limits the mass transfer of 
soluble DOX, the residence time of DOX in the liposome is inversely proportional to 
the membrane permeability km. 
 Now that we’ve discussed the liposomal escape of soluble DOX, it is necessary 
to consider how the reaction of precipitated DOX to soluble DOX affects drug 
release.  We can think of precipitated DOX, (DOX-NH3)2SO4, as a core in the center 
of the liposome that acts as a reservoir for soluble DOX, DOX-NH2.  A summary of 
the reactions occurring within the liposome is given below: 
N =
4
3
πR3C 
Jm = 4πR
2km C 
τL =
1
3
R
km
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  Total Reaction (6.10) 
         Simplified Reaction (6.11) 
 
For simplicity, we denote A=DOX-NH2, B=H+, D=SO42-, and C = (DOX-NH3)2SO4, 
and ppt designates a precipitate.  The forward reaction rate is kf and the reverse 
reaction rate is kb.  At equilibrium, the concentrations of C and A are not changing in 
time.  However, as A (soluble DOX) escapes the liposome and is depleted, the 
reaction is driven to dissolve more of C (precipitated DOX) by Le Chatelier’s 
principle in order to compensate for lost A.  As A escapes the liposome, this results in 
a small change δ in the concentration of A, [A], and we can determine the time 
required for the system to reach equilibrium again.  Assuming stoichiometric 
reaction rates, we can define the change in [A] with time: 
(6.12) 
We can define a small perturbation in equilibrium concentrations as such, where 
[X]0 denotes an equilibrium concentration: 
(6.13) 
(6.14) 
(6.15) 
(6.16) 
2DOX-NH2 +  2H
+ →← 2(DOX-NH3+)
2(DOX-NH3
+) + SO4
2- →← (DOX-NH3)2SO4 (ppt)
2DOX-NH2 +  2H
+ + SO4
2-
(DOX-NH3)2SO4 (ppt)→←
A  +  B + ½ D →← ½ C (ppt)
kf
kb
Total reaction  [10]
Simplif ied reaction  [11]
2DOX-NH2 +  2H
+ →← 2(DOX-NH3+)
2(DOX-NH3
+) + SO4
2- →← (DOX-NH3)2SO4 (ppt)
2DOX-NH2 +  2H
+ + SO4
2-
(DOX-NH3)2SO4 (ppt)→←
A  +  B + ½ D →← ½ C (ppt)
kf
kb
Total reaction  [10]
Simplif ied reaction  [11]
∂[A]
∂t
=  −kf A  B [D]
1/2 + kb[C]
1/2  
 A =  A 0 +  δ 
 B =  B 0 +  δ 
 C =  C 0 −  2δ 
 D =  D 0 +  2δ 
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Plugging (6.13)-(6.16) into (6.12) and using Taylor expansion, we find the O(1) 
differential equation: 
(6.17) 
Equation 6.13 is identically zero since it represents steady state.  We can also find the 
O(δ) differential equation: 
(6.18) 
Integrating (6.18), we find: 
(6.19) 
Thus, the concentration profile of A after a small perturbation in equilibrium is: 
(6.20) 
And the time required for the perturbation in equilibrium to dissipate, τR, is given in 
the exponential: 
  (6.21) 
This says that the faster the reaction rates kf and kb are, the shorter the time required 
for the system to reach equilibrium again. 
 Through the individual analyses of the lipid membrane and the reaction 
limitations to mass transport, we have identified the time constants associated with 
∂ A 0
∂t
=  −kf A 0 B 0 D 0
1/2
+ kb C 0
1/2
 
∂δ
∂t
=  −kfδ   A 0 B 0 D 0
−
1
2 +  A 0 D 0
1
2  +  B 0 D 0
1
2  − kbδ C 0
1/2
+  O(δ2) 
δ t =  δ0exp[t  −kf   A 0 B 0 D 0
−
1
2 +  A 0 D 0
1
2  +  B 0 D 0
1
2  − kb C 0
1
2 ] 
A t =   A 0 + δ0exp  t  −kf   A 0 B 0 D 0
−
1
2 +  A 0 D 0
1
2  +  B 0 D 0
1
2  
− kb C 0
1
2   
τR = [ −kf   A 0 B 0 D 0
−
1
2 +  A 0 D 0
1
2  +  B 0 D 0
1
2  − kb C 0
1
2 ]−1  
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each limit, as seen in Equations 6.9 and 6.21.   The ratio of Equation6.9 to 6.21 
represents another Damköhler number which relates the reaction time scale to the 
lipid permeation time scale: 
(6.22) 
If Da2≪1, then the time for precipitated DOX to dissolve is much faster than the time 
required for soluble DOX to pass through the lipid membrane.  In this case, drug 
release is limited by mass transport through the lipid bilayer.  On the contrary, if 
Da2≫1, the time for soluble DOX to pass through the lipid bilayer is faster and the 
dissolution of DOX is rate limiting.   
 Without knowledge of reaction rates kf and kb or membrane permeability km, 
we can still estimate whether the reaction or the lipid membrane constitutes the 
highest mass transport barrier.  As described by Equation 6.20, the release of DOX 
with respect to time should be exponential if reaction is limiting mass transfer.  On 
the other hand, if lipid bilayer permeability is the limitation, the flux in Equation 6.1 
suggests that the release of DOX should be linear in time with slope km.  Thus, DOX 
concentrations released from liposomes can be collected over time and be utilized to 
estimate the mass transport limitation. 
 In an effort to determine the mass transfer limitations in our system, drug 
release data was collected.  DOX-loaded liposomes were incubated in a dialysis tube 
which permits DOX transfer but no liposome transfer (Section 2.9).  The dialysis 
tube was incubated at physiological temperature (37˚C) and samples of fluid 
surrounding the dialysis tube were analyzed at various time points for DOX. Samples 
Da2 =
 −kf   A 0 B 0 D 0
−
1
2 +  A 0 D 0
1
2  +  B 0 D 0
1
2  − kb C 0
1
2 
3 
km
R
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were compared to a DOX fluorescence standard curve to determine drug 
concentration.  Two formulations with different liposomal ammonium sulfate 
concentrations were compared, as seen in Figure 6.6a.  We see that at 250 mM 
(NH4)2SO4, DOX release was linear with time, whereas at 10 mM (NH4)2SO4, DOX 
release seemed nonlinear.  Thus, if we assume that the system reached steady state 
within a day, DOX release was limited by lipid permeability at higher intra-liposomal 
ammonium sulfate concentrations.  However, at lower intra-liposomal ammonium 
sulfate concentrations, dissolution of precipitated DOX limited drug release.  This 
suggests that when less ammonium sulfate ions are available, DOX remains in the 
precipitated form.  Therefore, the release of DOX can be modified by changing the 
intra-liposomal ammonium sulfate concentration.  To promote exponential drug 
release with time, a low ammonium sulfate concentration can be utilized. However, 
by utilizing low concentrations of ammonium sulfate, one will sacrifice DOX 
encapsulation efficiency. 
 
Figure 6.6. Effect of membrane properties on liposomal drug release. 
 
Effect of (a) intra-liposomal ammonium sulfate concentration or (b) Chol content on DOX 
release from liposomes.  Liposomes with 45% Chol content and rehydrated in 250 mM 
(NH4)2SO4 buffer (circles) are compared to liposomes with 10% Chol content with 250 mM 
(NH4)2SO4 buffer (squares) and liposomes with 45% Chol content rehydrated in 10 mM 
(NH4)2SO4 buffer (triangles).  Data expressed as mean ± SD (n=3). 
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 High concentrations of ammonium sulfate are necessary for high DOX 
loading, but in this case, lipid membrane permeability poses the greatest barrier to 
DOX release.  One possible method to increase membrane permeability, or km, is to 
reduce the cholesterol (Chol) content.  Since Chol is embedded in the lipid bilayer, a 
reduction of Chol will reduce the hydrophobic interactions in the membrane and 
decrease the barrier for transport of water soluble molecules, including ammonium 
sulfate ions that maintain the transmembrane pH gradient.  DOX liposomes were 
fabricated with 250 mM ammonium sulfate and two different cholesterol mol 
fractions: 45% and 10%.  The release data are shown in Figure 6.6b.  In both 45% 
and 10% Chol liposomes, DOX release was linear with time, and only slightly more 
DOX was released with 10% Chol at earlier time points.  As a result, the slope 
relating DOX released and time was similar for both 10% and 45% Chol liposomes.  
As defined in Equation 6.1, km should have units of [m/s], but release data was 
collected as DOX mass rather than DOX concentration.  Thus the slopes of the 
release data have units of [µg/day] and still qualitatively represent km.  The slopes for 
45% and 10% cholesterol liposomes were respectively 2.07 µg DOX/day and 2.06 µg 
DOX/day.  The release data show that membrane permeability is not affected by 
Chol content within the range of 10-45 mol%. 
 Chol is known to exhibit multiple effects on lipid bilayer transport, which can 
account for this observed little difference in DOX release.  On one hand, Chol 
reduces permeability of ions and small molecules across the phospholipid membrane 
and hence hinders the ability of such molecules to disorder the bilayer [32].  
However, Chol has also been shown to prevent ordering of saturated lipid chains and 
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actually enhance membrane permeability [200].  The observed effects of Chol 
depend on both the saturation of phospholipids and amount of incorporated Chol 
relative to phospholipids.  Specifically, Chol has been shown to prevent ordering at 
above 30 mol% content in a bilayer containing saturated lipids, such as the lipids 
utilized here (DSPC).  Therefore, it is likely that 10 mol% Chol does not affect Tm of 
liposomes, but allows the diffusion of small molecules, whereas 45 mol% Chol 
reduces Tm but prevents the passage of small molecules.  These two regimes may 
ultimately elicit identical effects on liposome permeability km, and hence result in 
similar drug release rates. Therefore, altering Chol content between 10-45 mol% in  
DSPC-comprised bilayer is not a practical method for accelerating drug release from 
liposomes. 
 DOX release from liposomes can be characterized as membrane transport-
limited or reaction-limited.  Considering the nano-size of the liposomes and 
relatively high DOX diffusivity, diffusion of soluble DOX to the membrane seems 
negligible compared to its transport though the lipid membrane barrier.  Through 
mass transport analysis, it was found that in membrane-limited transport, the 
release of DOX with time should be linear.  In reaction-limited transport, DOX 
release is exponential with time.  Changing the ammonium sulfate concentration for 
DOX encapsulation can influence whether the release is membrane transport-limited 
or reaction-limited.  Despite this change in DOX release profiles, the reduction in 
ammonium sulfate concentrations does not drastically improve overall drug release. 
It was also shown that decreasing cholesterol content offers little enhancement in 
membrane permeability.  Therefore, to accelerate DOX release during cancer 
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treatments, other methods may need to be explored.  Alternative methods which 
increase membrane permeability may be of interest, such as physical membrane 
alterations.  Our studies in Chapter 4 involved the use of cationic lipids to promote 
ionic interactions with native negatively-charged lipids on cell membranes.  Current 
literature efforts in this area also include ultrasound or photo-switchable lipids 
which create a more porous and leaky structure when exposed to a particular 
wavelength of light.  Investigating stimuli for instantaneous membrane permeability 
can promote high local concentrations of toxic drugs at tumor sites and potentially 
more effective cancer treatments.  An analysis of the mass transport limitations in 
our current system has revealed how certain parameters can influence DOX release, 
but that other methods may need to be explored in order to significantly impact DOX 
release from liposomes. Moreover, optimizing single drug release with various 
stimuli will allow for the development of multi-drug loaded liposomes that release 
both drugs at acceptable rates and hence do not alter combination potency. 
 
6.5. Nanoparticle stability 
 Another chief determinant of the clinical applicability of nanoparticles is their 
shelf-life.  Size and drug leakage from nanoparticles can alter depending on the pH, 
temperature, and time of storage.  However, as nanoparticle fabrication is a time- 
and economically-consuming process, poor stability may render the nanoparticles 
impractical drug delivery solutions.  Here, the storage shelf-lives of liposomes and 
polymer-drug conjugates developed on Chapters 4 and 5 are compared, with the 
intent of evaluating their ease of clinical translations.  An efficient way to test 
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formulation stability is by determining D50 concentrations in vitro at various times 
after nanoparticle storage.  Presumably, if drug is released during storage, D50 
concentrations should become lower with increased storage time and should 
eventually mimic those of free drugs. 
 
 
Figure 6.7. Effect of nanoparticle age on cancer cell cytotoxicity. 
 
4T1 cancer cell viability after incubation with 4 day old (circles) or 8 day old (squares) (a) 10 
kDa CPT-HA-DOX (R=7.5) or (b) +DOX-L. Data expressed as mean ± SD (n≥6).  4 days old 
or 8 days old refers to the age of nanoparticle at the time of incubation with cells.  Dashed 
lines represent fits to the ME model. D50 and R2 values corresponding to 4 and 8 days old 
CPT-HA-DOX, respectively, are (0.55 ± 0.04 µM, 0.98) and (0.59 ± 0.04 µM, 0.97).  D50 and 
R2 values corresponding to 4 and 8 days old +DOX-L, respectively, are (11.9 ± 0.6 µM, 0.99) 
and (1.07 ± 0.1 µM, 0.93). 
 
 As seen in Figure 6.7, CPT-HA-DOX exhibited a similar dose-effect 
relationship when stored for 4 or 8 days, while the cell inhibitory effects of +DOX-L 
dramatically increased after 8 days (vs. 4 days) of storage.  ME model fits reflected 
little change in D50 of CPT-HA-DOX: 0.55 and 0.59 µM CPT after 4 and 8 days, 
respectively.  However, the D50 of +DOX-L was reduced 11-fold (11.9 vs. 1.07 µM 
DOX) between 4 and  8 days of storage, suggesting that liposomal drug 
encapsulation was not as stable as polymer-drug incorporation.  In both cases, 
nanoparticles were stored at 4ºC to slow drug leakage. Ideally, nanoparticles should 
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exhibit shelf-lives on the order of months, so that large batches could be synthesized 
at a time without the need of unrealistic and costly continuous manufacture. 
 One approach to improving formulation stabilities is lyophilization.  
Lyophilization removes water through sublimation, and since the presence of water 
can hydrolyze polymer-drug conjugates or facilitate diffusion of drugs from 
liposomes, this process can significantly reduce drug release upon storage.  In 
particular, liposomes can aggregate and fuse during aqueous storage [201].  
However, it is necessary to verify that formulation properties are not altered during 
lyophilization and reconstitution in water prior to administration.  Clinical polymer-
drug conjugates have successfully been lyophilized and easily re-dissolved in water 
without altering physicochemical properties such as drug incorporation and size 
[30]. Liposomes, however, have been shown to lose as much as 70% encapsulated 
drug, as well as its monodispersed shapes after reconstitution [32].  These findings 
suggest that lyophilization affects the physical reformation of lipid bilayers, but does 
not compromise chemical linkers between polymers and drugs.  Therefore, shelf-life 
may not be as presiding an issue for polymer-drug conjugates as it is for liposomes.  
To facilitate the implementation of liposomes for clinical combination chemotherapy 
delivery, efforts to improve stability and reduce drug release upon storage must be 
addressed. 
 
6.6. Summary of nanoparticle property effects 
 In this Chapter, various characteristics of nanoparticles were evaluated for 
their impact on single and combination chemotherapy activity.  For polymer-drug 
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conjugates, molecular weight and chemical tethers were investigated. Molecular 
weight dictates the distribution of polymers in tumor tissue, and as a result, 
influences therapeutic efficacy.  Low molecular weight polymers can penetrate 
deeper into tumor interstitium, while higher molecular weight entities remain on the 
tumor periphery.  Here, it was found that 10 kDa HA conjugates of CPT+DOX 
produced a lag in tumor reduction compared to 250 kDa HA conjugates of the same 
CPT+DOX ratio.  However, both conjugates achieved the same 50% reduction in 
tumor volume relative to controls.  Dose optimization studies of low and high 
molecular weight HA will further elucidate the therapeutic benefit of one over the 
other.  It was also found that poorly hydrolyzable chemical linkers are detrimental to 
both single and combination chemotherapy potency.  Amide-linked DOX abolished 
drug activity, and prevented synergistic cancer cell inhibition with ester-linked CPT.  
Hydrazone-linked and ester-linked DOX, however, represented highly biodegradable 
bonds, and resulted in high DOX activity, as well as preserved synergistic activity 
with CPT. These findings highlighted the therapeutic potential of low molecular 
polymer-drug conjugates for combination chemotherapy delivery, as well as 
illustrated the necessity of physiologically labile chemical linkers. 
 Similarly, release of DOX from liposomes bearing an ammonium sulfate 
gradient was explored, with an emphasis on membrane-limited and reaction-limited 
transport.  Simply altering the concentration of ammonium sulfate in the lipid 
hydration solution can switch the mass transport limitation and dictate whether 
DOX release is linear or exponential.  Despite these investigations, neither 
ammonium sulfate nor cholesterol content changes were found to significantly 
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improve drug release.  Hence, these studies emphasize the need for innovative 
liposomes which can both encapsulate high drug payloads and trigger their release in 
tumors. 
 Lastly, nanoparticle stability was addressed.  It was found that liposome-
encapsulated drugs were more prone to release in storage than polymer-conjugated 
drugs.  Moreover, lyophilization can prolong polymer-drug conjugate shelf-life 
without compromising drug incorporation, while it drastically reduces drug 
encapsulation of liposomes.  Prolonged shelf-life is therefore an added challenge of 
liposome co-delivery that must be optimized for these nanoparticles to become a 
clinically viable option for chemotherapy combination drug delivery. 
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Chapter 7 
Reflections and Future Directions 
7.1. Challenges with multi-drug delivery 
 The highly coveted therapeutic potential of anticancer drug combinations has 
lead to a massive pursuit, amounting to a quarter of all oncology clinical trials [202]. 
Despite this, very few successful pairs exist that provide both therapeutic and toxicity 
benefits over single drug treatments [13].  In Chapter 3, we demonstrated the 
incredible potency of chemotherapy combinations when exposed to isolated cancer 
cells.  Nearly 100% cancer cell kill can be achieved by drug combinations already 
implemented clinically, such as 5FU+DOX and top I + II inhibitors.  The low 
prevalence of complete tumor regression in the clinic [8, 9, 68, 94, 96], however, 
illustrates the stark disconnect between combination potency in vitro and 
therapeutic efficacy in vivo. This disparity represents the highly unmet need for drug 
delivery carriers that can translate combinations into successful therapies.  Research 
investigations throughout the course of my Ph.D. aimed to tackle this unmet need, 
and provide insight for future engineering of combination chemotherapy nano-
vehicles. 
 It must be reiterated that chemotherapy drug delivery has not even been 
perfected for single drugs.  Oncology therapeutics is a multi-disciplinary field 
diligently pursued by clinicians, pharmacists, chemists, chemical engineers, 
materials scientists, biologists, and many other professions, yet tumor environments 
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and cancer cells persist.  High drug encapsulations, nanoparticle tumor 
accumulation, drug release and preservation of drug activity are all required for a 
successful single chemotherapy nanoparticle.  These same challenges are amplified 
for multi-drug delivery.  When considering concurrent chemotherapy drug delivery, 
multiple drugs need to be incorporated in the same nanoparticle, and not only do 
individual drug activities need to be conserved, but so do their synergy. If synergistic 
drug interactions are not maintained, there may not be merit to co-administering 
multiple drugs. 
 Nanoparticle encapsulation of a single drug is a challenge in itself, since 
loading techniques often rely on hydrophobic or ionic interactions that can easily be 
reversed.  Empirical techniques are often derived to achieve high drug 
incorporations tuned to a specific drug, such as the transmembrane ammonium 
sulfate gradient for liposomal DOX entrapment [127], or copper ion complexation 
for 5FU liposomal incorporation [145].  However, different drugs bear unique 
chemical and physical properties, and a high encapsulation method for one drug may 
be ineffective for another.  This became immediately evident in Chapter 4, when the 
transmembrane ammonium sulfate method yielded <1 mol% 5FU liposomal 
entrapment (Table 4.2), a technique which has been reported to achieve as high as 
25 mol% DOX relative to lipid [14].  Therefore, identifying encapsulation methods 
which are compatible for both drugs in the combination, and are also not 
compromised by the presence of other drug, is a prominent challenge associated 
with multi-drug delivery. 
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 As for maintaining combination synergy, one approach is to controllably 
encapsulate fixed drug ratios in nanoparticles.  Chapter 3 demonstrated that two 
drugs can elicit synergistic, and antagonistic, or additive cancer cell kill depending 
on the drug ratio, R, exposed to cells. In particular, CPT+DOX exposed at R > 2 
(M:M CPT:DOX) elicited CI « 1 (Figure 3.8c), indicating extreme synergistic cancer 
cell inhibition, with no apparent upper limit of R.  However, when exposed as a 
mixture of polymer-drug conjugates, CPT-HA+DOX-HA exhibited a minimum CI at 
R = 4.5 (Figure 5.6b), suggesting that polymer-conjugation creates an upper limit of 
R for synergistic interactions.  This finding  demonstrates that synergy preservation 
upon nanoparticle encapsulation is a non-trivial feat, especially since optimal free 
drug synergistic R is not necessarily identical to that of nanoparticle-incorporated 
drugs.   While free drug synergistic screens such as those presented in Chapter 3 are 
helpful in identifying promising drug pairs, the screen for synergistic ratios will most 
likely need to be repeated for combinations of nanoparticle-incorporated drugs in 
order to determine the optimal R to be co-loaded in multi-drug nanoparticles. 
 Also imperative is the release of drugs once accumulated in tumor tissue, in 
order to allow the drugs to reach their intracellular targets and thereby initiate 
cascades for cell death.  In Chapter 6, DOX conjugated via stabile amide bonds to 
PVA was incapable of inhibiting cancer cell growth for a range of doses that ester-
conjugated DOX was considerably active (Figure 6.3a).  As a result, amide-
conjugated DOX bound to the same polymer as ester-conjugated CPT was only as 
active as CPT-PVA (Figure 6.4), and their synergistic interactions were abolished.  
For the two co-loaded nano-vehicles developed during my Ph.D., DAFODIL and 
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CPT-HA-DOX, uncoordinated release profiles were discovered (Figure 4.7c and 5.5).  
One drug would release faster than the other, and this differential drug release can 
potentially impact synergistic interactions.  In our studies, however, differential drug 
releases worked in the favor of synergy, and did not compromise the pair's ability to 
inhibit cancer cell growth.  For the development of multi-drug loaded nano-vehicles, 
however, uncoordinated drug release profiles must be generally assessed for their 
impact on combination therapeutic efficacy. 
 
7.2. Comparison of liposomes and polymer-drug conjugates 
 After arduously developing both liposomes and polymer-drug conjugates for 
combination chemotherapy delivery, the multi-drug encapsulation challenges 
addressed above were assessed for each particle type.  A summary of our findings is 
provided in Table 7.1.  
 
 
Table 7.1. Comparative properties of liposomes and polymer-drug conjugates 
for combination chemotherapy delivery. 
 
Liposomes Polymer-drug conjugates
Encapsulation methods
Gradient across lipid bilayer must 
be tuned to chemical properties of 
each drug
Requires reactive chemical 
moieties (i.e. -OH, -NH2)
Encapsulation yield 25 mol% drug:lipid 15 mol% drug:polymer
Size control Monodisperse Multi-modal DLS size distributions
Stability
Drug releases rapidly at 4C, 
Cannot be lyophilized
Slow drug release at 4C,                
Can be lyophilized
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 Drug encapsulations in liposomes are less intuitive than polymer-drug 
conjugations because it requires trial and error to develop appropriate gradients 
across the lipid bilayer.  The gradient must be created in order for the drug to prefer 
the inner aqueous phase rather than the outer one, and the type of gradient required 
is unique for each drug, depending on its chemical properties.  If the drug is basic, 
the liposome core should contain an excess of available protons, and vice versa.  
During our investigations, rather than modifying the well-established 
transmembrane ammonium sulfate gradient, we created pro-drugs of 5FU with 
proposed moieties to facilitate its compatibility with the gradient.  We super-
imposed chemical signatures required for encapsulation into an ammonium sulfate 
core onto a nucleobase analogue.  While this required more methodological tests and 
troubleshooting compared to polymer-drug conjugations, it also resulted in double 
the encapsulation yields observed for HA-conjugates.   
 Conjugation of drugs to polymers, on the other hand, is more straightforward 
as simple chemical reactions can be applied to various drugs.  The only prerequisite 
is that the drugs contain reactive chemical moieties, such as the nucleophilic 
hydroxyl and free amines found in CPT and DOX.  Because this does not require 
methodological empirical studies for the introduction of a new drug, polymer-drug 
conjugates are more universal than liposomes, and provides a broader platform for 
high throughput testing of chemotherapy combinations.  Combinations consisting of 
more than 2 drugs can also be conceivably incorporated in polymer-drug conjugates, 
while it would be considerably more challenging with liposomes. Incorporation is, 
however, limited by chemical reaction efficiency, which may require more 
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troubleshooting to improve.  Another limitation of polymer-drug conjugates is poor 
size control. Unlike liposomes, which can be extruded to a certain size range, 
polymer-drug conjugations can result in polymer cross-linking or hydrophobic drug 
aggregates that cause size polydispersity.  Because size can govern nanoparticle and 
hence drug fate in vivo, polydispersity can have immense ramifications on 
therapeutic efficacy. However, additional fabrication steps such as differential 
centrifugation and surfactant inclusion can be integrated with polymer-drug 
conjugates to control their size. 
 Lastly, stability is a greater issue with liposomes, as most incorporation 
methods rely on passively-loaded drugs, compared to polymer-bound drugs which 
are conjugated via strong chemical bonds.  In our studies, four day storage at 4ºC 
resulted greater liposome drug leakage than polymer-drug cleavage.  This was 
evident in the reduction of liposome drug D50 after storage compared to that of 
polymer-conjugated drugs (Figure 6.7).  Moreover, cryopreservation has been found 
in literature to prolong shelf-life of polymer-drug conjugates, but alters both size and 
drug encapsulation of liposomes.  Therefore, to translate multi-drug loaded 
liposomes to clinically viable therapeutics, their shelf-life must be enhanced. 
 As evident from the discussion above, it is difficult to clearly say which 
nanoparticle is better for multi-drug delivery.  Both liposomes and polymer-drug 
conjugates exhibit advantages where the other does not, and each of these 
advantages are detrimental for their clinical translation.  Further studies to improve 
stability, size, and drug encapsulations will allow for better assessment.  However, it 
is also probable that one nanoparticle is not truly better than the other for 
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combinatorial drug delivery.  Through ester-conjugated tryptophan modifications, 
we have shown that a nucleobase analogue and doxorubicin can be simultaneously 
incorporated in liposomes.  This method can be applied to all other nucleobase 
analogues, and may be a better fit for concurrent delivery than polymer-drug 
conjugates due to the high encapsulation yields.  Drugs which possess nucleophilic 
moieties, however, may be readily conjugated to polymers and should be co-
delivered via polymer-drug conjugates.  We have shown that both types of vehicles 
are successful at inhibiting tumor growth in vivo when armed with a well-designed 
synergistic chemotherapy combination. 
 
7.3. New methodology for developing combination chemotherapy nano-
vehicles 
 Experiences from the development of two multi-drug loaded nanoparticles 
has led to a new proposed, and hopefully more efficient, methodology for 
combination chemotherapy drug delivery.  Investigations of free drug combinations 
in vitro (Chapter 3) demonstrated that various drugs can be synergistic if exposed to 
cancer cells in the correct ratio.  Studies with combinations of chemotherapy 
nanoparticles also suggested (Chapters 4 and 5) that the optimal synergistic R of 
single drug-loaded nanoparticles do not always correlate with those of free drugs.  
Liposome studies also elucidated the challenge of combining chemically distinct 
drugs in the same vehicle.  To mediate these challenges, we propose that the 
development of combination chemotherapy nano-vehicles should start with synergy 
screens between single drug-loaded nanoparticles.  These screens will allow for the 
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facile determination of optimal synergistic R, which can then be co-incorporated into 
a single nanoparticle. 
 By screening for synergy among single-drug nanoparticles, only combinations 
which can be easily co-loaded in drug carriers are considered.  Therefore, only drugs 
whose pharmacokinetics can be unified, and whose concurrent accumulation in 
tumor tissue can be controlled will be assessed for combinations.  Concurrent tumor 
exposure will ensure that both drug mechanisms of cancer cell kill will be activated 
simultaneously.  This will also help mimic the in vitro concurrent drug exposure 
studies that often result in near perfect cell inhibition, and may help bridge the stark 
disconnect between in vitro and in vivo combination potency.  Furthermore, the 
effect of differential drug release from nanoparticles is embedded in the synergy 
screen among single drug nano-vehicles.  By testing various ratios of single drug 
nanoparticles for synergy, the differential drug release is already accounted for, and 
will not need to be further analyzed for impact on combination potency. 
 To clarify, however, this new approach does not suggest that all drugs which 
cannot be easily incorporated in nano-vehicles be excluded from combination 
studies.  Drugs which exhibit poor encapsulation yields must first be developed to 
achieve high single drug nanoparticle incorporation.  After these empirical studies, 
such as our 5FU analogue investigations, synergy screens among single drug-loaded 
nanoparticles can proceed.  However, the feat of high single drug encapsulation must 
first be accomplished.  Otherwise, encapsulation will need to be optimized after the 
identification of synergistic drug pairs, where the presence of the other drug may 
compound the challenge even further.  Due to the numerous classes and chemical 
153 
 
variations of drugs, an infinite number of combinations to be investigated exists.  It 
is our hope, that by imparting this new methodology for combination chemotherapy 
delivery, more efficient screens can be conducted, and lead to a more rapid discovery 
of successful therapies. 
  
7.4. Extension of our approach 
 The remarkable therapeutic efficacies of polychemotherapy nano-vehicles 
developed here has ignited new and exciting prospects within the Mitragotri lab.  
New studies are assessing the effect of drug scheduling and order on combination 
potency, which can theoretically be tuned and achieved in vivo by certain linkers in 
polymer-drug conjugates.  Targeting these potent, synergistic combinations 
specifically to tumors is also necessary as the combinations may be equally toxic to 
healthy tissue.  Therefore, additional studies focus on conjugating drug pairs to 
aptamers which can specifically identify surface markers over-expressed on certain 
cancer cells.  In this manner, the aptamer acts as a tumor-honing vehicle. A third 
effort is towards the development of nanoemulsions which can efficiently 
incorporate both hydrophobic and hydrophilic drugs.  Nanoemulsions can be made 
to comprise other emulsions, and potentially create a large barrier for drug release, a 
greater barrier than is currently achievable for hydrophobic drugs embedded in the 
lipid bilayer of liposomes.  By developing another vehicle for combination 
chemotherapy delivery, the repertoire of nanoparticles available for multi-drug 
delivery will expand and potentially encompass a wider variety of encapsulation 
methods to facilitate the assessment of even more chemotherapy combinations. 
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 Outside of the Mitragotri lab, studies performed during my Ph.D. can help 
emphasize challenges that should be considered during future investigations of 
combination chemotherapies.  First, identifying synergy should be prioritized, as 
antagonistic effects can result in poorer therapeutic efficacy in exchange for 
heightened adverse side effects - two outcomes which will automatically, and 
possibly falsely, negate the combination. Ratio can govern synergistic interactions 
and must be assessed amongst mixtures of single drug-loaded nanoparticles; free 
drug combination studies will not suffice, as nanoparticle encapsulation can alter the 
optimal R.  Lastly, trial and error of drug encapsulations here elucidate common 
challenges in multi-drug delivery, such as the development of pro-drugs or optimal 
chemical linkers.  While only liposomes and polymer-drug conjugates were explored, 
the lessons learnt have wide applicability to other systems and provide immense 
insight into the general development of nanoparticles for combination 
chemotherapies. 
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